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II 
SUMMARY	
Protein	import	into	the	mitochondrial	intermembrane	space	(IMS)	of	parasitic	protists	differs	
from	other	eukaryotes	despite	a	general	conservation	of	mitochondrial	protein	import	signals.	
Imported	proteins	typically	carry	conserved	cysteine-motifs	that	are	oxidized	in	the	IMS.	 In	
opisthokonta	such	as	yeast	and	mammals,	these	motifs	are	recognized	and	oxidized	by	the	
oxidoreductase	Mia40	 leading	to	the	formation	of	 intramolecular	disulfide	bonds.	Reduced	
Mia40	 is	 subsequently	 re-oxidized	 by	 the	 sulfhydryl	 electron	 transferase	 Erv1.	 In	
kinetoplastida,	 such	 as	 Leishmania	 tarentolae,	 and	 in	 apicomplexan	 parasites,	 such	 as	
Plasmodium	falciparum,	no	Mia40	homolog	could	be	identified	so	far.	However,	conserved	
substrates	 and	 an	 Erv	 homolog	 in	 these	 parasites	 suggest	 the	 existence	 of	 a	 Mia40	
replacement.	Indeed,	preliminary	results	revealed	two	disulfide-bonded	interaction	partners	
of	PfErv	as	demonstrated	by	western	blot	analyses.		
The	major	objective	of	this	thesis	was	the	identification	of	a	potential	Mia40	replacement	in	
the	parasite	L.	 tarentolae.	Numerous	experiments	were	performed	 in	order	 to	 trap	mixed	
disulfide	 intermediates between	 the	 model	 substrate	 LtsTim1	 or	 LtErv	 and	 a	 potential	
interaction	partner.	A	variety	of	protocols	with	alkylating,	oxidizing	or	reducing	agents	did	not	
reveal	mixed	disulfides	between	LtErv	and	the	adapter	replacement	in	western	blot	analyses.	
In	 addition,	 even	with	 highly	 enriched	 LtErv	 protein	 levels	 after	 denaturing	 or	 native	 pull-
down,	 no	 mixed	 disulfide	 intermediate	 could	 be	 identified.	 In	 contrast,	 staining	 against	
LtsTim1	in	western	blot	analyses	showed	disulfide-bridged	intermediates	indicating	potential	
heterodimers	 of	 LtsTim1	 and	Mia40	 replacement	 candidates.	 However,	 an	 enrichment	 of	
these	 intermediates	 by	 affinity	 chromatography	 and	 further	 analysis	 failed	 because	 of	
systematic	problems	with	the	hydrophobicity	of	the	substrate	and	the	LtsTim1-antibody.		
To	summarize,	a	potential	replacement	for	Mia40	in	parasitic	protists	remains	to	be	identified	
and	the	oxidative	folding	machinery	in	the	IMS	of	kinetoplastida	and	apicomplexa	could	not	
be	unraveled	during	this	PhD	project.	Four	alternative	cysteine-containing	substrates	of	the	
oxidative	protein	folding	pathway	in	the	IMS	were	already	designed	during	this	project	and	
might	lead	to	a	rather	fast	breakthrough	in	further	experiments.		
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Glutaredoxins	(Grx)	are	highly	conserved	enzymes	that	play	important	roles	in	redox	catalysis	
and	 iron	 metabolism	 and	 are	 found	 in	 almost	 all	 organisms.	 The	 traditional	 monothiol	
mechanism	 of	 Grx catalysis	 is	 divided	 into	 an	 oxidative	 half-reaction	 with	 the	 first	
glutathionylated	 substrate	 and	 a	 reductive	 half	 reaction	 with	 the	 reduced	 tripeptide	
glutathione	 (GSH)	as	 the	second	substrate.	However,	 this	 traditional	model	 cannot	explain	
how	exactly	the	two	different	substrates	of	Grx are	bound. Hence,	two	refined	models	of	Grx	
catalysis	namely	the	“glutathione	scaffold	model”	and	the	“glutathione	activator	model”	were	
previously	proposed	and	experimentally	confirmed	for	two	residues	of	ScGrx7.	This	model	can	
help	to	distinguish	protein	areas	that	either	interact	with	the	disulfide	substrate	(a	scaffold	
site,	including	Glu170	in	ScGrx7)	or	with	the	reducing	agent	(an	activator	site,	including	Lys105	
in	ScGrx7).		
The	second	objective	of	this	PhD	project	was	to	test	the	general	applicability	of	this	model	
using	the	non-related	enzyme	PfGrx.	Moreover,	four	additional	residues	that	were	previously	
suggested	to	contribute	to	the	glutathione	activator	site	in	ScGrx7	were	characterized	in	this	
thesis.		
Taken	together,	I	confirmed	the	existence	of	two	distinct	glutathione	interaction	sites	with	the	
non-related	model	 enzyme	PfGrx.	Moreover,	 I	 could	 identify	Arg153	of	ScGrx7	 as	 another	
potential	scaffold	site	residue.	In	addition,	I	could	show	that	the	two	charge	inversion	mutants	
with	a	positively	 charged	amino	acid	of	 the	helix	3	 residues	Asp144	and	Glu147	 in	ScGrx7	
enhanced	the	interaction	with	the	second	substrate	GSH.	Hence,	the	helix	3	of	these	“gain-of-
function”	mutants	indeed	seems	to	affect	the	glutathione	activator	site.	Furthermore,	I	could	
show	that	 the	 introduced	mutations	 influenced	 the	pKa	value	of	 the	active	site	cysteine	of	
ScGrx7	only	to	a	minor	degree,	except	for	ScGrx7K105E.	Modeling	of	the	transition	states	and	
analyses	of	the	different	mutants	by	roGFP	assays	may	help	to	elucidate	the	structure-function	
relationships	of	Grx	in	further	analyses.		
		
	 	
	 	 	
	
IV 
ZUSAMMENFASSUNG	
Der	 Proteinimport	 in	 den	 mitochondrialen	 Intermembranraum	 von	 parasitären	 Protisten	
unterscheidet	sich	trotz	einer	allgemeinen	Konservierung	der	mitochondrialen	Proteinimport-
Signalen	von	anderen	Eukaryoten.	Importierte	Proteine	weisen	typischerweise	konservierte	
Cysteinmotive	auf	und	werden	im	Intermembranraum	oxidiert.	In	Opisthokonta,	wie	z.B.	Hefe	
oder	Säugetieren,	werden	diese	Motive	durch	die	Oxidoreduktase	Mia40	erkannt	und	oxidiert,	
was	 zu	 der	 Bildung	 von	 intramolekularen	 Disulfidbrücken	 führt.	 Reduziertes	 Mia40	 wird	
anschließend	 durch	 die	 Sulfhydryl-Elektronentransferase	 Erv1	 wieder	 oxidiert.	 In	 Kineto-
plastida,	wie	 Leishmania	 tarentolae	 und	 Apicomplexa	wie	Plasmodium	 falciparum,	 konnte	
bislang	kein	Mia40-Homolog	identifiziert	werden.	Jedoch	deuten	konservierte	Substrate	und	
ein	 Erv-Homolog	 auf	 die	 Existenz	 eines	Mia40-Ersatzes	 in	 diesen	 Parasiten	 hin.	 In	 der	 Tat	
zeigten	 vorläufige	 Ergebnisse	 zwei	 disulfidverbrückte	 Interaktionspartner	 von	 PfErv	 in	
Western-Blot-Analysen.		
Das	Hauptziel	dieser	Arbeit	war	die	Identifizierung	eines	potentiellen	Mia40-Ersatzes	in	dem	
Parasiten	 L.	 tarentolae. Zahlreiche	 Experimente	 wurden	 durchgeführt, um	 ein	 gemischtes	
Disulfid	 zwischen	 dem	 Modellsubstrat	 LtsTim1	 oder	 LtErv	 und	 einem	 potentiellen	
Interaktionspartner	zu	stabilisieren.	Eine	Vielzahl	an	Protokollen	mit	Alkylierungs-,	Oxidations-	
oder	 Reduktionsmitteln ließ	 keine	 gemischten	Disulfide	 zwischen	 LtErv	 und	 einem	Mia40-
Ersatz	 in	 Western-Blot-Analysen	 erkennen.	 Darüber	 hinaus	 konnte	 selbst	 nach	 starker	
Proteinanreicherung	 durch	 denaturierende	 oder	 native	 Affinitätschromatographie	 kein	
gemischtes	 Disulfid	 nachgewiesen	 werden.	 Im	 Gegensatz	 dazu	 zeigte	 die	Markierung	 von	
LtsTim1	 in	Western-Blot-Analysen	disulfidverbrückte	 Zwischenprodukte,	welche	möglicher-
weise	Heterodimere	zwischen	LtsTim1	und	Mia40-Ersatzkandidaten	darstellen.	Allerdings	war	
eine	 Anreicherung	 dieser	 Intermediate	 durch	 Affinitätschromatographie	 und	 eine	 weitere	
Untersuchung	aufgrund	systematischer	Probleme	mit	der	Hydrophobizität	des	Substrates	und	
dem	Antikörper	gegen	LtsTim1	nicht	möglich.		
Zusammenfassend	konnte	in	diesem	Projekt	weder	ein	Mia40-Ersatz	in	parasitären	Protisten	
identifiziert,	 noch	 die	 oxidative	 Faltungs-Maschinerie	 im	 Intermembranraum	 von	
Kinetoplastida	 und	 Apicomplexa	 weiter	 aufgeklärt	 werden.	 Vier	 alternative,	 cysteinhaltige	
Substrate	 des	 oxidativen	 Proteinfaltungswegs	 im	 Intermembranraum	 wurden	 bereits	
während	 dieser	 Arbeit	 geplant	 und	 könnten	 zu	 einem	 eher	 schnellen	 Durchbruch	 in	
zukünftigen	Experimenten	führen.		
	 	 	
	
V 
Glutaredoxine	 (Grx)	 sind	 hochkonservierte	 Enzyme,	 die	 eine	 wichtige	 Rolle	 in	 der	
Redoxkatalyse	und	im	Eisen-Stoffwechsel	spielen	und	in	fast	allen	Organismen	vorkommen.	
Der	 traditionelle	 Monothiol-Mechanismus	 der	 Grx-Katalyse	 wird	 in	 eine	 oxidative	
Halbreaktion	mit	dem	ersten	glutahionylierten	Substrat	und	eine	reduktive	Halbreaktion	mit	
dem	reduzierten	Tripeptid	Glutathion	(GSH),	welches	als	zweites	Substrat	agiert,	unterteilt.	
Jedoch kann	 das	 traditionelle	 Modell nicht	 erklären,	 wie	 genau	 die	 zwei	 verschiedenen	
Substrate	von	Grx	gebunden	werden.	Daher	wurde	 zuvor	ein	verfeinertes	Modell	der	Grx-
Katalyse,	bestehend	aus	dem	„Glutathiongerüst-Modell“	und	dem	„Glutathionaktivierungs-
Modell“, vorgeschlagen und	experimentell	für	zwei	Aminosäure-Reste	von	ScGrx7	bestätigt.	
Dieses	Modell	kann	helfen,	Proteinbereiche	zu	unterscheiden,	die	entweder	mit	dem	Disulfid-
Substrat	 (eine	 „Glutathiongerüst“-Stelle,	 die	 Glu170	 von	 ScGrx7	 beinhaltet)	 oder	mit	 dem	
Reduktionsmittel	 interagieren	 (eine	 „Glutathionaktivierungs“-Stelle,	 die	 Lys105	 von	 ScGrx7	
beinhaltet).		
Ein	weiteres	Ziel	dieser	Arbeit	war	es,	durch	die	Analyse	des	nichtverwandten	Enzyms	PfGrx	
herauszufinden,	ob	dieses	Modell	eine	allgemeine	Anwendbarkeit	findet.	Außerdem	wurden	
vier	 weitere	 Aminosäurereste	 von	 ScGrx7,	 die	 zuvor	 als	 mögliche	 Elemente	 der	
„Glutathionaktivierungs“-Stelle	vorgeschlagen	wurden,	in	dieser	Arbeit	untersucht.	
Zusammengefasst	 konnte	 ich	 die	 Existenz	 zweier	 unterschiedlicher	 Glutathion-
Interaktionsstellen	durch	die	Analyse	des	nichtverwandten	Modell-Enzyms	PfGrx	bestätigen.	
Zudem	 konnte	 ich	 Arg153	 von	 ScGrx7	 als	 eine	 weitere	 mögliche	 „Glutationgerüst“-Stelle	
nachweisen.	Darüber	hinaus	konnte	ich	zeigen,	dass	die	beiden	Ladungsinversionsmutanten	
der	Aminosäurereste	Asp144	und	Glu147	in	der	Helix	3	von	ScGrx7	die	Interaktion	mit	dem	
zweiten	Substrat	GSH	verbesserten.	Demzufolge	scheint	die	Helix	3	dieser	„Funktionsgewinn”-
Mutanten	tatsächlich	die	“Glutathionaktivierungs”-Stelle	zu	beeinflussen.	Außerdem	konnte	
ich	zeigen,	dass	die	eingefügten	Punktmutationen	nur	einen	geringen	Einfluss	auf	den	pKS-
Wert	 des	 Cysteins	 im	 aktiven	 Zentrum	 von	 ScGrx7	 haben.	 Eine	 Modellierung	 der	
Übergangszustände	 und	 weitere	 Analysen	 der	 verschiedenen	 Mutanten	 durch	
Untersuchungen	mit	 roGFP	 könnten	 zukünftig	 helfen,	 die	 Struktur-Funktions-Beziehungen	
von	Grx	weiter	aufzuklären.		
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1	Introduction 
	
1.1	Mitochondrial	protein	import	
1.1.1	Mitochondria	
Mitochondria	are	ubiquitous	organelles	that	can	be	found	in	all	eukaryotes.	They	are	crucial	
for	 different	 cellular	 processes	 including	 energy	 metabolism,	 apoptotic	 cell	 death	 and	
essential	metabolic	 pathways	 such	 as	 iron-sulfur	 cluster	 biosynthesis	 [1,	 2].	 The	 organelle	
evolved	from	endosymbiosis	of	an	anaerobe	progenitor	cell	that	had	engulfed	an	aerobe	a-
proteobacterium	[3].	Thus,	 the	organelle	contains	 its	own	genome	encoding	mitochondrial	
proteins	 that	are	 synthesized	at	 ribosomes	 in	 the	mitochondrial	matrix	 and	are	 crucial	 for	
oxidative	phosphorylation	[1].	However,	these	mitochondrial-encoded	proteins	represent	less	
than	1%	of	the	around	1000	(yeast)	[4-6]	to	1500	(human)	[7,	8]	overall	mitochondrial	proteins.	
The	majority	of	mitochondrial	proteins	(more	than	99%)	are	synthesized	at	ribosomes	in	the	
cytosol	 and	 consequently	 have	 to	 be	 transported	 to	 one	 of	 the	 four	 mitochondrial	
compartments	 (Figure	 1)	 [1].	 For	 trafficking	 proteins	 to	 the	 outer	 membrane	 (OM),	 the	
intermembrane	space	(IMS),	the	inner	membrane	(IM)	or	the	matrix,	different	mitochondrial	
protein	import	(MPI)	pathways	evolved	that	are	described	in	the	following	section.		
	
 
	
 
Figure	1	|	Biogenesis	of	mitochondrial	proteins.	More	than	99%	of	all	mitochondrial	proteins	are	synthesized	at	
cytosolic	ribosomes	and	are	subsequently	imported	into	one	of	the	four	mitochondrial	compartments	(OM,	IMS,	
IM	or	matrix).	Less	than	1%	of	the	mitochondrial	proteins	are	a	relict	of	endosymbiosis	and	are	synthesized	at	
mitochondrial	ribosomes.	OM:	outer	mitochondrial	membrane;	IMS:	intermembrane	space;	IM:	inner	mitochon-
drial	membrane.	Adapted	from	Chacinska	et	al.	2009	[1].	
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1.1.2	Mitochondrial	protein	import	machineries	
Most	of	the	knowledge	of	MPI	derives	from	studies	on	Saccharomyces	cerevisiae,	Neurospora	
crassa or	 mammals,	 which	 are part	 of	 the	 same	 group	 of	 the	 evolutionary	 tree	 – the	
opisthokonts.	The	five	principles	of	MPI	pathways	described	in	this	section	are	mainly	based	
on	these	studies	(Figure	2)	[9,	10].	The	classical	and	first	discovered	pathway	for	MPI	is	called	
the	presequence	pathway.	Precursor	proteins	carrying	a	presequence	are	imported	through	
the	translocase	of	the	OM	(TOM)	complex	as	well	as	the	translocase	of	the	IM	(TIM)	complex.	
Hydrophilic	 proteins	 are	 transported	 to	 the	 matrix	 with	 the	 help	 of	 the	 presequence	
translocase-associated	motor	(PAM),	whereas proteins	with	a	hydrophobic	sorting	signal	are	
inserted	 into	 the	 IM	 [11,	12].	 The	mitochondrial	processing	peptidase	 (MPP)	 in	 the	matrix	
subsequently	removes	the	presequence	and	releases	mature	proteins	[13].	Another	pathway	
for	the	insertion	of	proteins	into	the	IM	is	the	carrier	protein	pathway.	Here,	proteins	enter	
the	 mitochondria	 through	 the	 TOM	 complex	 and	 are	 guided	 by	 the	 help	 of	 small	 TIM	
chaperones	 of	 the	 IMS	 to	 the	 carrier	 translocase	 TIM22,	 which	 subsequently	 inserts	 the	
proteins	 into	 the	 IM	 [14-16].	 Proteins	 of	 the	matrix	 and	 IM	 represent	 around	 80%	 of	 all	
mitochondrial	 proteins	 [17-19].	 All	 proteins	 of	 the	 IMS	 are	 synthesized	 in	 the	 cytosol	 and	
subsequently	have	to	be	transported	to	the	mitochondria	[20].	Cysteine-rich	proteins	of	the	
IMS	usually	 carry	 conserved	motifs	 (twin	Cx3C	or	Cx9C)	and	are	 imported	by	TOM	and	 the	
redox-regulated	MIA	(mitochondrial	IMS	import	and	assembly)	pathway.	This	pathway	acts	as	
a	folding	trap	by	inserting	intramolecular	disulfide	bonds	into	the	substrates,	preventing	them	
from	diffusing	back	to	the	cytosol	 [21].	b-barrel	proteins	of	the	OM	are	 inserted	via	the	b-
barrel	pathway	through	TOM	and	the	sorting	and	assembly	machinery	(SAM)	by	the	help	of	
small	 TIM	 chaperones	 in	 the	 IMS	 [22].	 The	 insertion	 of	a-helical	 proteins	 into	 the	 OM	 is	
achieved	via	the	mitochondrial	import	(MIM)	complex	[9,	22,	23].		
Despite	 significant	 compositional	 differences	 of	 the	MPI	machineries	 in	 several	 eukaryotic	
groups,	the	general	protein	import	pathways	seem	to	be	conserved	among	eukaryotes.	This	
was	previously	shown	using	the	model	organism	Leishmania	tarentolae	(non-opisthokont)	and	
S.	 cerevisiae	 (opisthokont).	 In	 that	 study,	 different	 marker	 proteins	 could	 be	 successfully	
imported	 into	 mitochondria	 of	 the	 respective	 other	 species	 [24].	 For	 this	 work,	 the	
compositional	differences	of	the	oxidative	protein	folding	pathway	of	the	IMS	are	of	major	
interest	and	are	therefore	described	in	detail	below.		
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Figure	 2	 |	 Overview	 of	 the	 five	 mitochondrial	 protein	 import	 pathways.	 Nuclear	 encoded	 mitochondrial	
proteins	 are	 transported	 into	 the	 organelle	 via	 different	 import	 machineries.	 Precursor	 proteins	 carrying	 a	
presequence	are	imported	through	the	TOM-	and	TIM-complex	into	the	matrix	with	the	help	of	PAM	(hydrophilic	
proteins)	 or	 the	 IM	 (proteins	 with	 a	 hydrophobic	 sorting	 signal).	 The	 MPP	 subsequently	 removes	 the	
presequences.	Proteins	of	the	IMS	are	mainly	cysteine-rich	and	are	imported	by	TOM	and	the	MIA	system,	which	
acts	as	a	folding	trap	by	inserting	intramolecular	disulfide	bonds	into	the	substrates.	b-barrel	proteins	that	are	
inserted	into	the	OM	are	translocated	through	TOM	and	SAM	by	the	help	of	small	TIM	chaperones	in	the	IMS.	
Proteins	 of	 the	 IM	 are	 imported	 via	 TOM	 by	 the	 help	 of	 small	 TIM	 chaperones	 of	 the	 IMS	 and	 the	 carrier	
translocase	 TIM22.	 The	MIM	 complex	 imports	a-helical	 proteins	 of	 the	 OM.	 TOM:	 translocase	 of	 the	 outer	
mitochondrial	 membrane,	 TIM:	 translocase	 of	 the	 inner	 mitochondrial	 membrane,	 PAM:	 presequence	
translocase-associated	motor,	 IM:	 inner	mitochondrial	membrane,	MPP:	mitochondrial	processing	peptidase,	
IMS:	intermembrane	space,	MIA:	mitochondrial	IMS	import	and	assembly,	OM:	outer	mitochondrial	membrane,	
SAM:	sorting	and	assembly	machinery,	MIM:	mitochondrial	import.	The	figure	was	taken	from	Wiedemann	et	al.	
2017	[9].		
	
1.1.3	The	Mia40-Erv1	disulfide	relay	system	in	opisthokonta	
The	majority	of	proteins	in	the	IMS	of	yeast	and	other	opisthokonts	are	targeted	and	trapped	
by	oxidative	protein	folding	by	the	help	of	the	oxidoreductase	Mia40	in	cooperation	with	the	
flavoprotein	 Erv1	 (essential	 for	 respiration	 and	 viability;	 Figure	 3	 A)	 [1,	 25,	 26].	 This	MPI	
pathway	was	first	discovered	in	S.	cerevisiae	independently	by	several	groups	in	2004	[21,	27,	
28].	Substrates	of	the	oxidative	folding	pathway	enter	the	IMS	in	a	reduced	and	unfolded	state	
via	the	TOM	complex.	Mia40	exerts	two	functions.	First,	it	serves	as	an	adapter	and	recognizes	
the	 mainly	 conserved	 twin	 Cx3C-	 or	 Cx9C-motif	 of	 its	 substrates.	 Second,	 it	 acts	 as	 an	
oxidoreductase	and	oxidizes	the	cysteine	residues	of	the	unfolded	protein,	yielding	mature	
proteins	 that	 are	 trapped	 in	 the	 IMS	because	of	 the	 formation	of	 intramolecular	 disulfide	
bonds.	An	intermediate	of	this	import	mechanism	is	a	mixed	disulfide	between	Mia40	and	the	
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incoming	substrate.	Once	the	substrate	is	released,	Erv1	re-oxidizes	Mia40.	An	intermediate	
of	 this	 reaction	 is	 a	 mixed	 disulfide	 between	 Mia40	 and	 Erv1	 [29,	 30].	 Reduced	 Erv1	
subsequently	 transfers	 electrons	 to	 the	 respiratory	 chain	 via	 cytochrome	 c [31]. It	 was	
suggested,	that	Erv1	can	also	use	fumarate	and/or	molecular	oxygen	as	alternative	electron	
acceptors	[32,	33].		
	
1.1.4	Mitochondrial	protein	import	in	kinetoplastida	and	apicomplexa	
The	pathway	for	mitochondrial	protein	import	into	the	IMS	via	the	MIA	pathway	was	analyzed	
extensively	in	yeast	(Figure	3	A)	and	was	long	considered	to	be	highly	conserved	in	eukaryotes.	
But	yeast	 together	with	all	mammals	represent	 just	one	out	of	six	or	eight	supergroups	of	
eukaryotes	 (Figure	 4)	 [34-36].	 In	 silico	 analyses	 failed	 to	 reveal	 a	 Mia40	 homolog	 in	
kinetoplastida	and	apicomplexa,	which	belong	to	different	branches	of	the	evolutionary	tree.	
Hence,	the	pathway	for	MPI	into	the	IMS	differs	among	various	eukaryotes	[24,	25,	37,	38].	
However,	conserved	substrates	with	distinct	cysteine-motifs	and	Erv	homologs	can	be	found	
in	 these	parasites.	The	 lack	of	Mia40	suggests	 the	existence	of	a	novel,	 so	 far	unidentified	
component	in	kinetoplastida	and	apicomplexa	that	could	act	as	a	Mia40	replacement	(Figure	
3	B	and	C)	[24,	38].	A	Mia40	adapter	replacement	in	parasitic	protists	might	be	an	interesting	
target	for	future	intervention	strategies	and	drug	development	because	this	novel	component	
is	parasite-specific	and	most	likely	essential.	
 
 
	
Figure	 3	 |	 Comparison	 of	 oxidative	 protein	 folding	 in	 the	 intermembrane	 space	 of	mitochondria.	 Current	
models	of	the	pathway	for	oxidative	protein	folding	in	the	mitochondrial	IMS	of	yeast	and	other	opisthokonta	
(A),	 the	 kinetoplastid	 parasite	 L.	 tarentolae	 (B)	 and	 the	 apicomplexan	 parasite	P.	 falciparum	 (C)	 are	 shown.	
Absent	 or	 unknown	 components	 are	 highlighted	with	 dashed	 lines	 or	 question	marks.	 In	 kinetoplastida	 and	
apicomplexa	 a	 Mia40	 homolog	 is	 missing	 and	 a	 replacement	 candidate	 is	 not	 known	 so	 far.	 OM:	 outer	
mitochondrial	membrane;	IMS:	intermembrane	space;	IM:	inner	mitochondrial	membrane.	Adapted	from	Eckers	
et	al.	2012	[24].		
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Figure	 4	 |	 Opisthokonts	 represent	 just	 one	 of	 several	 eukaryotic	 supergroups.	 The	 parasitic	 protists	 L.	
tarentolae	(Excavata)	and	P.	falciparum	(Chromalveolata)	belong	to	different	branches	of	the	evolutionary	tree.	
The	figure	was	adapted	from	Eckers	et	al.	2012	[24]	and	is	based	on	the	publication	of	Adl	et	al.	2005	[34].	
	
	
1.2	Parasitic	protists	
Parasitic	protists	can	be	found	in	different	branches	of	the	evolutionary	tree	(Figure	4),	for	
instance	apicomplexan	parasites	in	the	branch	of	Chromalveolata	or	kinetoplastid	parasites	in	
the	branch	of	Excavata.	Parasitic	protists	can	cause	severe	human	diseases	and	are	responsible	
for	more	than	a	million	deaths	per	year	worldwide	[39,	40].	Among	these	diseases,	malaria	is	
the	major	cause	of	morbidity	and	mortality	with	0.4-1.1	million	deaths	per	year	between	1990	
and	 2015	 [40-42].	 The	 disease	 is	 caused	 by	 an	 apicomplexan	 parasite	 of	 the	 genus	
Plasmodium.	Only	five	species	out	of	around	200	are	known	to	infect	humans.	Plasmodium	
falciparum	is	the	most	virulent	species	and	responsible	for	most	of	the	severe	cases	of	malaria	
infections	[43,	44].	The	parasite	is	transmitted	by	infected	female	Anopheles	mosquitos	and	
has	a	complex	life	cycle	alternating	between	the	insect	vector	and	the	vertebrate	host.	Other	
major	human	parasitic	diseases	are	caused	by	kinetoplastida	as	outlined	below.		
	
1.2.1	Kinetoplastida		
Kinetoplastida	belong	to	the	phylum	Euglenazoa	and	comprise	several	eukaryotic,	unicellular	
and	flagellated	parasites.	This	class	is	named	after	the	kinetoplast,	a	unique	network	of	DNA	
inside	the	single	mitochondrion	[45].	The	kinetoplast	is	placed	at	the	flagellar	basal	body	of	
the	 organism	 and	 represents	 the	 structurally	 most	 complex	 mitochondrial	 DNA,	 which	 is	
organized	 in	 interlocked	 maxi-	 and	 minicircles	 that	 are	 20-40	 kb	 and	 0.7-2.5	 kb	 in	 size,	
respectively	[46].	The	kinetoplastida	Trypanosoma	brucei,	T.	cruzi	and	different	Leishmania	
species,	which	all	belong	to	the	order	Trypanosomatida,	can	cause	severe	human	diseases	and	
are	one	of	the	oldest	eukaryotic	groups	[47].	Trypanosoma	brucei	is	transmitted	by	the	tsetse	
fly	vector,	is	the	causative	agent	of	African	Trypanosomiasis	(also	called	sleeping	sickness)	and	
caused	 devastating	 epidemics	 in	 the	 past	 century.	 However,	 the	 reported	 cases	 have	
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decreased	every	year	from	around	9000	deaths	in	2010	[40]	to	less	than	3000	cases	in	2015	
[48]	 and	 the	 disease	 is	 targeted	 to	 elimination	 by	 the	World	 Health	 Organization	 (WHO).	
Chagas	disease is	caused	by	infection	with	T.	cruzi	and	threatens	the	lives	of	about	6-7	million	
people	worldwide,	mainly	in	Latin	America	[49].	The	parasite	is	transmitted	by	contact	with	
faeces	or	urine	of	an	infected	triatomine	bug.	The	second	most	deadly	parasitic	disease	after	
malaria, and	the	most	deadly	kinetoplastid	disease	with	estimated	0.7 to	1	million	new	cases	
and	20	000	to	30	000	deaths	per	year,	is	Leishmaniasis	caused	by	different	Leishmania	species	
[50,	 51].	 There	 are	 20	 different	 species	 of	 Leishmania	 that	 cause	 three	 different	 types	 of	
leishmaniasis: cutaneous leishmaniasis (CL,	see	Figure	5 for	epidemiological	situation), which
represents	 the	 most	 common	 type,	 muccocutaneous	 leishmaniasis,	 which	 leads	 to	
deformation	of	the	mouth,	throat	or	nose	and	visceral	leishmaniasis	(VL,	also	called	kala-azar),	
which	represents	the	most	severe	type	[51].	The	most	dangerous	species	for	humans	are	L.	
braziliensis,	 which	 cause	 muccocutaneous	 leishmaniasis	 and	 L.	 donovani	 together	 with	 L.	
infantum,	which	cause	visceral	leishmaniasis	and	lead	to	death	in	95%	of	the	cases	when	left	
untreated	[51].	The	protozoan	parasite	is	transmitted	to	its	mammalian	host	by	the	bite	of	an	
infected	female	phlebotomine	sandfly.	In	the	vertebrate	host,	the	exflagellated,	extracellular	
promastigotic	insect	stage	develops	into	intracellular	amastigotes	[39].	
	
 
Figure	5	|	Epidemiological	situation	of	cutaneous	leishmaniasis.	The	map	shows	the	worldwide	epidemiological	
situation	of	cutaneous	leishmaniasis	 in	2015.	The	majority	of	reported	cases	occurred	in	Afghanistan,	Algeria,	
Brazil,	 Colombia,	 Iran,	 Pakistan,	 Peru,	 Saudi	 Arabia	 and	 the	 Syrian	 Arab	 Republic.	 Source:	 Word	 Health	
Organization	[51].		
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1.2.2	Leishmania	tarentolae	as	a	model	organism	
Leishmania	tarentolae	 is	closely	related	to	the	virulent	Leishmania	species	described	in	the	
previous	section.	It	was	isolated	from	the	gecko	Tarentola	mauritanica,	is	non-infectious	for
humans	and	can	therefore	be	handled	under	S1	security	 level	[52].	Non-infectious	parasite	
species	can	be	useful	to	gain	further	 insights	 into	the	biology	of	their	pathogenic	relatives.	
Leishmania tarentolae, for	instance,	can be	used	as	a	model	organism	for	drug	development	
against	the	infective	agents	of	visceral	and	cutaneous	leishmaniasis	[53].		
Moreover,	the	parasite	is	a	commonly	used	model	organism	for	the	investigation	of	principle	
mechanisms	 such	 as RNA	 editing	 [54-57]. As	 a	 unicellular	 eukaryote, it	 can	 also	 help	 to	
understand	fundamental	processes	in	more	complex	eukaryotic	cells.	For	instance,	it	was	the	
first	parasitic	protist	used	for	the	analysis	of	non-opisthokont	mitochondrial	protein	import	
into	 all	 compartments	 revealing	 a	 functional	 conservation	 among	 eukaryotes	 [24].	
Furthermore,	 studies	 on	 kinetoplastid	 parasites	 were	 crucial	 for	 the	 research	 field	 of	
glycosylphosphatidylinositol	(GPI)	anchors	[58].	The	model	organism	is	particularly	suited	for	
mitochondrial	analyses	as	it	has	only	one	big	mitochondrion	showing	autofluorescence	[59].	
As	 a	 consequence,	 staining	 of	 the	 mitochondria	 for	 microscopy	 is	 not	 necessary.	 Results	
obtained	 from	 analyses	 of	 kinetoplastida	 could	 often	 be	 transferred	 to	 other	 eukaryotes.	
Consequently,	analyses	of	the	mitochondrial	protein	import	in	L.	tarentolae	might	be	helpful	
to	 gain	 more	 insights	 about	 general	 mechanisms	 of	 the	 mitochondrial	 protein	 import	 in	
eukaryotes.		
Furthermore,	 L.	 tarentolae	 became	 an	 important	 tool	 for	 the	 production	 of	 recombinant	
proteins	 in	 recent	 years.	 These	 recombinant	proteins	are	well	 suited	 for	 structural	 studies	
owing	to	their	homogenous	structure	[52].	There	are	a	lot	of	examples	in	literature	showing	
that	biologically	active	and	natively	processed	proteins	could	be	produced	in	L.	tarentolae	[60-
64].	High	yields	of	recombinant	protein	can	be	obtained	because	L.	tarentolae	has	fast	growth	
rates	and	reaches	high	cell	densities	in	culture.	Moreover,	the	parasites	grow	in	comparatively	
cheap	medium	without	serum	[52]	and	under	normal	atmosphere	[61].	Another	advantage	of	
this	expression	system	is	that	the	parasite	cells	can	easily	be	disrupted	compared	to	yeast	cells	
[60].	 In	 conclusion,	 sufficient	 amounts	 of	 mitochondria	 can	 be	 generated	 for	 analyses	 of	
mitochondrial	protein	import	[56]	on	the	basis	of	previously	established	protocols	from	our	
lab	[24].		
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1.3	Methods	for	the	identification	of	potential	interaction	partners
In	 general,	 there	 are	 two	 major	 strategies	 for	 the	 identification	 of	 potential	 interaction	
partners	of	a	known	protein:	(i)	Screening	of	protein	libraries	with	the	known	bait	protein	(a	
classical	 approach	 of	 this	 strategy	 is	 the	 yeast-two	 hybrid	 method)	 or	 (ii)	 the	 de	 novo	
purification	of	protein	complexes	with	the	known	protein	and	subsequent	analyses	by	mass	
spectrometry	 [65].	 Stable	 isotope	 labeling	of	 amino	acids	 in	 cell	 culture	 (SILAC)	 leads	 to	 a	
higher	 specificity	 of	 the	 later	 strategy.	 A	 relatively	 new	 method	 for	 the	 identification	 of	
unknown	 interaction	 partners	 of	 a	 protein	 of	 interest	 is	 the	 proximity-dependent	 biotin	
identification	(BioID)	or	proximity	labeling	by	ascorbate	peroxidase	(APEX).		
	
1.3.1	Stable	isotope	labeling	of	amino	acids	in	cell	culture	(SILAC)	
SILAC	 in	 combination	 with	 semi-quantitative	 mass	 spectrometry	 is	 a	 popular	 method	 for	
proteome-wide	quantification	or	comparison	of	 tagged	and	untagged	bait	protein	samples	
from	a	pull-down	experiment	(Figure	6).	SILAC	was	first	described	in	2002	[66-68]	and	is	based	
on	 the	 metabolic	 incorporation	 of	 essential,	 isotopically	 enriched	 amino	 acids	 into	 the	
proteome	 of	 living	 cells	 [69,	 70].	 One	 subpopulation	 of	 cells,	 expressing	 the	 tagged	 bait	
protein,	is	grown	in	“light”	medium	(containing	normal	isotope	abundance	amino	acids	with	
1H,	12C,	14N),	whereas	the	control	cells	are	grown	in	“heavy”	medium	(containing	the	heavy	
isotope	amino	acids	arginine	and	lysine	with	2H,	13C,	15N)	for	at	least	five	generations	to	ensure	
efficient	 labeling	 of	 the	 proteome	 [69].	 Afterwards,	 the	 cells	 can	 be	 combined	 for	 further	
processing	 to	 ensure	 reproducibility	 of	 the	 experimental	 workflow.	 The	 samples	 are	
subsequently	 fractionated,	 purified	 by	 affinity	 chromatography	 and	 analyzed	 by	 mass	
spectrometry.	Isotopically	labeled	proteins	can	be	distinguished	from	their	normal	isoforms	
because	 of	 a	 mass	 shift.	 Protein-protein	 interactions	 can	 therefore	 be	 identified	 and	
quantified	 with	 the	 advantage	 to	 discriminate	 between	 unspecific	 binding	 and	 actual	
interaction	 partners.	 This	 method	 is	 already	 established	 for	 a	 wide	 range	 of	 organisms	
including	 the	 protist	 L.	 infantum	 [71,	 72].	 Label-free	 mass	 spectrometry	 is	 a	 cheaper	
alternative	for	SILAC	[73].		
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Figure	6	|	Workflow	of	a	SILAC	experiment.	Leishmania	tarentolae	cells	containing	the	tagged	bait	protein	or	
the	respective	control	without	a	tag	are	cultured	in	“light”	medium	(containing	normal	isotope	abundance	amino	
acids)	 or	 “heavy”	medium	 (containing	 the	heavy	 isotope	amino	acids	 arginine	 and	 lysine).	After	 at	 least	 five	
generations,	the	cells	are	fractionated	and	purified	by	affinity	chromatography.	Subsequently,	the	samples	are	
analyzed	by	mass	spectrometry.		
	
1.3.2	Proximity-dependent	biotin	identification	(BioID)	
In	2012,	Roux	et	al.	published	a	new	method	called	proximity-dependent	biotin	identification	
(BioID)	for	the	identification	of	potential	interaction	partners	of	a	protein	of	interest	[74].	The	
approach	is	based	on	an	optimized	prokaryotic	biotin	ligase	from	E.	coli	called	BirA*	that	is	
fused	to	the	protein	of	interest.	The	fusion	construct	is	expressed	in	living	cells	and	was	already	
successfully	used	in	a	variety	of	different	cell	types	including	the	protistic	parasites	T.	brucei	
[75,	76],	Toxoplasma	gondii	[77]	and	different	Plasmodium	species	[78-80].	The	method	was	
also	successfully	used	 in	various	 subcellular	compartments	 including	mitochondria	 [81-83].	
BirA*	generates	reactive	biotinyl-AMP	from	biotin	and	ATP.	Subsequently	the	biotinyl-AMP	
covalently	 reacts	 with	 primary	 amines	 [84].	 Proteins	 in	 the	 close	 proximity	 of	 the	 fusion	
protein	 in	 a	 labeling	 radius	 of	 around	 10-15	 nm	 are	 biotinylated	 [83,	 85,	 86]	 and	 can	
subsequently	be	affinity-purified	by	streptavidin	beads	for	further	analyses	(Figure	7).	There	
are	several	advantages	of	BioID	over	classical	approaches.	First,	the	biotinylated	proteins	can	
be	purified	under	denaturing	conditions	because	of	the	strong	interaction	of	streptavidin	and	
biotin	[85].	Second,	also	weak	and/or	transient	interactions	can	be	potentially	detected	that	
could	 be	 missed	 with	 classical	 approaches	 because	 the	 biotinylated	 interacting	 proteins	
accumulate	over	time	[84].	Third,	protein	interactions	in	their	natural	cellular	context	can	be	
identified	with	BioID.	A	disadvantage	of	 this	approach	 is	 that	 it	does	not	distinguish	actual	
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interacting	proteins	from	proteins	that	are	only	in	close	proximity	of	the	fusion	protein	[84].	
Furthermore,	 the	 labeling	 is	 rather	 slow	 compared	 to	 APEX	 that	 might	 be	 used	 as	 an	
alternative	for	BioID [87].	
 
 
Figure	7	|	Proximity-dependent	biotin	identification	(BioID).	A	fusion	construct	between	the	protein	of	interest	
and	the	optimized	E.	coli	biotin	ligase	BirA*	is	expressed	in	living	cells.	After	incubation	of	the	cells	for	24	h	with	
150	µM	biotin,	proteins	that	are	proximate	to	the	BirA*-fusion	protein	are	biotinylated	and	are	subsequently	
affinity-purified	under	denaturing	conditions	by	streptavidin	beads.	The	potential	 interacting	proteins	can	be	
analyzed	by	western	blotting	and	mass	spectrometry.	Adapted	from	Roux	et	al.	2012	[74].	
	
	
1.4	Glutaredoxins	
	
1.4.1	Functions	of	glutaredoxins	
Glutaredoxins	(Grx)	are	highly	conserved	enzymes	that	play	important	roles	in	redox	catalysis	
and	iron	metabolism	and	can	be	found	in	almost	all	organisms	ranging	from	prokaryotes	to	
yeast,	plants	and	animals	[88-91].	The	small	redox	enzymes	catalyze	thiol-disulfide	exchange	
reactions	with	the	reduced	tripeptide	glutathione	(GHS;	Glu-Cys-Gly)	as	electron	donor	with	
the	major	function	of	reducing	glutathionylated	proteins	[91,	92].	Glutaredoxins	are	part	of	
the	 glutathione	 system	 consisting	 of	 NADPH,	 the	 flavoenzyme	 glutathione	 reductase,	
glutathione	and	Grx	[92].	Glutaredoxins	play	a	crucial	role	for	DNA	synthesis	because	oxidized	
ribonucleotide	reductase	(RR),	an	enzyme	catalyzing	the	production	of	deoxyribonucleotides	
from	 ribonucleotides	 [93],	 is	 a	 physiological	 substrate	 of	 Grx	 [94-97].	 Moreover,	 several	
studies	 showed	 that	 Grx	 plays	 a	 role	 in	 the	 regulation	 of	 apoptosis	 [98-101].	 Altered	 Grx	
contents	and	activities	in	the	cell	may	also	have	medical	implications	as	reviewed	by	Mieyal	et	
al.	or	Lillig	et	al.	for	diabetes,	Parkinson’s	disease,	cancer	and	many	other	diseases	[102-104].		
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1.4.2	Structure	and	classification	
Glutaredoxins	structurally	belong	to	the	superfamily	of	thioredoxins	(Trx),	which	are	defined	
by	a	characteristic	Trx	fold	consisting	of	about	80	residues	that	are	arranged	in	four	b-strands	
and	three	flanking	a-helices	[105].	The	Grx-family	is	highly	diverse	and	isoforms	are	therefore	
often	 classified	 according	 to	 their	 subcellular	 localization,	 enzymatic	 activity	 or	 structural	
property.	Traditionally,	the	different	Grx	isoforms	are	grouped	into	two	subfamilies,	the	so-
called	monothiol	and	dithiol	Grx.	The	classification	depends	on	the	motif	at	the	active	site:	
enzymes	with	a	CxxC-	and	CxxS-motif	are	assigned	as	dithiol	or	monothiol	Grx,	respectively	
[106].	 The	 latter	 ones	 are	 usually,	 except	 for	 ScGrx6/7	 from	 yeast,	 inactive	 in	 standard	
enzymatic	in	vitro	assays	[107-115].	Due	to	moderately	conserved	polar	and	charged	residues	
around	its	active	site,	enzymatically	active	Grx	show	a	preference	for	GSH	and	are	reduced	
non-enzymatically	in	contrast	to	Trx,	which	is	reduced	enzymatically	by	a	specific	reductase	
[106,	113,	116-118].		
	
1.4.3	Mechanism	of	catalysis	
The	traditional	model	of	Grx	catalysis	is	based	on	analyses	of	dithiol	Grx	[119-122]	and	can	be	
separated	 into	 a	 monothiol	 and	 dithiol	 mechanism	 (Figure	 8).	 This	 model	 illustrates	 the	
reduction	of	disulfide	bonds	in	either	glutathionylated	substrates	(monothiol	mechanism)	or	
protein	disulfide	substrates	(dithiol	mechanism).		
The	monothiol	mechanism	 requires	 only	 the	more	 N-terminal	 active	 site	 cysteine	 residue	
[104]	and	is	used	by	classical	dithiol	Grx	as	well	as	monothiol	Grx.	It	occurs	via	a	ping-pong	
mechanism	 that	 can	be	 separated	 into	an	oxidative	and	 reductive	half-reaction	 [106].	 The	
glutathionylated	substrate	 is	 reduced	by	Grx	during	 the	oxidative	half-reaction,	 releasing	a	
deglutathionylated	product	and	a	disulfide	intermediate	between	Grx	and	glutathione	(Grx-
SSG).	During	the	rate-limiting	reductive	half-reaction,	Grx	is	regenerated	by	GSH,	producing	
glutathione	disulfide	(GSSG)	and	deglutathionylated	Grx.		
In	 the	 dithiol	 mechanism,	 protein	 disulfide	 substrates	 are	 reduced	 by	 a	 disulfide	 bond	
exchange	reaction	that	requires	both	cysteines	of	the	active	site	motif.	A	mixed	disulfide	bond	
between	the	substrate	and	Grx	is	formed	as	an	intermediate	before	the	C-terminal	cysteine	
residue	of	the	active	site	motif	generates	an	intramolecular	disulfide	bond	with	the	N-terminal	
cysteine	residue	of	the	CxxC-motif.	Two	molecules	of	GSH	recycle	Grx	in	two	steps	yielding	
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GSSG	 [106].	 The	glutathione	disulfide	 is	 in	both	mechanisms	 subsequently	 regenerated	by	
glutathione	reductase	using	NADPH	as	an	electron	donor	[104].	
		
 
Figure	8	 |	 The	 traditional	monothiol	 and	dithiol	mechanism	of	 glutaredoxin	 catalysis.	On	 the	 left	 side,	 the	
monothiol	mechanism	of	Grx	catalysis	 for	glutathionylated	substrates	 is	 shown.	On	the	right	side,	 the	dithiol	
mechanism	for	the	reduction	of	substrates	with	protein	disulfides	is	shown.	For	the	monothiol	mechanism,	the	
second	cysteine	in	the	active	site	is	not	needed.	The	figure	was	taken	from	Deponte,	2013	[106].	
	
However,	the	traditional	model	does	not	answer	the	question how	exactly the	two	different	
substrates	of	Grx	(the	glutathionyl	moiety	of	protein-bound	RSSG	during	the	oxidative	half-
reaction	and	GSH	during	the	reductive	half-reaction)	are	bound.	Hence,	two	refined	models	
of	 Grx	 catalysis	 namely	 the	 “glutathione	 scaffold	 model” and	 the	 “glutathione	 activator	
model”	 were	 previously	 proposed	 based	 on	 the	 reaction	 geometry	 of	 SN2	 reactions.	 The	
refined	model	could	help	to	distinguish	protein	areas	that	either	interact	with	the	disulfide	
substrate	 (a	 scaffold	 site)	 or	 the	 reducing	 agent	 (an	 activator	 site)	 (Figure	 9)	 [106,	 113].	
Modifications	of	 the	 two	distinct	 substrate	 interaction	 sites	 could	 also	help	 to	 explain	 the	
differences	between	active	and	inactive	monothiol	Grx	in	standard	enzymatic	assays.	Previous	
kinetic	experiments	with	the	model	enzyme	ScGrx7	could	confirm	two	different	glutathione	
interaction	 sites.	 The	 glutathione	 scaffold	 site	 includes	 Glu170	 and	 interacts	 with	 the	
glutathionylated	disulfide	 substrate	 and	 the	 glutathione	 activator	 site	 includes	 Lys105	 and	
interacts	with	GSH	[116].		
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Figure	9	|	The	two	refined	models	of	glutaredoxin	catalysis.	Those	models	could	help	 to	distinguish	protein	
areas	that	either	interact	with	the	glutathione	moieties	of	GSSR	(a	scaffold	site,	marked	in	red)	or	the	reducing	
agent	GSH	(an	activator	site,	marked	in	blue).	The	two	models	are	nonexclusive	and	might	also	be	combined	to	
one	mechanistic	model.	The	figure	was	taken	from	Begas	et	al.	2017	[116].	
	
1.4.4	Glutaredoxin	assays	
Different	 enzymatic	 assays	 exist	 to	 study	 the	 exact	 structure-function	 relationships	 and	
differences	among	enzymatically	active	and	inactive	Grx	that	have	so	far	remained	elusive.	
These	assays	use	either	physiological	substrates	such	as	RR	or	artificial	low	molecular	weight	
disulfide	substrates.	A	set	of	GSH-dependent	coupled	spectrophotometric	assays	with	bis(2-
hydroxyethyl)disulfide	 (HEDS)	 as	 a	 non-glutathione	 substrate	 or	 L-cysteine-glutathione	
disulfide	(GSSCys)	as	a	glutathionylated	substrate	were	established	for	ScGrx7	from	yeast	as	a	
model	enzyme	 in	previous	studies	 from	our	group	(Figure	10)	 [112,	116,	123].	Glutathione	
disulfide	 (GSSG)	 is	 a	 product	 of	 this	 reaction	 and	 is	 subsequently	 recycled	 by	 glutathione	
reductase.	The	enzyme	activity	is	monitored	spectrophotometrically	by	the	consumption	of	
NADPH	[123].	The	HEDS	assay	was	already	established	in	1968	by	Nagai	and	Black	[124]	and	
since	then	the	assay	was	used	to	determine	the	activity	of	various	Grx	isoforms	from	different	
organisms	such	as	Grx	from	P.	falciparum	[125],	Grx1	and	Grx2	from	T.	brucei	[126],	the	dithiol	
ScGrx1,	 ScGrx2	 [127,	 128]	 and	 ScGrx8	 [113]	 from	 S.	 cerevisiae	 as	 well	 as	 the	 unusual	
monothiols	ScGrx6	and	ScGrx7	[112].		
 
 
	
	
Figure	10 |	Substrates	of	glutaredoxins. Several	coupled	enzymatic	assays	exist	to	measure	the	activity	of	Grx.	
Besides	physiological	substrates	such	as	ribonucleotide	reductase,	artificial	low	molecular	weight	substrates	are	
often	used.	On	the	left	side,	the	reduction	of	high-	and	low-molecular	weight	glutathione	disulfide	substrates	
such	as	GSSCys	is	shown.	On	the	right	side,	the	reduction	of	non-glutathione	disulfide	substrates	such	as	HEDS	is	
displayed.	GSH	is	used	as	an	electron	donor	for	the	reduction	and	glutathione	disulfide	(GSSG)	is	produced.	The	
figure	was	taken	from	Begas	et	al.	2017	[116].	
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1.4.5	Glutaredoxins	in	yeast	
Saccharomyces	cerevisiae	has	eight	Grx,	from	which	five	belong	to	the	group	of	monothiol	Grx	
(ScGrx3-7)	and	three	are	dithiol	Grx	(ScGrx1/2/8) [104,	112,	113,	129].	The	different	Grx	vary	
in	their	active	site	and	subcellular	localization	(Figure	11).	The	two	dithiol	ScGrx1	and	ScGrx2	
share	a	typical	CPYC-motif	in	their	active	site	and	a	high	identity	of	64%	with	respect	to	their	
amino	acid	residues [127].	ScGrx8 was	discovered	much	later	and	has	an	unusual	CPDC-motif	
in	its	active	site	[113].	All	three	dithiol	Grx	from	yeast	were	shown	to	be	active	in	the	classical	
HEDS	assay,	although	ScGrx8	has	very	little	activity	[113,	130].	ScGrx2	is	dually	targeted	to	the	
cytosol	and	mitochondria,	 in	contrast	to	ScGrx1	and	ScGrx8 that	do	not	contain	a	targeting	
signal	[113,	131].	The	two	monothiol	enzymes	ScGrx3	and	ScGrx4	are	both	dually	localized	to	
the	cytosol	and	nucleus	and	play	an	important	role	in	iron	trafficking	and	iron	sensing	[132].	
The	monothiol	ScGrx5	possesses	a	mitochondrial	targeting	sequence	and	is	therefore	localized	
in	 the	 mitochondrial	 matrix.	 It	 was	 the	 first	 Grx-isoform	 shown	 to	 play	 a	 role	 in	 iron	
metabolism	[133]	and	is	important	for	the	protection	against	oxidative	damage	[134].	The	two	
monothiol	 isoforms	ScGrx6	and	ScGrx7	are	remarkable	due	to	 their	 subcellular	 localization	
and	their	activity	in	the	HEDS	assay.	They	were	the	first	Grx	that	were	found	in	the	secretory	
pathway	 of	 eukaryotes	 and	 are	 anchored	 in	 the	 Golgi	 with	 a	 suggested	 role	 in	 redox	
homeostasis	[114,	115].	Furthermore,	they	were	the	first	and	only	monothiol	Grx	that	were	
shown	to	be	active	in	the	HEDS	assay	[112,	135].	ScGrx7	is	an	excellent	model	enzyme	owing	
to	its	high	activity	in	kinetic	assay.	Moreover,	the	reaction	is	neither	further	complicated	by	
an	additional	cysteine	in	the	active	site	nor	by	iron-sulfur	cluster	binding	[123].	Not	much	is	
known	about	the	physiological	substrates	and	the	exact	catalytic	mechanisms	of	the	different	
Grx	in	yeast,	which	is	surprising	since	Grx	were	already	described	four	decades	ago	[94].		
	
 
Figure	11	|	Intracellular	distribution	of	the	glutaredoxins	in	yeast.	The	intracellular	distribution	of	the	two	dithiol	
Grx	(ScGrx1/2)	and	the	five	monothiol	Grx	(ScGrx3-7)	is	shown.	The	active	site	is	marked	in	red.	Please	note,	that	
dithiol	ScGrx8	is	not	shown	in	this	overview.	TM:	transmembrane	domain,	M:	mitochondrial	signal	peptide,	Trxl:	
thioredoxin-like	domain.	The	figure	was	taken	from	Lillig	et	al.	2008	[104].		
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1.4.6	Glutaredoxins	in	Plasmodium	falciparum	
Plasmodium	falciparum	only	possesses	one	known	classical	dithiol	Grx	that	is	located	in	the	
cytosol [125,	136,	137].	PfGrx	has	three	cysteines	in	total,	of	which	two	are	in	a	classical	CPYC-
motif	(residue	29	and	32)	and	one	additional	cysteine	is	 in	a	GGC-motif	at	positon	88	[123,	
138].	The	fully	functional	monothiol	mutant	PfGrxC32S/C88S,	that	was	recently	established	in	our	
lab,	 does	 not	 have	 complicated	 side	 reactions	 and	 allows	 a	 direct	 comparison	with	 other	
monothiol	glutaredoxins	[138].	The	crystal	structure	of	PfGrx	was	resolved	in	2014	revealing	
structural	conservation	of	the	glutathione-binding	motifs	with	other	Grx	[139].	A	proteomic	
approach	 identifying	 17	 hypothetically interacting	 partners	 of	 PfGrx	 could	 show that	 the	
functions	of	PfTrx	and	PfGrx	seem	to	partially	overlap	[140].	The	identified	candidate	target	
proteins	point	 to	a	 function	of	PfGrx	 in	different	processes	 such	as	anti-oxidative	defense,	
transcription/translation,	 protein	 folding	 and	 signal	 transduction	 [140].	 In	 addition	 to	 the	
classical	 dithiol	 Grx,	P.	 falciparum	 has	 three	monocysteinic	 Grx-like	 proteins	 (PfGlp1-3)	 of	
unknown	physiological	function	with	the	second	cysteine	replaced	by	a	serine	in	the	active	
site	 [108,	 136].	 Due	 to	 solubility	 reasons	 it	 was	 not	 yet	 possible	 to	 investigate	 the	
mitochondrial	 PfGlp3	 with	 a	 CKYS-motif	 in	 the	 active	 site	 [108,	 137].	 The	 two	 other	
cytosolically	located	Grx-like	proteins	of	P.	falciparum	were	not	active	in	a	classical	Grx	assay,	
which	is	in	accordance	with	typical	monothiol	Grx	[108,	137].		
	
 
1.5	Aim	of	this	work	
The	main	objective	of	this	PhD	was	the	identification	of	a	Mia40	adapter	replacement	in	the	
non-pathogenic	 parasite	 L.	 tarentolae,	 which	 is	 a	 close	 relative	 to	 human	 pathogenic	
kinetoplastida.	As	the	mitochondrial	protein	import	into	the	IMS	is	redox-regulated,	different	
approaches	 were	 tested	 for	 potential	 trapping	 of	 mixed	 disulfide	 intermediates.	 For	 this	
purpose,	L.	tarentolae	small	Tim1	(LtsTim1)	could	serve	as	a	reference	substrate	with	a	twin	
Cx3C-motif	that	should	interact	with	the	oxidized	Mia40	adapter	replacement.	The	reduced	
adapter	 should	 subsequently	 interact	 with	 LtErv.	 Methods	 such	 as	 chemical	 trapping	 for	
stabilization	of	the	mixed	disulfide	intermediates,	SILAC	or	BioID	could	be	helpful	to	identify	
the	so	far	unknown	protein	in	the	oxidative	folding	pathway	of	the	IMS.	The	already	published	
genome	sequence	of	L.	tarentolae	will	be	helpful	for	a	potential	SILAC	experiment	followed	by	
mass	spectrometry	[141].	
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The	 second	 objective	 of	 this	 PhD	 was	 to	 analyze	 the	 general	 applicability	 of	 the	 results	
obtained	 from	prior	 analysis	 of	 ScGrx7,	which	 revealed	 a	 distinct	 glutathione	 scaffold	 and	
activator	site during	the	MD	thesis	of	Patricia	Begas.	Thus, PfGrx	should	be	analyzed	as	a	non-
related	model	system.	Additional	residues	of	ScGrx7	that	were	previously	suggested	to	be	part	
of	 the	 glutathione	 activator	 site	 should	 be	 analyzed	 to	 gain	 more	 insights	 into	 the	 exact	
structure-function	relationships	of	Grx and	to	define	the	substrate	interaction sites in	more	
detail.		
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2	Materials	and	Methods	
	
	
2.1	Materials	and	equipment	
	
2.1.1	Technical	equipment		
Table	1	|	List	of	technical	equipment.	
Technical	equipment	 Description	and	Manufacturer	
Autoclave	 VX-95;	Systec	GmbH	
Balance	 TE124S-OCE;	Sartorius	
Kern	EW;	Kern	&	Sohn	GmbH	
Blotting	device	(semi-dry)	 PerfectBlue	SEDEC	M;	Peqlab	
Centrifuges	 5417R;	Eppendorf	
J-6B,	J2-21M/E	with	JA-10/17	rotor;	Beckman	Coulter	GmbH	
Counting	chamber	 Neubauer	counting	chamber	improved;	Carl	Roth	GmbH	
Developing	machine		 Curix	60;	AGFA	
DNA	electrophoresis	apparatus	 Bio-Rad	
Electroporator	for	L.	tarentolae	 Nucleofector™	2b	Device;	Lonza	
Gel	chambers	for	SDS-PAGE Mini-PROTEAN™ Tetra	Cell;	BioRad
Gel	documentation	device	 E.A.S.Y	440	K,	UV	transilluminator	(UVT-28L);	Herolab	
Heating	block	 MBT	250;	Kleinfeld	Labortechnik	
Thermomixer comfort;	Eppendorf
Incubator	for	E.	coli	 Heraeus;	Thermo	Fisher	Scientific	
Incubator	for	L.	tarentolae	 Memmert	
Magnetic	stirrer	 MR	Hei-Standard;	Heidolph	Instruments	
Microscope	 AE30;	Motic	
Zeiss	LSM780	
Microwave	 AEG	
Peristaltic	pump	 Pump	P-1;	GE	Healthcare	
pH	electrode	 pH	electrode	PY-P10;	Sartorius	
pH-meter	 Basic	Meter	PB-11;	Sartorius	
Pipettes	 PIPETMAN™;	Gilson	
Pipetus		 Accu-jet™	pro;	Brand	
Portable	photometer	 Ultrospec	10;	Amersham	Biosciences	
Power	supply	 PowerPac™	Basic;	Bio-Rad	
EPS	601;	Amersham	Biosciences	
Red-light	lamp	 Electric	Petra	
Rotating	wheel	 Grant-bio	PTR30	
Shaking	device	for	L.	tarentolae	 Rotamax	120;	Heidolph	Instruments	
Shaking	device	for	western	blotting	 Duomax	1030;	Heidolph	Instruments	
Shaking	incubator	for	E.	coli	 Innova	4000	shaker;	Infors	AG	
Spectrophotometer	 NanoDrop™;	Thermo	Fisher	Scientific	
Sterile	hood	for	E.	coli		 	 Gelaire™	BSB	3A	
Sterile	hood	for	L.	tarentolae	 SAFE	2020;	Thermo	Fisher	Scientific	
Thermocycler	 Mastercycler	gradient;	Eppendorf	
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Ultrasonic	device	 Sonoplus	HD	2070;	BANDELIN	electronic	
UV/Vis	spectrophotometer	 V-650	spectrophotometer;	JASCO	
Vortex-mixer	 Heidolph	Instruments	
Water	bath	 F12-ED;	JULABO	
	
2.1.2	Disposables	
Table	2	|	List	of	disposables.		
Disposable	 Supplier	
0.2	µm	sterile	filters	 Merck	KGaA	
125	ml	Erlenmeyer	flasks	 Corning	
1.5	and	2	ml	reaction	tubes	 Sarstedt	AG	&	Co	
15	and	50	ml	reaction	tubes	 Sarstedt	AG	&	Co	
Cell	culture	flasks	(25	cm2	T-flasks)	 Corning	
Cryotubes	 Greiner	Bio-One	
Cuvettes	(single-use)	 Sarstedt	AG	&	Co	
Microscope	slides		 Buddeberg	
Needles	 BD	Microlance	3	needle,	0.4	x	19	mm	
Nitrocellulose	membrane	 GE	Healthcare	
Parafilm	 Sigma-Aldrich	
PCR	reaction	tubes	 Kisker	Biotech	
Petri	dishes	 Sarstedt	AG	&	Co	
Pipette	tips	 Steinbrenner	
Poly-Prep	chromatography	columns	 Bio-Rad	
Quartz	cuvettes	104B-OS	 Hellma	
Scalpel	 B.	Braun	Melsungen	AG	
Serological	pipettes	 Sarstedt	AG	&	Co	
Super	RX	western	blot	films	 Fuji	
Syringes	 BD	
Whatman™	paper	 GE	Healthcare	
2.1.3	Chemicals	
Table	3	|	List	of	chemicals.		
Chemical	 Supplier	
Acetic	acid	 Merck	KGaA	
Acetone	 Honeywell	
Acrylamide/bisacrylamide	solution	37.5:1	 Serva	Electrophoresis	GmbH	
Agar	 Sigma-Aldrich	
Agarose	 Serva	
AlbuMax™	II	Lipid-Rich	BSA	 Thermo	Fisher	Scientific	
Amersham™	ECL™	Western	Blotting	Reagent	 GE	Healthcare	
Ammonium	persulfate	(APS)	 Sigma-Aldrich	
Ampicillin	 AppliChem	GmbH	
Atto	594-Streptavidin	 Sigma-Aldrich	
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Biotin	 Sigma-Aldrich	
β-mercaptoethanol	 Sigma-Aldrich	
Bradford	reagent	 Bio-Rad	Laboratories	GmbH	
BSA	 Serva	Electrophoresis	GmbH	
Bromophenol	blue	 Waldeck	GmbH	&	Co.	KG	
Calcium	chloride	 Merck	KGaA	
cOmplete™	EDTA-free	protease-inhibitor	cocktail	 Roche	
Coomassie	Brilliant	Blue	G-250	 AppliChem	GmbH	
D-glucose	monohydrate	 Merck	KGaA	
Diamide	 Sigma-Aldrich	
Digitonin	 AppliChem	
DMSO	 Sigma-Aldrich	
DNA	ladder	(100	bp,	1	kb)	 New	England	Biolabs	
dNTPs	 Thermo	Scientific	
DTT	 Sigma-Aldrich	
EDTA	 Sigma-Aldrich	
Ethanol	 Zentralbereich	Neuenheimer	Feld	
Ethanol	absolute	 VWR	Chemicals	
FCS,	dialyzed	 Silantes	
FCS,	heat-inactivated	 Life	Technologies	GmbH	
Folic	acid	 Sigma-Aldrich	
G418-disulfate	solution	 AppliChem	GmbH	
Gel	loading	dye,	Purple	6´	 New	England	Biolabs	
Glycerol	 AppliChem	GmbH	
Glycine	 Merck	KGaA	
GSH	 Sigma-Aldrich	
GSSCys	 Toronto	Research	Chemicals	
GSSG	 Sigma-Aldrich	
Hydrochloric	acid	 VWR	
HEDS	 Alfa	Aesar	
Hemin	chloride	 Calbiochem	
HEPES Merck	KGaA
Imidazole	 AppliChem	GmbH	
Iodoacetamide	 Sigma-Aldrich	
IPTG Serva
Luria	Bertani	(LB)	medium	 Carl	Roth	GmbH	+	Co.	KG	
Luria	Bertani	(LB)	agar	 Carl	Roth	GmbH	+	Co.	KG	
Manganese(II)	chloride	 Merck	KGaA	
Methanol	 Honeywell	Research	Chemicals	
Midori	Green	Advance	 Nippon	Genetics	
Milk	powder	 Carl	Roth	GmbH	+	Co.	KG	
MMTS	 Thermo	Fisher	Scientific	
MOPS	 GERBU	Biotechnik	GmbH	
NADPH	 GERBU	Biotechnik	GmbH	
NEM	(N-ethylmaleimide)	 Sigma-Aldrich	
Ni-NTA	agarose	 Qiagen	
Paraformaldehyde	 Sigma-Aldrich	
PonceauS	 Serva	Electrophoresis	GmbH	
Potassium	acetate	 Sigma-Aldrich	
Potassium	chloride	 AppliChem	GmbH	
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Potassium	dihydrogenphosphate		 Merck	KGaA	
Prestained	protein	ladder	 Thermo	Scientific	
2-propanol	 Sigma-Aldrich	
Protease	inhibitor	cocktail	tablets	cOmplete,	EDTA-free	 Roche	
Rubidium	chloride	 AppliChem	GmbH	
Saponin	 Sigma-Aldrich	
Sodium	acetate	 Sigma-Aldrich	
Sodium	borohydride	 AppliChem	GmbH	
Sodium	chloride	 Sigma-Aldrich	
Sodium	dihydrogen	phosphate	 Merck	KGaA	
Sodium	dodecyl	sulfate	 Serva	Electrophoresis	GmbH	
Sodium	hydroxide	 Sigma-Aldrich	
Sodium	phosphate	dibasic	 Merck	KGaA	
Streptavidin-HRP	 Abcam	
Sucrose	(D-sucrose)	 AppliChem	
TEMED	 Serva	Electrophoresis	GmbH	
Trichloroacetic	acid	 Merck	KGaA	
Tri-sodium	citrate	dihydrate	 Merck	KGaA	
Tris		 Carl	Roth	GmbH	+	Co.	KG	
Triton™	X-100	 Merck	KGaA	
Tween™	20	 Sigma-Aldrich	
Unstained	protein	ladder	 Thermo	Scientific	
Urea	 Serva	Electrophoresis	GmbH	
	
2.1.4	Enzymes		
Table	4	|	List	of	enzymes.		
Enzyme	 Supplier	
DNaseI	 Sigma-Aldrich	
Lysozyme	 Serva	Electrophoresis	GmbH	
Pfu	Polymerase	 Promega	
Restriction	enzymes	 New	England	Biolabs	
RNAse	A	 Sigma-Aldrich	
ScGR	 Sigma-Aldrich	
T4-ligase	 Fermentas	
	
2.1.5	Cell	culture	media	
Table	5	|	List	of	cell	culture	media.		
Cell	culture	medium	 Supplier	
BHI	 BD	
DMEM	(#42430025)	 Thermo	Fisher	Scientific	
DMEM/F-12	(#11330032)	 Thermo	Fisher	Scientific	
IMDM	(#12440053)	 Thermo	Fisher	Scientific	
McCoy’s	5A	(#26600023)	 Thermo	Fisher	Scientific	
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MEM	(#31095029)	 Thermo	Fisher	Scientific	
RPMI-1640	(#52400-041)	 Thermo	Fisher	Scientific	
	
2.1.6	Kits	
Table	6	|	List	of	kits.	
Kit	 Supplier	
Basic	Parasite	Nucleofector™	Kit	2	 Lonza	
Qiagen	Plasmid	Midi	Kit	 Qiagen	
Qiaprep™	Spin	Miniprep	Kit	 Qiagen	
Wizard™	SV	Gel	and	PCR	Clean-Up	System	 Promega	
	
2.1.7	Plasmids	and	constructs	
Table	7	|	List	of	plasmids/constructs.		
Plasmid	 Details	 Reference	
pQE30	 AmpR,	N-terminal	MRGSH6GS-tag,	T5-Promoter	 Qiagen	
pQE30	SCGR	 SCGR	(BamHI/HindIII),	N-terminal	His6-tag	 Urscher	et	al.	2012	[142]	
pQE30	SCGRX7	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag	
Mesecke	et	al.	2008	[112]	
pQE30	SCGRX7K105A	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	K105A	
Begas	et	al.	2017	[116]	
pQE30	SCGRX7K105E	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	K105E	
Begas	et	al.	2017	[116]	
pQE30	SCGRX7Y110A	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	Y110A	
this	work	
pQE30	SCGRX7Y110F	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	Y110F	
this	work	
pQE30	SCGRX7Y110H	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	Y110H	
this	work	
pQE30	SCGRX7D144A	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	D144A	
this	work	
pQE30	SCGRX7D144K	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	D144K	
this	work	
pQE30	SCGRX7E147A	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	E147A	
this	work	
pQE30	SCGRX7E147K	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	E147K	
this	work	
pQE30	SCGRX7R153A	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	R153A	
this	work	
pQE30	SCGRX7R153E	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	R153E	
this	work	
pQE30	SCGRX7E170A	 SCGRX7	(BamHI/SalI)	starting	from	amino	acid	V34,	
N-terminal	His6-tag,	point	mutation	E170A	
Begas	et	al.	2017	[116]	
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pQE30	PFGRXC32S/C88S	 PFGRX	(BamHI/HindIII),	N-terminal	His6-tag,	point	
mutation	C32S	and	C88S	
Djuika	et	al.	2013	[138]	
pQE30	PFGRXC32S/C88S/K26A	 PFGRX	(BamHI/HindIII),	N-terminal	His6-tag,	point	
mutation	C32S,	C88S	and	K26A	
this	work	[116]	
pQE30	PFGRXC32S/C88S/D90A	 PFGRX	(BamHI/HindIII),	N-terminal	His6-tag,	point	
mutation	C32S,	C88S	and	D90A	
this	work	[116]	
pX	 AmpR,	NeoR,	C-terminal	TAP-tag	 LeBowitz	et	al.	1990	[143]	
pX-backbone	 removal	of	TAP-tag	(CBP,	TEV-site,	ProtA)	and	Flag-
tag,	introduction	of	N-terminal	His8-tag	and	MCS	
this	work	
pX	LTERV	 LTERV	(BamHI/HindIII)	in	pX-backbone	 this	work	
pX	His8-LTERV	 LTERV	(XbaI/HindIII)	in	pX-backbone,	N-terminal	
His8-tag	
this	work	
pX	LTERVC63S	 LTERV	(BamHI/HindIII)	in	pX-backbone,	point	
mutation	C63S	
this	work	
pX	His8-LTERV
C63S	 LTERV	(XbaI/HindIII)	in	pX-backbone,	N-terminal	
His8-tag,	point	mutation	C63S	
this	work	
pX	LTsTIM1	 LTsTIM1	(BamHI/HindIII)	in	pX-backbone	 this	work	
pX	His8-LTsTIM1	 LTsTIM1	(XbaI/HindIII)	in	pX-backbone,	N-terminal	
His8-tag	
this	work	
pX	LTsTIM1C1-3S	 LTsTIM1	(BamHI/HindIII)	in	pX-backbone,	point	
mutations	C36S,	C40S	and	C58S	
this	work	
pX	His8-LTsTIM1
C1-3S	 LTsTIM1	(XbaI/HindIII)	in	pX-backbone,	N-terminal	
His8-tag,	point	mutations	C36S,	C40S	and	C58S	
this	work	
pX	LTsTIM1C2-4S	 LTsTIM1	(BamHI/HindIII)	in	pX-backbone,	point	
mutations	C40S,	C58S	and	C62S	
this	work	
pX	His8-LTsTIM1
C2-4S	 LTsTIM1	(XbaI/HindIII)	in	pX-backbone,	N-terminal	
His8-tag,	point	mutations	C40S,	C58S	and	C62S	
this	work	
pX	PFERV	 PFERV	(BamHI/HindIII)	 this	work	
pX	His8-PFERV	 PFERV	(XbaI/HindIII),	N-terminal	His8-tag	 this	work	
	
2.1.8	Oligonucleotides	(primers)	
Table	8	|	List	of	primers.	Name	and	sequence	of	the	primers	used	for	side-directed	mutagenesis,	cloning	and	
sequencing	 are	 listed.	 The	mutation	 introduced	 by	 the	mutagenesis-primers	 is	 highlighted.	 All	 primers	were	
purchased	from	Metabion	or	were	selected	from	the	GATC	repertoire	for	sequencing.	
	
Mutagenesis	primer	 Sequence	
SCGRX7/Y110A/s	 5’-GCAAGACTGGCTGCCCAGCTAGCAAAAAACTGAAAGC-3’	
SCGRX7/Y110A/as	 5’-GCTTTCAGTTTTTTGCTAGCTGGGCAGCCAGTCTTGC-3’	
SCGRX7/Y110F/s	 5’-GCAAGACTGGCTGCCCATTTAGCAAAAAACTGAAAGC-3’	
SCGRX7/Y110F/as	 5’-GCTTTCAGTTTTTTGCTAAATGGGCAGCCAGTCTTGC-3’	
SCGRX7/Y110H/s	 5’-GCAAGACTGGCTGCCCACATAGCAAAAAACTGAAAGC-3’	
SCGRX7/Y110H/as	 5’-GCTTTCAGTTTTTTGCTATGTGGGCAGCCAGTCTTGC-3’	
SCGRX7/D144A/s	 5’-CACACAAAAGAACTACAAGCCCAGATTGAAAAAGTCACTGG-3’	
SCGRX7/D144A/as	 5’-CCAGTGACTTTTTCAATCTGGGCTTGTAGTTCTTTTGTGTG-3’	
SCGRX7/D144K/s	 5’-CACACAAAAGAACTACAAAAACAGATTGAAAAAGTCACTGG-3’	
SCGRX7/D144K/as	 5’-CCAGTGACTTTTTCAATCTGTTTTTGTAGTTCTTTTGTGTG-3’	
SCGRX7/E147A/s	 5’-GAACTACAAGACCAGATTGCAAAAGTCACTGGTAGGAGAAC-3’	
SCGRX7/E147A/as	 5’-GTTCTCCTACCAGTGACTTTTGCAATCTGGTCTTGTAGTTC-3’	
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SCGRX7/E147K/s	 5’-GAACTACAAGACCAGATTAAAAAAGTCACTGGTAGGAGAAC-3’	
SCGRX7/E147K/as	 5’-GTTCTCCTACCAGTGACTTTTTTAATCTGGTCTTGTAGTTC-3’	
SCGRX7/R153A/s	 5’-GAAAAAGTCACTGGTAGGGCAACAGTCCCAAACGTTATCATC-3’	
SCGRX7/R153A/as	 5’-GATGATAACGTTTGGGACTGTTGCCCTACCAGTGACTTTTTC-3’	
SCGRX7/R153E/s	 5’-GAAAAAGTCACTGGTAGGGAAACAGTCCCAAACGTTATCATC-3’	
SCGRX7/R153E/as	 5’-GATGATAACGTTTGGGACTGTTTCCCTACCAGTGACTTTTTC-3’	
PFGRX/32S/88S/K26A/s	 5’-GAACATCATTGCTGTATTTGCAGCAACGGAATGCCCATATAG-3’	
PFGRX/32S/88S/K26A/as	 5’-CTATATGGGCATTCCGTTGCTGCAAATACAGCAATGATGTTC-3’	
PFGRX/32S/88S/D90A/s	 5’-CGTTGTCGGCGGAAGTGATGCTTTAGTTAAAGAAAATGATG-3’	
PFGRX/32S/88S/D90A/as	 5’-CATCATTTTCTTTAACTAAAGCATCACTTCCGCCGACAACG-3’	
Cloning	primer	 Sequence	
p/LTERV/BamHI/s	 5’-GATCGGATCATGTCGGACGACGACGTACACG-3’	
p/LTERV/SpeI/as	 5’-GATCACTAGTGAGCTTGAGTTCTTCGTCCTCTG-3’	
p/pX/backbone/s	 5’-GATCCATGCATCATCACCATCATCACCATCACTCTAGAAAGCTTGC-3’	
p/pX/backbone/as	 5’-GGCCGCAAGCTTTCTAGAGTGATGGTGATGATGGTGATGATGCATG-3’	
p/pX/BirA/XmaI/s	 5’-GATCCCCGGGATGGAACAAAAACTCATCTCAGAAGAG-3’	
p/pX/BirA/BamHI/as	 5’-GATCGGATCCGCGGTTTAAGCTTAAGCTTGG-3’	
p/pX/PFERV/BamH1/s	 5’-GATCGGATCCATGATATTTATTGAAAAGTGCTATGAAC-3’	
p/pX/PFERV/HindIII/as	 5’-GATCAAGCTTTTAATCAACTGTTTTGTACTTGTCAATT-3’	
p/pX/PFERV/XbaI/s	 5’-GATCTCTAGAATATTTATTGAAAAGTGCTATGAAC-3’	
Sequencing	primer	 Sequence	
pQE/s	 5’-CGGATAACAATTTCACACAG-3’	
pQE/as	 5’-GTTCTGAGGTCATTACTGG-3’	
p/pX/LS/s	 5’-CACCCTCAACCACCCCTCA-3’	
p/pX/far/as	 5’-CACCCCAGGCTTTACACTT-3’	
	
2.1.9	Antibodies	
Table	 9	 |	 List	 of	 antibodies.	 Name	 and	 origin	 of	 the	 antibodies	 used	 for	 western	 blot	 analyses	 and	
immunofluorescence	microscopy	are	listed.	All	antibodies	used	for	western	blot	analyses	were	diluted	in	5%	milk	
in	TBS	as	indicated.		
	
Primary	antibody	 Dilution	 Origin	
Mouse	αEF1α	 1:10000	 Merck	Millipore	
Mouse	αMyc 1:1000 abcam
Rabbit	αLtErv	 1:500	 Eckers	et	al.	2012	[24]	
Rabbit	αLtsTim1	 1:500	 Eckers	et	al.	2012	[24]	
Rabbit	αPfErv 1:200 Eckers	et	al.	2013 [38]
Secondary	antibody	 	 	
Goat	αMouse	IgG	(H+L)-HRP	conjugate	 1:5000	–	1:10000	 BioRad	
Goat	αMouse	Alexa	Fluor	488	 1:500	 Invitrogen	
Goat	αRabbit	IgG	(H+L)-HRP	conjugate 1:5000	– 1:10000 BioRad
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2.1.10	Software	and	Databases	
Table	10	|	List	of	software,	databases	and	online	tools.	
Software	 Copyright,	Webpage	
BioEdit	7.2.5	 Tom	Hall	
Clustal	Omega	 www.ebi.ac.uk/Tools/msa/clustalo/	
Corel	Draw	X7	 Corel	Corporation	
EndNote	X6	 Thomson	Reuters	
Excel	2010	 Microsoft	
JustBio	 www.justbio.com	
Power	Point	 Microsoft	
SigmaPlot	12.5	and	SigmaPlot	13	 Systat	Software	Inc.	
Spectra	Manager	 JASCO	
TriTrypDB	 www.tritrypdb.org	
Word	2010	 Microsoft	
ZEN2010	 Zeiss	
 
2.2	Molecular	biological	methods	
2.2.1	Generation	of	chemically	competent	E.	coli	XL1-Blue	cells	
Chemically	 competent	E.	 coli	 XL1-Blue	 cells	were	 used	 for	 the	 production	 of	 recombinant	
proteins	and	for	cloning	of	plasmids.	All	buffers	were	sterilized	using	a	0.2	µm	filter	before	use	
and	aliquots	were	stored	at	-	20°C.	A	50	µl	aliquot	of	an	old	batch	of	competent	XL1-Blue	cells	
was	transferred	to	a	4	ml	pre-culture.	This	culture	was	inoculated	in	500	ml	LB	medium	in	two	
1	l	flasks	the	next	morning.	The	cultures	were	incubated	overnight	at	20°C	and	160	rpm	in	the	
Innova	4000	shaker.	Aliquots	of	150	ml	TFB1	and	10	ml	TFB2	were	thawed	and	transferred	to	
an	ice-water	bath	before	use.	After	reaching	an	OD600nm	of	0.5,	the	cells	were	pre-cooled	in	an	
ice-water	bath	 for	 10	min	 and	 centrifuged	 at	 2600	×	g	 for	 15	min	 at	 4°C.	Afterwards,	 the	
supernatant	was	discarded	and	the	pellet	was	resuspended	in	75	ml	ice-cold	TFB1	buffer	per	
250	 ml	 culture.	 The	 suspensions	 were	 incubated	 for	 15	 min	 in	 the	 ice-water	 bath	 and	
centrifuged	at	2600	×	g	 for	15	min	at	4°C.	After	discarding	the	supernatant,	 the	cells	were	
resuspended	 in	 5	ml	 ice-cold	 TFB2	 buffer	 per	 250	ml	 starting	 culture.	 Aliquots	 containing	
100	µl	each	were	frozen	in	liquid	nitrogen	and	subsequently	transferred	to	-80°C.	
	
Transformation	buffer	TFB	1 30	mM	potassium	acetate
	 	 	 	 	 10	mM	CaCl2	
	 	 	 	 	 50	mM	MnCl2	
	 	 	 	 	 100	mM	RbCl	
	 	 	 	 	 15%	glycerol	
	 	 	 	 	 pH	5.8	at	RT	(adjusted	with	acetic	acid)	
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Transformation	buffer	TFB	2	 	 10	mM	MOPS	
	 	 	 	 	 75	mM	CaCl2	
	 	 	 	 	 10	mM	RbCl	
	 	 	 	 	 15%	glycerol	
	 	 	 	 	 pH	6.5	at	RT	(adjusted	with	1	M	KOH)	
	
2.2.2	Transformation	of	chemically	competent	E.	coli	cells		
For	all	 transformations	done	 in	 this	work,	self-made	chemically	competent	E.	coli	XL1-Blue	
cells	(section	2.2.1)	were	used.	An	aliquot	of	these	cells	was	thawed	on	ice	prior	to	the	addition	
of	0.5-10	µl	plasmid	DNA.	The	suspension	was	incubated	on	ice	for	30	min	after	mixing	the	
tube	1-3	times	by	flicking.	A	heat	shock	was	performed	in	a	42°C	heating	block	for	exactly	90	s	
without	 shaking	 the	 cells.	 Afterwards,	 the	 cells	 were	 cooled	 on	 ice	 for	 5	 min	 before	 ten	
volumes	of	pre-warmed	LB	medium	were	added.	After	shaking	 the	cells	at	500	rpm	 in	 the	
thermomixer	comfort	(Eppendorf)	for	up	to	1	h	at	37°C,	20-200	µl	of	the	cell	suspension	were	
spread	on	agar	plates	containing	100	µg/ml	ampicillin.	The	plates	were	incubated	overnight	
at	37°C,	afterwards	sealed	with	parafilm	and	stored	at	4°C	for	up	to	one	week.	
	
2.2.3	Isolation	of	plasmid	DNA	from	E.	coli	–	Miniprep	
The	following	protocol	 is	based	on	the	publication	of	Birnboim	and	Doly	[144].	A	colony	of	
transformed	E.	coli cells	 from	a	fresh	LB agar	plate	was	 inoculated	 in	3 ml	LB	medium	and	
incubated	overnight	at	37°C	with	130	rpm	in	the	Innova	4000	shaker	(Infors	AG).	The	next	day,	
1-2	ml	of	the	culture	were	transferred	to	a	2	ml	reaction	tube	and	centrifuged	at	13000	×	g	for	
30 s	at	4°C.	The	supernatant	was	discarded	and	the	pellet	was	completely	dried	by	tapping	the	
inverted	tube	onto	a	paper	towel.	The	following	steps	of	the	protocol	were	performed	on	ice.	
The	bacterial	pellet	was	resuspended	in	100	µl	ice-cold	buffer	P1	by	using	a	plastic	rack	as	a	
ratchet.	Afterwards	200 µl	of	lysis	buffer	P2	were	added	to	the	suspension	and	the	alkaline	
cell	lysis	was	performed	by	inverting	the	tube	five	times	without	shearing	the	genomic	DNA.	
The	pH	was	neutralized	and	the	genomic	DNA	was	precipitated	by	the	addition	of	150	µl	ice-
cold	buffer	P3.	The	suspension	was	centrifuged	again	at	13000	×	g	for	10	min	at	4°C.	The	clear	
supernatant	was	transferred	to	a	fresh	reaction	tube	and	the	plasmid	DNA	was	precipitated	
by	adding	600	µl	of	isopropanol	at	RT.	The	suspension	was	centrifuged	at	13000	×	g	for	5	min	
at	4°C.	The	supernatant	was	completely	removed	by	aspiration.	The	DNA	was	subsequently	
washed	by	adding	600	µl	ice-cold	70%	ethanol	stored	at	-20°C.	The	sample	was	centrifuged	at	
13000	×	g	for	5	min	at	4°C	and	the	supernatant	was	completely	removed	by	aspiration.	The	
DNA	pellet	was	dried	under	a	red-light	lamp	and	subsequently	resuspended	in	30	µl	sterile	
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ddH2O.	Alternatively,	 the	QIAprep™	Spin	Miniprep	Kit	 from	Qiagen	was	used	when	higher	
purities	were	needed.	
	
Miniprep	buffer	P1	 	 	 50	mM	Tris	
10	mM	EDTA	
0.1	mg/ml	RNAse	A	
pH	8.0	(adjusted	before	the	addition	of	RNAse	A)	
stored	at	4°C	
	
Miniprep	buffer	P2	 	 	 0.2	M	NaOH	
	 	 	 	 	 1%	(w/v)	SDS		
	 	 	 	 	 stored	at	RT	
	
Miniprep	buffer	P3	 	 	 60	ml	3	M	potassium	acetate	
	 	 	 	 	 11.5	ml	glacial	acid	
	 	 	 	 	 28.5	ml	ddH2O	
	 	 	 	 	 stored	at	4°C	
	
2.2.4	Isolation	of	plasmid	DNA	from	E.	coli	–	Midiprep	
Plasmid	preparations	were	done	with	the	Qiagen	Plasmid	Midi	Kit	when	higher	DNA	yields	and	
purities	 were	 needed	 for	 transfection	 of	 L.	 tarentolae.	 The	 preparation	 was	 performed	
according	to	the	manufacturer’s	protocol.		
	
2.2.5	Polymerase	chain	reaction	
Polymerase	 chain	 reactions	 (PCR)	were	performed	 for	 the	 amplification	of	DNA	or	 for	 the	
introduction	of	point	mutations	 via	 side-directed	mutagenesis.	 The	pipetting	 scheme	 for	a	
standard	cloning	PCR	is	shown	in	Table	11.	The	reaction	was	prepared	in	a	total	volume	of	
50	µl.	Pfu	polymerase	was	used	for	DNA-fragments	bigger	than	500	bp	taking	advantage	of	
the	proofreading-activity	of	this	polymerase	to	prevent	mutations.		
	
Table	11 | Pipetting	scheme	for	a	standard	cloning	PCR.	
Component	 Volume	
ddH2O	 40.5	µl	
Pfu	buffer	containing	MgSO4	 5	µl	
Template	DNA	 0.5	µl	(minipreps	1:100	diluted)	
Sense	primer	 0.5	µl	(after	1:10	dilution	of	a	100	µM	stock)	
Antisense	primer	 0.5	µl	(after	1:10	dilution	of	a	100	µM	stock)	
dNTPs	 2	µl	
Pfu	polymerase	 1	µl	
The	 DNA	 was	 initially	 denatured	 at	 94°C	 for	 120	 s	 in	 the	 thermocycler.	 After	 this	 initial	
denaturation,	 30	 cycles	 of	 denaturation	 (45	 s	 at	 94°C),	 annealing	 (30	 s,	 temperature	
dependent	on	the	Tm	of	the	primer)	and	elongation	(72°C,	duration	dependent	on	length	of	
amplificate;	2	min/kb)	were	performed.	After	a	final	elongation	step	(twice	as	long	as	the	prior	
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elongation	steps),	the	reaction	was	cooled	down	to	4°C.	The	annealing	temperature	of	the	
primers	was	determined	according	to	the	following	formula:		
	
Tm	=	4	×	N	(G	+	C)	+	2	×	N	(A	+	T)	–	5°C.	
	
2.2.6	Side-directed	mutagenesis	
Point	 mutations	 were	 introduced	 by	 PCR	 using	 the	 double	 stop-codon	 construct	 of	
pQE30/SCGRX7	 (Mesecke	et	al.	 [112])	or	 the	double	mutant	construct	pQE30/PFGRXC32S/C88S	
(Djuika	 et	 al.	 2013	 [138])	 as	 a	 template.	 Pfu	 polymerase	 was	 used	 for	 side-directed	
mutagenesis.	 The	used	mutagenesis	primers	 are	 listed	 in	 Table	8	 (section	2.1.8)	 and	were	
designed	according	to	the	following	criteria:	the	length	of	the	complementary	primers	should	
be	between	25	and	45	bases,	primers	should	end	with	a	G	or	C	for	stability	reasons,	primers	
should	have	a	Tm	>	78°C	and	the	point	mutation	should	be	introduced	in	the	middle	of	the	
primer.	Template	DNA,	forward	and	reverse	primers,	dNTPs,	buffer	and	Pfu	polymerase	were	
mixed	in	a	total	reaction	volume	of	50	µl	according	to	Table	12	and	the	reactions	were	placed	
in	a	pre-heated	thermocycler.	After	an	initial	denaturation	step	at	94°C	for	90	s,	16	cycles	each	
comprising	30	s	denaturation,	60	s	annealing	and	2	min/kb	elongation	at	72°C	for	the	SCGRX	
mutants	or	68°C	for	the	PFGRX	mutants	were	performed.	The	samples	were	cooled	down	to	
4°C	after	a	final	elongation	step	that	was	twice	as	long	as	the	prior	elongation	steps.	Following	
digestion	of	the	methylated	template	DNA	with	2	µl	DpnI	overnight	at	37°C,	plasmids	were	
transformed	into	chemically	competent	E.	coli	XL1-Blue	cells.	After	isolation	of	plasmid	DNA,	
the	correct	mutations	were	confirmed	by	sequencing	the	protein	coding	sequence	by	GATC.		
	
Table	12	|	Pipetting	scheme	for	a	standard	mutagenesis	PCR.	
Component	 Volume	
ddH2O	 37	µl	
DMSO	 2	µl	
Pfu	buffer	containing	MgSO4	 5	µl	
Template	DNA	 2	µl	
Sense	primer	 0.5	µl	(after	1:10	dilution	of	a	100	µM	stock)	
Antisense	primer	 0.5	µl	(after	1:10	dilution	of	a	100	µM	stock)	
dNTPs	 2	µl	
Pfu	polymerase	 1	µl	
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2.2.7	Agarose	gel	electrophoresis	
Horizontal	agarose	gel	electrophoresis	was	used	to	separate	DNA-fragments	according	to	their	
size	and	to	check	for	the	quality	of	DNA	preparations. DNA-samples	were	supplemented	with	
6	×	loading	dye	containing	1%	midori	green.	The	samples	were	loaded	on	an	agarose	gel	(1-
2%	agarose	in	1	×	TAE)	together	with	a	DNA-ladder	(100	bp-	or	1	kb-ladder)	and	separated	in	
1 ×	TAE-buffer	at 100 V for	around	30 min.	Afterwards, the DNA	was	visualized	on	a	trans-
illuminator	and	documented	with	the	attached	camera.	
	
1	×	TAE	 	 	 	 	 40	mM	Tris/HAc	
	 	 	 	 	 1	mM	EDTA	
	 	 	 	 	 pH	7.6	
	
2.2.8	Restriction	digest	of	DNA	
Restriction	digests	were	either	performed	to	analyze	different	constructs	or	for	subcloning.	
Enzymes	and	 corresponding	buffers	were	purchased	 from	New	England	Biolabs.	Analytical	
digests	were	performed	in	a	reaction	volume	of	20	µl	containing	15	µl	ddH2O,	2	µl	appropriate	
buffer,	2	µl	plasmid	DNA	and	0.5	µl	of	each	restriction	enzyme.	The	reaction	was	incubated	
for	1-3	h	at	37°C.	For	preparative	restriction	digests	the	reaction	volume	was	scaled	up	to	50	µl	
and	the	digested	fragment	was	cut	from	a	preparative	agarose	gel	followed	by	purification	
with	 the	 Promega	 Wizard	 and	 PCR	 Clean-up	 system	 according	 to	 the	 manufacturer’s	
instructions.		
	
2.2.9	Ligation	of	DNA	fragments	
For	 ligation	 of	 two	 DNA-fragments	 the	 T4-DNA	 ligase	 was	 used.	 A	 typical	 reaction	 was	
performed	in	a	20	µl	total	reaction	volume	containing	14	µl	ddH2O,	2	µl	buffer,	1	µl	plasmid,	
1	µl	insert	and	1	µl	T4	ligase.	The	ligation	reaction	was	performed	at	16°C	overnight	followed	
by	transformation	of	E.	coli	XL1-Blue	cells	with	1-5	µl	of	the	ligation	reaction.	
	
2.2.10	Sequencing	
The	introduction	of	correct	mutations	after	mutagenesis	PCR	and	the	results	of	cloning	were	
analyzed	 by	 sequencing.	 Therefore,	 the	 DNA	 derived	 from	 the	miniprep	 protocol	 (section	
2.2.3)	was	diluted	1:10	in	ddH2O	and	sent	to	GATC	for	sequencing	of	both	strands	either	with	
standard	primers	from	GATC	or	with	primers	indicated	in Table	8 (section	2.1.8). The	results
were	analyzed	with	help	of	the	software	BioEdit,	JustBio	and	Clustal	Omega.	
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2.2.11	Determination	of	DNA	concentration	
The	concentration	of	plasmid	DNA	was	determined	for	transfection	of	L.	tarentolae	(section	
2.3.5).	 The	 absorption	 at	 280 nm	 and	 260 nm	 was	 measured with	 a	 NanoDrop™
spectrophotometer.	Nucleic	acids	show	a	specific	absorption	at	260	nm	and	the	concentration	
can	 be	 calculated	 with	 help	 of	 the	 Lambert-Beer	 law.	 The	 purity	 of	 the	 preparation	 was	
determined	with	the	quotient	A260nm/A280nm and a	value	between	1.8	and	2.0	was	considered	
as	DNA	of	sufficient	quality	without	major	protein	contamination.		
	
2.2.12	Sterilization	of	DNA	
The	DNA	derived	from	plasmid	midipreps	was	sterilized	before	transfection	of	L.	tarentolae.	
The	concentration	of	the	DNA	was	calculated	and	10	µl	of	3	M	sodium	acetate,	pH	5	were	
added	to	20	µg	of	DNA	and	filled	up	to	100	µl	with	ddH2O.	The	DNA	was	precipitated	by	the	
addition	of	250	µl	100%	ethanol	and	incubation	for	at	least	30	min	at	-20°C.	The	sample	was	
centrifuged	at	20800	×	g	for	30	min	at	4°C	and	the	supernatant	was	discarded.	The	resulting	
pellet	was	rinsed	with	500	µl	70%	ethanol	and	centrifuged	again	at	20800	×	g	for	15	min	at	
4°C.	The	supernatant	was	removed	and	the	pellet	was	dried	under	sterile	conditions	for	5-
10	min.	The	DNA	was	subsequently	resuspended	in	10	µl	sterile	ddH2O	and	stored	at	-20°C	or	
directly	used	for	the	transfection	of	L.	tarentolae.		
	
	
2.3	Methods	of	Leishmania	tarentolae	cultivation	and	manipulation	
In	 this	 work,	 the	 L.	 tarentolae	 UCLA	wild-type	 strain	 obtained	 from	 André	 Schneider	 and	
different	transfectants	derived	from	this	strain	were	used.	The	parasites	were	cultured	in	the	
promastigote	stage.	
	
2.3.1	Standard	cultivation	of	Leishmania	tarentolae	
The	standard	cultivation	of	L.	tarentolae	promastigotes	was	performed	in	brain	heart	infusion	
(BHI)	liquid	medium	at	27°C	shaking	at	50	rpm	(Rotamax	120	shaker;	Heidolph	Instruments).	
Usually	the	parasites	were	cultivated	in	25	cm2	culture	flasks	containing	10	ml	cell	suspension.	
If	higher	amounts	of	cells	were	needed,	they	were	transferred	to	50	ml	pre-cultures	in	125	ml	
Erlenmeyer	plastic	flasks.	The	cells	were	maintained	in	the	mid-log	phase	at	approximately	
5	×	107	cells/ml.	For	transfected	parasites,	the	BHI	medium	was	supplemented	with	0.1	mg/ml	
G418	selection	marker.	
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hemin	solution	(2	mg/ml)	 	 2	mg/ml	hemin	chloride	in	0.05	M	NaOH	
	 	 	 	 	 sterilized	with	a	0.2	µm	filter	
	
BHI	medium	 	 	 	 37	g	BHI	powder	
	 	 	 	 	 ad	1	l	ddH2O	
	 	 	 	 	 autoclaved	for	20	min	at	120°C	
	 	 	 	 	 10	µg/ml	hemin	solution	
	
G418	solution	 	 	 	 diluted	1:500	in	BHI	(final	concentration	of	0.1	mg/ml)	
	
2.3.2	Cryoconservation	of	Leishmania	tarentolae	
L.	 tarentolae	 strains	 were	 cryoconserved	 in	 liquid	 nitrogen.	 Therefore,	 parasites	 in	 the	
logarithmic	phase	(5-9	×	107	cells/ml)	were	mixed	with	the	same	volume	of	sterile	BHI	freezing	
medium	 and	 transferred	 to	 labeled	 cryotubes.	 The	 tubes	 were	 wrapped	 in	 paper	 towels,	
incubated	at	-80°C	for	24	h	and	finally	transferred	to	liquid	nitrogen.	
	
BHI	freezing	medium	 	 	 37	g/l	BHI	
	 	 	 	 	 30%	(v/v)	glycerol	
10	µg/ml	hemin	solution	 	 	 	 	 	
sterilized	with	a	0.2	µm	filter	
	
2.3.3	Thawing	of	Leishmania	tarentolae	cryocultures	
For	starting	a	L.	tarentolae	culture,	the	parasites	were	removed	from	the	liquid	nitrogen	and	
thawed	in	a	water	bath	at	27°C.	After	completely	thawing	the	cells,	they	were	transferred	to	
10	ml	pre-warmed	BHI	medium,	properly	mixed	and	centrifuged	at	1500	×	g	at	RT	for	10	min	
to	get	rid	of	the	glycerol	included	in	the	freezing	medium.	The	cell	pellet	was	resuspended	in	
1	 ml	 fresh	 BHI	 medium	 and	 incubated	 for	 24	 h	 without	 shaking	 and	 without	 antibiotics.	
Afterwards,	 the	 parasites	 were	 cultivated	 under	 standard	 cultivation	 conditions	 (section	
2.3.1).		
	
2.3.4	Determination	of	the	cell	density	of	Leishmania	tarentolae	cultures	
L.	tarentolae	cells	were	counted	before	splitting	or	for	experiments	that	needed	a	defined	cell	
number.	 An	 aliquot	 of	 the	 parasite	 culture	 was	mixed	with	 1 × SSC	 fixation	 solution and	
incubated	for	5	min	at	RT.	Afterwards	the	cells	were	resuspended,	transferred	to	a	Neubauer	
counting	chamber	and	counted	under	the	microscope	after	complete	settling.		
	
1	×	SSC	fixation	solution	 	 	 10%	(w/v)	paraformaldehyde	in	1	×	SSC	
	
20	×	SSC		 	 	 	 3	M	NaCl	
	 	 	 	 	 0.3	M	Na3citrate	
	 	 	 	 	 pH	7.4	at	RT	
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2.3.5	Transfection	of	Leishmania	tarentolae	
For	transfection	of	the	parasites,	L.	tarentolae	cells	in	the	mid-logarithmic	phase	were	used.	
The	 protocol	 is	 based	 on	 the	 manufacturer’s	 protocol	 of	 the	 utilized	 kit	 (Basic	 Parasite	
Nucleofector™	Kit,	Lonza).	After	counting	the	cells,	5	×	107	cells	were	centrifuged	for	3	min	at	
1500	 ×	 g	 at	 RT.	 The	 supernatant	 was	 discarded	 and	 the	 pellet	 was	 resuspended	 in	 1	 ml	
transfection	buffer.	The	suspension was	centrifuged	again	for	3 min	at 1500 × g at	RT and	the	
pellet	was	resuspended	in	100	µl	Nucleofector	Solution	that	was	pre-warmed	to	RT.	The	cell	
suspension	was	combined	with	20	µg	sterile	DNA	(section	2.2.12)	that	was	dissolved	in	10	µl	
ddH2O.	 The mixture	 was	 transferred	 into	 an	 electroporation	 cuvette	 and	 the	 cells	 were	
electroporated	with	 the	program	U-033	 in	 the	Nucleofector™	2b	Device	 (Lonza).	Once	 the	
program	was	finished,	500	µl	of	pre-warmed	BHI	medium	were	added	to	the	cells.	Then,	the	
cells	 were	 transferred	 to	 a	 culture	 flask	 containing	 9.5	 ml	 BHI	 medium.	 The	 culture	 was	
subsequently	incubated	overnight	at	27°C	without	antibiotics	and	without	selection	marker	
and	the	next	day	centrifuged	at	1500	×	g	for	10	min	at	RT.	The	resulting	pellet	was	resuspended	
and	spread	on	BHI	agar	plates	that	were	sealed	properly	with	parafilm	to	avoid	moisture	loss.	
Growth	of	parasites	was	observed	after	around	2-3	weeks	after	incubating	the	plates	at	27°C.		
BHI	agar	 	 	 	 3.7%	BHI	
	 	 	 	 	 0.08%	(w/v)	folic	acid	
	 	 	 	 	 0.8%	(w/v)	agar	
	 	 	 	 	 10%	(v/v)	heat-inactivated	FCS	
	 	 	 	 	 20	µg/ml	hemin	
	 	 	 	 	 40	µg/ml	G418	
	
transfection	buffer	 	 	 21	mM	HEPES	
	 	 	 	 	 137	mM	NaCl	
	 	 	 	 	 5	mM	KCl	
	 	 	 	 	 0.7	mM	NaH2PO4	
	 	 	 	 	 6	mM	Glucose
	 	 	 	 	 pH	7.4		
	
2.3.6	Preparation	of	Leishmania	tarentolae	cell	lysates	
L.	tarentolae	whole	cell	lysates	for	western	blot	analyses	contained	5	×	107	cells	per	sample.	
The	cell	number	was	determined	by	counting	the	cells	in	a	Neubauer	chamber.	The	parasites	
were	 centrifuged	 at	 1500	 ×	 g	 for	 10	min	 and	 directly	 lysed	 in	 5	 ×	 Laemmli-buffer	 either	
containing	10-15%	β-ME	for	reducing	conditions	or	without	β-ME	for	non-reducing	conditions.	
The	samples	were	sheared	10	times	over	a	centrifugation	tube	rack	to	disrupt	the	genomic	
DNA	and	 to	 improve	 the	 running	behavior	of	 the	 samples	on	 the	SDS-gel.	Afterwards,	 the	
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samples	were	boiled	at	95°C	for	10	min.	If	an	additional	treatment	of	the	cells	was	needed,	
the	protocol	was	modified	as	follows.		
2.3.6.1	Preparation	of	NEM-	or	MMTS-treated	Leishmania	tarentolae	cell	lysates	
L.	tarentolae	cells	were	treated	with	the	alkylating	substances	NEM	or	MMTS	to	trap	mixed	
disulfide	 intermediates	 by	 blocking	 free	 thiols.	 Different	 concentrations	 of	 NEM	or	MMTS	
were	tested	in	a	first	experiment	and	in	following	experiments	incubation	with	100	mM	NEM	
for	5	min	was	used	as	the	standard	condition.	The	NEM-solution	was	always	prepared	freshly	
due	 to	 stability	 reasons.	 After	 determination	 of	 the	 cell	 density, the	 cell	 suspension	 was	
centrifuged	at	RT	at	1500	×	g	for	10	min.	The	cells	were	resuspended	in	PBS	containing	100	mM	
NEM	 for	5	min.	Afterwards,	 the	cells	were	centrifuged	at	4°C	 for	1	min	at	10000	×	g.	 The	
resulting	pellet	was	resuspended	in	5	×	Laemmli	buffer	containing	10%	of	the	initial	NEM	or	
MMTS	 concentration.	 Subsequently,	 samples	 for	 western	 blot	 analyses	 were	 prepared	
according	to	the	standard	protocol	in	the	previous	section.		
	
2.3.6.2	Preparation	of	diamide-	or	DTT-treated	Leishmania	tarentolae	cell	lysates	
L.	 tarentolae	 parasites	 were	 treated	 either	 with	 the	 thiol	 oxidizing	 agent	 diamide	 or	 the	
reducing	agent	dithiothreitol	(DTT)	prior	to	NEM-blocking	of	free	thiols	to	stabilize	potential	
mixed	disulfide	intermediates.	After	determination	of	the	cell	number,	5	×	107	cells/sample	
were	 centrifuged	 at	 1500	 ×	g	 for	 10	min	 at	 RT.	 Parasites	were	 treated	with	 either	 2	mM	
diamide	or	2	mM	DTT	in	PBS	for	1-120	min.	After	another	centrifugation	step,	the	cells	were	
incubated	with	100	mM	NEM	in	PBS	for	5	min	at	RT.	Parasites	treated	only	with	PBS	or	100	mM	
NEM	 served	 as	 control	 samples.	 The	 samples	 for	western	 blot	 analyses	were	 prepared	 as	
described	above.	
	
2.3.7	Differential	fractionation	of	Leishmania	tarentolae	whole	cell	lysates	
To	 analyze	 the	 localization	 of	 proteins,	 L.	 tarentolae	 whole	 cell	 lysates	were	 differentially	
fractionated	by	 hypotonic	 swelling	 followed	by	 digitonin	 treatment.	 A	 control	 sample	was	
removed	from	the	cell	culture	with	5	×	107	cells	(=input	sample).	This	sample	was	centrifuged	
at	1500	×	g	for	10	min	at	4°C	and	resuspended	in	20	µl	5	×	Laemmli	buffer	containing	15%	(v/v)	
β-ME.	 All	 buffers	 and	 solutions	 were	 pre-cooled	 on	 ice	 and	 109	 cells	 were	 harvested	 by	
centrifugation	at	1500	×	g	for	10	min	at	4°C.	The	resulting	cell	pellet	was	washed	once	with	
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10	ml	ice-cold	PBS.	For	hypotonic	swelling,	the	cell	pellet	was	resuspended	in	1.66	ml	freshly	
prepared,	ice-cold	DT	buffer	per	109	cells.	The	cells	were	lysed	by	manually	shearing	them	ten	
times	through	a	needle	(BD	Microlance 3	needle,	0.4 × 19 mm).	Before	shearing,	an aliquot	of	
cells	was	removed	for	SDS-PAGE	analysis	(=control	without	shearing).	The	hypotonic	swelling	
was	 stopped	by	 the	addition	of	 sucrose	 in	a	 final	 concentration	of	7.5%	 (w/v)	 followed	by	
mixing	 the	 lysate. Aliquots	 of	 the	 cell	 lysate	 containing	 108 cells/tube	were	 prepared	 and	
subsequently	treated	with	0,	50,	100,	150,	200,	250	or	2000	µg	digitonin	or	2%	(v/v)	Triton™	X-
100	 (=positive	 control).	 The	 samples	were	mixed,	 incubated	 on	 ice	 for	 1	 h	 interrupted	 by	
several	mixing	steps.	The	 lysates	were	centrifuged	at	20000 × g for	30 min	at	4°C	and	the	
resulting	pellets	were	resuspended	in	50	µl	5	×	Laemmli	buffer	containing	15%	(v/v)	β-ME.	The	
supernatants	obtained	from	the	centrifugation	were	transferred	to	fresh	reaction	tubes	and	
precipitated	 with	 acetone	 according	 to	 Fic	 et	 al.	 2010	 [145].	 The	 supernatants	 were	
supplemented	with	5-6	volumes	of	ice-cold	acetone	and	thoroughly	mixed.	The	samples	were	
incubated	for	at	least	1	h	at	-20°C	and	afterwards	centrifuged	at	15000	×	g	for	15	min	at	4°C.	
The	supernatant	was	removed	and	the	resulting	pellets	were	completely	dried	at	RT	for	about	
15	min.	 The	pellets	were	 dissolved	 in	 50	 µl	 5	 ×	 Laemmli	 buffer	 containing	 15%	β-ME	 and	
vortexed	twice	for	30	s	until	the	pellets	were	completely	dissolved.	All	samples	were	incubated	
for	5	min	at	95°C	and	subsequently	loaded	on	a	SDS-PAGE	gel.	The	different	fractions	were	
analyzed	by	western	blot	analysis.	EF1α	served	as	a	cytosolic	marker	and	LtErv	and	LtsTim1	
served	as	markers	for	the	IMS.	
	
DT	buffer	 	 	 	 1	mM	Tris/HCl	
	 	 	 	 	 pH	7.9	(at	4°C)	
	 	 	 	 	 1	×	cOmplete	EDTA	free	protease	inhibitor		
	
2.3.8	Affinity	chromatography	of	Leishmania	tarentolae	proteins	
Different	 protocols	 for	 affinity	 chromatography	 of	 up-regulated	 L.	 tarentolae	 proteins	
produced	in	L.	tarentolae	were	tested	for	the	enrichment	of	these	proteins	and	their	potential	
interaction	partners.	All	protocols	were	based	on	Ni-NTA	affinity	chromatography	interacting	
with	the	N-terminal	His8-tag	of	the	respective	proteins.	
	
2.3.8.1	Native	affinity	chromatography	of	LtErvwt	
A	native	affinity	chromatography	experiment	was	performed	with	recombinant	N-terminally	
His8-tagged	LtErv
wt	from	L.	tarentolae.	The	untagged	version	of	the	protein	served	as	a	control.	
	 	 2	Materials	and	Methods	
 
	
34 
Cells	lysis	was	performed	by	shearing	hypotonically	swelled	cells.	Membrane	proteins	were	
further	solubilized	with	digitonin.	All	buffers	and	solutions	were	pre-cooled	on	ice	and	kept	
cool during	the	whole	experiment.	An	input	sample	of	the	culture	containing	5 × 107 cells	per	
SDS-sample	was	prepared	for	western	blot	analysis	(“input”)	after	determination	of	the	cell	
number.	1	L	of	parasites	in	the	mid-log	phase	were	centrifuged	at	1500	×	g	for	10	min	at	RT.	
The	cells	were	resuspended	in	10 ml	PBS	containing	100 mM	NEM and	incubated	for	5 min	at	
RT	in	the	dark.	Afterwards,	the	cells	were	centrifuged	at	4000	×	g	for	15	min	at	4°C	and	the	
resulting	pellet	was	resuspended	in	0.83	ml	fresh,	ice-cold	DT	buffer	per	109	cells	for	hypotonic	
swelling. The	 swollen	 cells	 were	 sheared	 twice	 through	 a	 needle	 (BD	 Microlance	 3	
0.4	×	19	mm)	with	6	bar.	The	cell	 lysate	was	collected	on	 ice	and	 the	 success	of	 lysis	was	
controlled	under	the	microscope.	The	lysis	was	stopped	by	adding	7.5%	(w/v)	sucrose.	From	
this	step,	a	sample	“lysate”	was	taken	for	western	blot	analysis.	The	lysate	was	centrifuged	at	
16000	×	g	for	20	min	at	4°C	and	the	supernatant	(except	for	an	aliquot	for	western	blot	analysis	
“supernatant”)	was	discarded.	The	remaining	pellet	was	resuspended	in	1	ml	ST20	buffer	per	
2.5	×	1010	cells.	The	protein	concentration	of	the	lysate	was	determined	with	a	Bradford	assay	
and	adjusted	to	5	mg/ml	with	ST20	buffer.	A	sample	“pellet	1”	was	prepared	for	western	blot	
analysis.	Digitonin	 (1%	 (w/v)	 final	 concentration)	was	 added	 to	 the	 sample	 and	 the	buffer	
concentration	was	adjusted	with	5	×	ST20	buffer	to	obtain	a	1	×	ST20	buffer	concentration.	
This	resulted	in	a	further	dilution	of	the	protein	concentration	to	3.3	mg/ml.	The	sample	was	
inverted	several	times	and	manually	sheared	through	a	needle	twice	for	mixing	followed	by	
incubation	for	1	h	on	ice.	In	the	meantime,	20	µl	Ni-NTA	beads	were	equilibrated	with	ST20-
buffer.	Therefore,	the	Ni-NTA	beads	were	washed	three	times	with	1	ml	buffer	followed	by	
centrifugation	 at	 1000	 ×	 g	 for	 1	 min	 at	 4°C.	 The	 Ni-NTA	 beads	 were	 incubated	 with	 the	
digitonin-treated	cell	lysate	for	1	h	at	4°C	on	a	rotating	wheel.	Afterwards,	the	protein-agarose	
mixture	was	centrifuged	for	1	min	at	1000	×	g	at	4°C	and	a	sample	“depleted	supernatant”	
was	removed	for	western	blot	analysis.	The	beads	were	washed	once	with	1	ml	ST20-buffer	
(“W1”)	and	three	times	with	2	ml	of	ST20-buffer	(“W2-W4”)	and	samples	of	each	washing	step	
were	 removed	 for	western	blot	analysis.	The	protein	was	eluted	by	 the	addition	of	100	µl	
elution	buffer	(ST20-buffer	+	500	mM	imidazole	+	10	mM	NEM)	to	the	pellet	and	incubation	
for	5	min	on	ice.	The	sample	was	centrifuged	for	3	min	at	1000	×	g	and	an	aliquot	of	the	elution	
fraction	was	prepared	together	with	the	other	samples	 for	western	blot	analysis	on	a	15%	
SDS-PAGE	gel.	
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PBS	 	 	 	 	 1.84	mM	KH2PO4	
	 	 	 	 	 10	mM	Na2HPO4	
	 	 	 	 	 137	mM	NaCl	
	 	 	 	 	 2.7	mM	KCl	
pH	7.4	(at	24°C)	
	
DT	buffer	 	 	 	 1	mM	Tris/HCl	
	 	 	 	 	 10	mM	NEM	 	
pH	7.9	(at	4°C)	
1	×	cOmplete	EDTA	free	protease	inhibitor		
	
ST20	buffer	 	 	 	 250	mM	sucrose	
	 	 	 	 	 25	mM	Tris/HCl	
	 	 	 	 	 20	mM	imidazole	
	 	 	 	 	 10	mM	NEM	
pH	7.9	(at	4°C)	
1	×	cOmplete	EDTA	free	protease	inhibitor		
	
2.3.8.2	Denaturing	affinity	chromatography	of	LtErvC63S	and	LtsTim1	mutants	
A	 denaturing	 affinity	 chromatography	 experiment	 was	 performed	 with	 recombinant	 N-
terminally	His8-tagged	LtErv
C63S	or	His8-tagged	LtsTim1
mut	 from	L.	 tarentolae.	The	untagged	
version	of	the	mutants	served	as	a	control.	All	buffers	and	solutions	were	precooled	on	ice	
and	kept	cool	during	the	whole	experiment.	A	sample	of	the	input	containing	5	×	107	cells	was	
removed	after	determination	of	 the	cell	number.	1	L	of	 the	parasites	 in	 the	mid-log	phase	
were	centrifuged	at	1500	×	g	for	10	min	at	RT.	The	supernatant	was	discarded,	the	resulting	
pellet	resuspended	in	10	ml	PBS	containing	100	mM	NEM	and	incubated	for	5	min	on	ice.	After	
centrifugation	of	the	parasites	at	1500	×	g	for	15	min	at	4°C,	the	pellet	was	resuspended	on	
ice	with	10	ml	lysis	buffer	and	incubated	for	1	h	on	ice.	The	cell	suspension	was	centrifuged	at	
10000	×	g	for	30	min	at	4°C.	For	affinity	chromatography,	an	empty	reaction	tube	with	100	µl	
Ni-NTA	(200	µl	of	50%	slurry)	was	equilibrated	with	1.5	ml	of	lysis	buffer.	The	supernatant	was	
mixed	with	the	Ni-NTA	agarose	beads	and	incubated	for	1	h	on	ice.	Afterwards,	the	Ni-NTA	
agarose	beads	were	washed	with	1.5	ml	of	washing	buffer	in	three	steps	of	centrifugation	at	
1000	×	g	at	4°C	for	3	min.	The	Ni-NTA	beads	were	incubated	with	100	µl	of	elution	buffer	for	
protein	elution.	After	3	min	of	incubation,	the	sample	was	centrifuged	at	1000	×	g	for	3	min	
at	4°C.	The	supernatant	was	transferred	to	a	fresh	reaction	tube	and	one	sample	for	reducing	
conditions	(containing	15%	β-ME)	and	one	sample	for	non-reducing	conditions	(without	β-ME)	
was	prepared	for	further	analysis.	The	Ni-NTA	beads	were	resuspended	in	Laemmli-buffer	and	
analyzed	as	“beads	fraction”.	Samples	of	all	steps	were	taken	for	SDS-PAGE	and	western	blot	
analyses	and	supplemented	with	2	×	Laemmli-buffer	containing	15%	(v/v)	β-ME.		
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PBS	 	 	 	 	 1.84	mM	KH2PO4	
	 	 	 	 	 10	mM	Na2HPO4	
	 	 	 	 	 137	mM	NaCl	
	 	 	 	 	 2.7	mM	KCl	
	 	 	 	 	 pH	7.4	at	RT	
	
lysis	buffer	 	 	 	 20	mM	sodium	phosphate	
	 	 	 	 	 8	M	urea	
	 	 	 	 	 20	mM	imidazole	
	 	 	 	 	 500	mM	NaCl	
	 	 	 	 	 2%	(v/v)	Triton™	X-100	
	 	 	 	 	 1	×	Protease	Inhibitor		
	 	 	 	 	 pH	8.0	at	4°C	 	
washing	buffer	 	 	 	 20	mM	sodium	phosphate	
	 	 	 	 	 8	M	urea	
	 	 	 	 	 20	mM	imidazole	
	 	 	 	 	 500	mM	NaCl	
	 	 	 	 	 1	×	Protease	Inhibitor		
pH	8.0	at	4°C
	
elution	buffer	 	 	 	 20	mM	sodium	phosphate	
	 	 	 	 	 8	M	urea	
	 	 	 	 	 400	mM	imidazole	
	 	 	 	 	 500	mM	NaCl	
	 	 	 	 	 1	×	Protease	Inhibitor		
	 	 	 	 	 pH	8.0	at	4°C	
	
2.3.9	Screen	of	different	media	for	the	cultivation	of	Leishmania	tarentolae	
The	following	media	with	a	defined	composition	were	tested	as	potential	replacements	for	
the	undefined	standard	BHI	medium:	DMEM,	RPMI-1640,	DMEM/F-12,	 IMDM,	McCoy’s	5A	
(Modified)	Medium	and	MEM.	McCoy’s	5A	(Modified)	Medium	and	MEM	were	supplemented	
with	25	mM	HEPES	and	sterile	filtered	through	a	0.2	µM	filter	prior	to	use.	Heat	inactivated	
fetal	bovine	serum	was	added	to	the	media	in	different	concentrations	(0%,	5%	or	10%	(v/v)).	
As	a	serum	free	alternative	0.5%	AlbuMax™	II	Lipid-Rich	BSA	was	tested.	The	different	media	
were	also	supplemented	with	folic	acid	(0	µg/ml,	10	µg/ml	or	50	µg/ml)	and	hemin	chloride	
solution	(5	µg/ml,	10	µg/ml	or	20	µg/ml).	L.	tarentolae	cells	in	the	mid-logarithmic	phase	were	
centrifuged	 at	 1500	×	g	 for	 10	min	 at	 RT	 and	washed	once	with	 the	 appropriate	medium	
(without	any	supplements).	After	another	centrifugation	step,	the	pellet	was	resuspended	in	
the	appropriate	medium	obtaining	a	concentration	of	5	×	106	cells/ml.	A	volume	of	500	µl	cell	
suspension	was	seeded	per	well	in	a	48-well	plate.	The	different	supplements	were	directly	
added	resulting	 in	216	different	 test-conditions.	The	parasites	were	cultivated	at	27°C	and	
their	morphology	was	checked	under	a	microscope	every	24	h	to	visually	evaluate	the	best	
growth	 conditions.	Growth	 kinetics	 of	 L.	 tarentolae	 cells	 cultivated	 in	 the	 following	media	
were	determined	in	25	cm2	culture	flasks:	IMDM	supplemented	with	5%	FCS,	10%	FCS	or	0.5%	
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AlbuMax™,	 McCoy’s	 5A	 (Modified)	 Medium	 supplemented	 with	 5%	 or	 10%	 FCS,	 MEM	
supplemented	with	25	mM	HEPES	and	5%	or	10%	FCS.	Cells	cultivated	with	BHI	liquid	medium	
served	as	a	positive	control.	All	media were	supplemented	with	10 µg/ml hemin	chloride.	L.	
tarentolae	cells	in	the	mid-log	phase	were	centrifuged	at	1500	×	g	for	10	min	at	RT	and	washed	
once	with	the	appropriate	medium	containing	the	supplements	named	above.	After	another	
centrifugation	 step, the	 pellet	 was	 resuspended	 in	 the	 appropriate	 medium	 obtaining	 a	
concentration	of	5	×	106	parasites/ml	in	a	total	volume	of	10	ml.	The	parasites	were	cultivated	
under	normal	cultivation	conditions	(27°C	shaking	at	50	rpm	on	the	Rotamax	120	shaker)	and	
the	cells	were	counted	every	24 h. After	counting, the	cells	were	centrifuged	at	1500 × g for	
10	 min	 at	 RT	 and	 the	 pellet	 was	 resuspended	 in	 10	 ml	 fresh	 medium	 to	 avoid	 nutrient	
depletion.	The	data	was	analyzed	with	SigmaPlot	using	a	sigmoidal	curve	fit	with	the	equation	
f	=	y0	+	a	/	(1	+	exp	(-	(x	-	x0)	/	b)).	The	maximum	growth	rate	(L)	was	determined	using	the	
equation	L	=	b	+	y0.	The	doubling	time	(tD)	was	determined	in	the	exponential	phase	using	the	
following	 equation:	 tD	 =	 log2	 ×	 (t	 -	 t0)	 /	 (logN	 -	 logN0).	 L.	 tarentolae	 promastigotes	 in	 the	
respective	medium	were	used	for	determination	of	the	morphology.	A	thin	layer	of	parasites	
in	the	mid-logarithmic	phase	was	dropped	on	a	microscope	slide	and	sealed	with	paraffin.	The	
living	cells	were	directly	analyzed	using	a	Zeiss	LSM780	microscope	and	the	software	ZEN2010.	
	
2.3.10	BioID	for	identification	of	proximal	and	interacting	proteins	
Leishmania	 tarentolae	 cells	 transfected	 with	 pX/BirA*-LTERV	 or	 pX/BirA*-LTsTIM1	 were	
cultivated	in	the	logarithmic	phase	according	to	the	standard	protocol.	The	cell	number	was	
determined	and	10	ml	cell	suspension	diluted	to	8	×	106	cells/ml	(8	×	107	cells	in	total)	were	
centrifuged	 for	10	min	at	RT	with	1500	×	g.	 The	parasites	were	 resuspended	 in	10	ml	BHI	
containing	 150	 µM	 biotin	 and	 incubated	 for	 24	 h	 according	 to	 Chen	 et	 al.	 [77]	 before	
harvesting.	In	parallel,	untreated	(without	biotin)	control	samples	were	prepared.	After	biotin	
treatment,	 the	 cells	were	harvested	 for	western	blot	 analysis.	 Several	 independent	 clones	
were	analyzed	by	western	blotting	with	an	αMyc	antibody,	streptavidin-HRP	(1:10000)	and	an	
antibody	against	LtErv	or	LtsTim1.	The	parasites	were	also	analyzed	by	immunofluorescence	
microscopy	 with	 the	 help	 of	 Jessica	 Kehrer.	 Therefore,	 5	 ×	 107	 cells	 were	 centrifuged	 at	
1500	×	g	for	10	min	at	RT	and	washed	once	with	1	ml	PBS.	The	cells	were	fixed	with	4%	(w/v)	
PFA	in	PBS	overnight	at	4°C.	Then,	the	cells	were	washed	three	times	with	100	µl	PBS	before	
the	membrane	 was	 permeabilized	 with	 100	 µl	 0.5%	 Triton	 X-100	 in	 PBS	 for	 10	min.	 The	
parasites	were	washed	three	times	with	100	µl	PBS	and	resuspended	in	100	µl	PBS	containing	
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the	αMyc-antibody	(1:500).	After	one	hour	of	incubation	at	RT	the	cells	were	washed	again	
three	times	with	100	µl	PBS	and	resuspended	in	100	µl	PBS	containing	the	secondary	antibody	
against	αMyc	(Alexa	Fluor	488,	goat	anti-mouse,	2	mg/ml,	Invitrogen,	1:500),	Hoechst	(1:500)	
and	labeled	Streptavidin	(1:500).	After	another	hour	of	incubation	at	RT,	the	cells	were	washed	
three	times	with	100	µl	PBS,	resuspended	in	50	µl	PBS	and	analyzed	under	the	Zeiss	LSM780	
microscope.	
	
	
2.4	Preparation	of	Plasmodium	falciparum	cell	lysates	
P.	 falciparum	 trophozoites	 of	 the	 strain	 3D7	were	 used	 for	 the	 identification	 of	 potential	
interaction	partners	of	PfErv.	The	parasites	were	cultured	by	Verena	Staudacher	according	to	
a	standard	protocol	[146]	at	37°C	in	fresh	human	erythrocytes	(A+)	with	a	hematocrit	of	3%	in	
RPMI-1640	medium.	The	medium	was	supplemented	with	0.45%	(w/v)	AlbuMax™	II,	0.2	mM	
hypoxanthine	 and	 2.7	 µg/ml	 gentamicin.	 After	 reaching	 a	 parasitemia	 of	 about	 4%,	 the	
cultures	were	centrifuged	at	300	×	g	for	5	min.	The	pellet	was	resuspended	in	100	mM	NEM	
in	PBS	and	incubated	for	5	min	at	RT.	The	culture	was	centrifuged	5	min	at	755	×	g	and	the	
pellet	was	resuspended	in	ice-cold	PBS	containing	10	mM	NEM	and	0.05%	saponin.	Cell	lysis	
was	performed	for	60	s	on	ice	and	the	culture	was	subsequently	centrifuged	at	1800	×	g	for	
10	min	at	4°C.	The	parasite	pellet	was	washed	once	with	10	mM	NEM	in	PBS	and	once	with	
PBS	containing	a	protease	inhibitor	(cOmplete	EDTA-free	protease-inhibitor	cocktail,	Roche).	
A	control	sample	was	prepared	in	parallel	without	NEM	in	all	steps.	The	cell	density	of	the	
parasite	samples	was	determined	in	a	Neubauer	chamber.	The	pellet	was	resuspended	in	PBS,	
frozen	in	liquid	nitrogen	and	stored	at	-80°C	until	western	blot	analyses	were	performed.	For	
each	sample	107	parasites	were	lysed	in	5	×	Laemmli	buffer	(±	30%	β-ME),	boiled	for	10	min	
at	95°C	and	analyzed	on	a	15%-SDS	gel	under	reducing	and	non-reducing	conditions.	
	
	
2.5	Protein	biochemical	methods	
	
2.5.1	Expression	and	purification	of	recombinant	proteins	
Recombinant	 N-terminally	 MRGS(H)6-tagged	 S.	 cerevisiae	 or	 P.	 falciparum	 Grx	 (ScGrx7	 or	
PfGrx),	different	Grx	mutants	of	both	species	and	PfGR	were	produced	in	E.	coli	XL1-Blue	cells.	
Therefore,	1	µl	of	pQE30-plasmid	containing	the	coding	sequence	for	the	respective	protein	
was	transformed	into	chemically	competent	XL1-Blue	cells	according	to	the	standard	protocol	
	 	 2	Materials	and	Methods	
 
	
39 
(section	 2.2.2).	 A	 starter	 culture	 was	 prepared	 with	 20	 ml	 ampicillin-containing	 medium	
inoculated	with	one	colony	of	the	transfectant.	The	pre-culture	was	incubated	at	37°C	shaking	
at 130 rpm	in	the Innova	4000	shaker	overnight. The	next	morning, the	OD600nm	of	the	starter	
culture	was	determined.	 The	 starter	 culture	was	diluted	 into	 a	main	 culture	 resulting	 in	 a	
starting	OD600nm	of	0.04.	The	main	culture	was	incubated	at	37°C	shaking	at	130	rpm	in	the	
Innova	4000	shaker until	an	OD600nm of	0.5-0.6	was	reached.	For	expression	of	PfGR	the	culture
was	 incubated	at	37°C	at	130	rpm	 in	 the	 Innova	4000	shaker	until	an	OD600nm	of	0.15	was	
reached	and	then	shifted	to	28°C.	At	an	OD600nm	of	0.4	the	culture	was	shifted	to	16°C	until	an	
OD600nm of	 0.6	 was	 reached.	 Protein	 production was	 induced	 by	 adding	 0.5 mM	 IPTG	 for	
expression	of	GRX	or	0.3	mM	IPTG	for	expression	of	PFGR	to	the	culture,	which	subsequently	
was	incubated	for	another	4	h	for	GRX	expression	or	14	h	for	PFGR	expression.	Afterwards,	
the	 culture	 was	 transferred	 to	 precooled	 1	 L	 buckets	 and	 the	 cells	 were	 harvested	 by	
centrifugation	at	4000	×	g	 for	15	min	at	4°C.	The	pellet	obtained	from	a	1	L	of	culture	was	
resuspended	on	 ice	with	10	ml	buffer	 I,	divided	 into	 two	aliquots	and	stored	at	 -20°C.	For	
kinetic	analyses	the	protein	was	freshly	purified.	For	cell	lysis,	the	pellet	was	therefore	thawed	
on	ice,	10	mg	lysozyme	and	a	spatula	tip	of	DNaseI	were	added	to	the	cell	suspension	(derived	
from	 a	 500	ml	 culture)	 and	 the	mixture	was	 incubated	 for	 1	 h	 on	 ice	whilst	 stirring.	 The	
suspension	was	 sonicated	on	 ice	with	 60-70%	power	 for	 5	 cycles	with	 10	 s	 for	 each	 cycle	
(including	a	10	s	pause	on	ice	between	the	steps).	Afterwards,	the	lysates	were	centrifuged	
for	30	min	at	4°C	at	10000	×	g.	Meanwhile,	a	column	with	750	µl	Ni-NTA	was	prepared	and	
equilibrated	with	10	ml	buffer	I.	The	supernatant	derived	from	centrifugation	of	the	cell	lysate	
was	loaded	with	a	peristaltic	pump	(flow	rate	set	to	10	×)	and	the	column	was	washed	with	
10	ml	buffer	I	prior	to	elution	with	one	column	volume	of	buffer	II.	To	recycle	the	column,	it	
was	washed	with	10	ml	buffer	I	and	stored	at	4°C.	The	eluate	was	analyzed	on	a	SDS-gel	and	
the	concentration	was	determined	by	Bradford	assay.	
	
Buffer	I	Grx	 	 	 	 10	mM	imidazole	
300	mM	NaCl	
50	mM	NaxHyPO4	
pH	8.0	at	4°C	
	
Buffer	II	Grx	 	 	 	 125	mM	imidazole	
300	mM	NaCl	
50	mM	NaxHyPO4	
pH	8.0	at	4°C	
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Buffer	I	GR	 	 	 	 20	mM	imidazole	
300	mM	NaCl	
50	mM	NaxHyPO4	
pH	8.0	at	4°C	
	
Buffer	II	GR	 	 	 	 200	mM	imidazole	
300	mM	NaCl	
50	mM	NaxHyPO4	
pH	8.0	at	4°C	
	
2.5.2	Bradford	assay	for	determination	of	protein	concentrations	
The	determination	of	the	protein	concentrations	was	based	on	the	protocol	of	Bradford	[147].	
A	calibration	curve	with	0-14	µg/ml	BSA	was	prepared	freshly	for	every	measurement.	The	
protein	 solutions	 (appropriate	 dilutions	 determined	 before)	 were	 pipetted	 into	 cuvettes	
containing	800	µl	ddH2O	minus	the	volume	of	the	protein	solution.	All	samples	were	prepared	
in	triplicates	and	two	different	dilutions	of	the	protein	sample	were	measured.	The	reaction	
was	started	by	the	addition	of	200	µl	Bradford	reagent	followed	by	thorough	mixing.	After	
exactly	15	min	incubation	of	the	solution	at	RT,	the	absorbance	at	595	nm	was	followed	with	
the	software	“spectra	manager”.	The	calibration	curve	was	fitted	hyperbolically	in	Sigma	Plot	
and	the	protein	concentration	was	calculated	from	the	following	formula	using	the	absorption	
values:	y	=	a*x	/	(b	+	x).	
	
2.5.3	SDS-Polyacrylamide	gel	electrophoresis	(SDS-PAGE)	
SDS-Polyacrylamide	gel	electrophoresis	was	used	to	separate	protein	solutions	in	an	electrical	
field	according	to	the	molecular	weight	of	 the	proteins	 [148].	The	pore	size	of	 the	gel	was	
varied	 using	 different	 acrylamide-concentrations	 for	 the	 separating	 gel	 according	 to	 the	
expected	size	of	the	proteins.	The	acrylamide	polymerizes	after	the	addition	of	ammonium	
persulfate	(APS)	and	tetramethylethylenediamine	(TEMED).	The	proteins	were	denatured	in	
5	×	Laemmli	buffer	by	boiling	the	samples	for	10	min	at	95°C	directly	before	loading	onto	the	
gel.	For	reducing	conditions,	the	samples	contained	10-20%	β-ME	to	reduce	disulfide	bonds.	
The	negative	charge	of	the	SDS	covers	the	intrinsic	charge	of	the	proteins	and	therefore,	the	
separation	 is	 only	 based	 on	 the	molecular	weight	 of	 the	 proteins.	 The	 proteins	were	 first	
focused	 in	 the	 stacking	 gel	 and	 then	 separated	 in	 a	12-18%	gel.	 The	gels	were	 run	 in	 SDS	
running	buffer	with	maximum	30	mA	for	each	small	SDS-gel	for	about	1	h.	Afterwards	the	gels	
were	either	stained	with	Coomassie	Brilliant	Blue	for	visualization	of	the	protein	bands	or	the	
proteins	were	transferred	to	a	nitrocellulose	membrane	by	western	blotting.	
	
	 	 2	Materials	and	Methods	
 
	
41 
stacking	gel	 	 	 	 5%	(w/v)	acrylamide	
	 	 	 	 	 0.03%	(w/v)	bisacrylamide	
	 	 	 	 	 60	mM	Tris-HCl,	pH	6.8	
	 	 	 	 	 0.1%	(w/v)	SDS	
	 	 	 	 	 0.05%	(w/v)	APS	
	 	 	 	 	 0.1%	(v/v)	TEMED	
	
separating	gel	 	 	 	 12-18%	(w/v)	acrylamide	
	 	 	 	 	 0.1%	(w/v)	bisacrylamide	
	 	 	 	 	 375	mM	Tris-HCl,	pH	8.8	
	 	 	 	 	 0.1%	(w/v)	SDS	
	 	 	 	 	 0.05%	(w/v)	APS	
	 	 	 	 	 0.15%	(v/v)	TEMED	
SDS	running	buffer	 	 	 25	mM	Tris	
	 	 	 	 	 250	mM	glycine	
	 	 	 	 	 0.1%	(w/v)	SDS	
	 	 	 	 	 pH	8.3	
	
5	×	Laemmli	buffer	 	 	 50	mM	Tris-HCl,	pH	6.8	
25%	glycerol
	 	 	 	 	 10%	(w/v)	SDS	
	 	 	 	 	 0.1%	bromophenol	blue	
	 	 	 	 	 0-20%	β-ME	
	
2.5.4 Coomassie	Brilliant	Blue	staining	of	SDS-gels
To	 visualize	 protein	 bands	 after	 separation	 by	 SDS-PAGE,	 the	 gels	 were	 stained	 with	
Coomassie	Brilliant	Blue.	Therefore,	 the	gels	were	 transferred	 to	 the	 staining	 solution	and	
incubated	 on	 a	 vertical	 shaker	 at	 RT	 for	 at	 least	 one	 hour.	 For	 destaining,	 the	 gels	 were	
transferred	 to	 a	 destaining	 solution,	 which	 was	 replaced	 several	 times.	 To	 increase	 the	
contrast	of	the	protein	bands,	the	background	was	completely	destained	by	incubating	the	gel	
overnight	in	ddH2O	without	shaking.	
	
Staining	solution		 	 	 65%	(v/v)	ddH2O	
25%	(v/v)	isopropanol	
10%	(v/v)	acetic	acid	
0.05%	(w/v)	Coomassie	Brilliant	Blue	G-250	
	
Destaining	solution	 	 	 65%	(v/v)	ddH2O	
25%	(v/v)	isopropanol
10%	(v/v)	acetic	acid	
	
2.5.5	Western	blotting	
Proteins	 that	 were	 separated	 according	 to	 their	 molecular	 weight	 by	 SDS-PAGE	 were	
subsequently	 transferred	 to	 a	 nitrocellulose	 membrane	 by	 semi-dry	 blotting	 for	
immunodetection.	Hence,	the	stacking	gel	of	the	SDS-gel	was	removed	and	the	separating	gel	
was	incubated	in	transfer	buffer.	For	each	gel,	one	membrane	and	10	Whatman	papers	were	
prepared	and	incubated	in	transfer	buffer.	The	blotting	sandwich	was	assembled	without	air	
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bubbles	 as	 follows:	 i)	 anode,	 ii)	 5	Whatman	 papers,	 iii)	 nitrocellulose	membrane,	 iv)	 SDS	
separating	gel,	v)	5	Whatman	papers	and	vi)	cathode.	The	semi-dry	blotting	was	performed	
with a	constant	electric	current	at 100 mA	per	small	gel	or	250 mA	per	big	gel	for	1 h.	The	
successful	 transfer	 of	 the	 proteins	 was	 checked	 by	 PonceauS	 staining	 of	 the	 membrane.	
Therefore,	the	membrane	was	shortly	incubated	in	PonceauS	solution	followed	by	destaining	
of	 the	 background	 with	 ddH2O.	 After	 documentation, the	 membrane	 was	 completely	
destained	with	TBS	for	several	minutes	on	the	shaker.	
	
transfer	buffer	 	 	 	 150	mM	glycine	
20	mM	Tris	
0.02%	(w/v)	SDS	
20%	(v/v)	methanol	
pH	8.3	
	
PonceauS	solution	 	 	 0.2%	(w/v)	PonceauS	
	 	 	 	 	 3%	(w/v)	trichloroacetic	acid	
	
2.5.6	Immunodetection	of	proteins	
Proteins	 that	 were	 immobilized	 on	 nitrocellulose	 membranes	 by	 western	 blotting	 were	
subsequently	detected	by	immunostaining	with	protein	specific	antibodies.	Unspecific	binding	
sites	of	the	membrane	were	blocked	by	incubation	for	1	h	at	RT	in	blocking	buffer.	Afterwards,	
the	 membrane	 was	 incubated	 in	 TBS	 with	 5%	 (w/v)	 milk	 powder	 containing	 the	 primary	
antibody	(dilutions	see	Table	9)	overnight	at	4°C	on	a	horizontal	shaker.	Subsequently,	 the	
membrane	was	washed	three	times	for	10	min	with	TBS	and	incubated	with	the	secondary	
HRP-conjugated	antibody	diluted	1:5000-1:10000	in	blocking	buffer	for	1	h	at	RT.	Then,	the	
membrane	was	washed	again	three	times	for	10	min	with	TBS	or	TBST.	For	detection	of	the	
proteins, the	membrane	was	incubated	with	an	ECL-Mix	(Amersham™ ECL™ Western	Blotting	
Reagent,	GE	Healthcare)	and	covered	with	a	film	in	the	dark	for	a	few	seconds	until	overnight	
depending	on	the	intensity	of	the	luminescence	signal.	The	film	was	developed	and	afterwards	
documented	by	scanning.
	
blocking	buffer	 	 	 	 5%	milk	(w/v)	in	TBS	
	
TBS	 	 	 	 	 10	mM	Tris	
0.9%	(w/v)	NaCl	
pH	7.4	(adjusted	with	HCl)
	
TBST	 	 	 	 	 10	mM	Tris	
0.9%	(w/v)	NaCl	
pH	7.4	(adjusted	with	HCl)	
0.05%	(v/v)	Tween™	20	
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2.5.7	Stripping	of	membranes	
A	mild	stripping	buffer	according	to	a	protocol	from	Abcam	was	used	to	remove	primary	and	
secondary	antibodies	from	a	western	blot	membrane	for	redecoration with	further primary	
antibodies.	The	membrane	was	washed	twice	for	10	min	with	TBS	and	three	times	for	10	min	
with	mild	stripping	buffer.	Afterwards,	the	membrane	was	washed	twice	for	10	min	with	TBS	
and	twice	for	5 min	with	TBST (0.1%	Tween™ 20).	The	membrane	was	subsequently incubated	
in	blocking	buffer	and	further	processed	according	to	the	standard	protocol.		
	
mild	stripping	buffer	 	 	 15	g	glycine	
1	g	SDS	
10	ml	Tween™	20	
ad	1	l	ddH2O	
pH	2.2	
	
2.5.8	Glutathione	reductase	assay	
Glutathione	 reductase	was	 needed	 for	 the	 coupled	 spectrophotometric	 GSSCys	 and	HEDS	
oxidoreductase	assays	 and	 therefore	 its	 activity	was	measured	prior	 to	 these	assays.	 Pure	
ScGR	or	PfGR	was	diluted	1:100	with	elution	buffer.	A	4	mM	stock	solution	of	NADPH	and	a	
20	mM	 stock	 solution	 of	 GSSG	were	 prepared	 in	 assay	 buffer.	 The	 assay	 buffer	 was	 pre-
warmed	to	25°C	and	the	whole	assay	was	performed	at	25°C.	The	total	reaction	volume	in	the	
cuvette	 (green	 quartz	 cuvette)	 was	 1000	 µl	 and	 contained	 assay	 buffer	 with	 a	 final	
concentration	of	100	µM	NADPH	and	5	µl	of	diluted	GR.	A	baseline	was	 recorded	 for	30	s	
before	the	reaction	was	started	by	the	addition	of	GSSG	in	a	final	concentration	of	1	mM.	The	
decrease	of	absorbance	of	NADPH	at	340	nm	was	determined	spectrophotometrically	with	
the	software	JASCO	Spectra	Manager.	The	reaction	was	repeated	five	times	and	the	baseline	
was	subtracted	from	the	decrease	of	absorption	for	each	value.	The	mean	of	the	five	values	
was	calculated	as	ΔAbs.korr/min.	With	the	extinction	factor	of	NADPH	(ε340nm	=	6.22	mM-
1cm-1)	the	decrease	of	NADPH	was	calculated	with	the	following	formula:	Δ[NADPH]	/	min	=	
(ΔAbs.korr	´	1	cm)	/	 (6.22	mM-1cm-1).	The	units	contained	 in	 the	assay	were	calculated	as	
follows:	Units	in	assay	=	(Δ[NADPH]	´	Vtotal)	/	min.	To	obtain	the	volume	activity	(Units)	of	GR	
in	the	stock	solution	the	following	formula	was	used:	Units	in	stock	solution	=	(units	in	assay	
´	dilution	factor)	/	volume.	The	GR	was	diluted	to	200	U/ml	prior	to	its	use	in	the	GSSCys	or	
HEDS	assay.	
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GR	assay	buffer	 	 	 	 0.1	M	Tris	
1	mM	EDTA	
pH	8.0	at	25°C	
	
2.5.9	GSSCys	and	HEDS	oxidoreductase	assays	
Steady-state	kinetics	of	wild-type	and	mutant	ScGrx7	or	PfGrx	were	determined	in	a	coupled	
spectrophotometric	GSSCys	and	HEDS	assay.	The	assays	are	based	on	the	oxidation	of	GSH	by	
Grx	yielding	GSSG,	which	is	subsequently	reduced	by	glutathione	reductase	(GR)	using	NADPH	
as	an	electron	donor.	The	consumption	of	NADPH	can	be	followed	spectrophotometrically	at	
340	nm.	Stock	solutions	of	NADPH,	GSH	and	GSSCys	or	HEDS	were	prepared	freshly	 in	Grx	
assay	buffer,	whereas	the	enzymes	ScGrx7	or	PfGrx	and	ScGR	or	PfGR	were	diluted	in	buffer	II	
(section	2.5.1)	to	keep	the	imidazole-concentration	in	the	assay	constant.	The	protocols	were	
based	on	 the	publication	of	Mesecke	et	al.	 [112].	All	measurements	were	performed	with	
freshly	purified	Grx	in	a	reaction	volume	of	1	ml	in	Grx	assay	buffer	at	25°C.	The	obtained	data	
were	analyzed	using	the	software	JASCO	Spectra	Manager.	For	both	assays	0.1	mM	NADPH	
and	1	U/ml	ScGR	or	PfGR	was	used.	Final	concentrations	of	the	ScGrxY110X	mutants	were	5	nM	
to	150	nM,	for	the	Asp144	and	Glu147	mutants	10	nM	and	for	the	Arg153	mutants	25	to	50	
nM.	A	final	concentration	of	5-10	nM,	50-100	nM	and	5-12.5	nM	was	used	for	PfGrxC32S/C88S,	
PfGrxC32S/C88S/K26A	and	PfGrxC32S/C88S/D90A,	respectively.	The	GSH	concentration	was	varied	in	the	
GSSCys	 assay	 of	 the	 ScGrx	 mutants	 between	 50	 µM	 and	 1.5	 mM	 at	 fixed	 GSSCys	
concentrations	(25,	50,	100	and	150	µM	GSSCys).	For	the	GSSCys	assay	with	the	PfGrx	mutants,	
either	GSH	was	varied	between	50	µM	and	2.0	mM	at	fixed	GSSCys	concentrations	(25,	50,	
100	 and	 150	 µM	GSSCys)	 or	 GSSCys	was	 varied	 between	 25	 and	 200	 µM	with	 fixed	 GSH	
concentrations	 (0.3,	 0.5,	 1.0	 and	 2.0	mM	GSH).	 A	 baseline	 for	 the	 background	 activity	 of	
NADPH,	GSH,	GR	and	Grx	was	recorded	for	30	s	before	the	assay	was	started	by	the	addition	
of	GSSCys.	For	the	HEDS	assay	of	the	ScGrx	mutants,	fixed	concentrations	of	HEDS	were	used	
(0.18,	0.37,	0.55	and	0.74	mM)	and	GSH	was	varied	between	100	µM	and	2.0	mM.	For	the	
PfGrx	mutants	either	GSH	was	varied	between	250	µM	and	3.0	mM	at	fixed	concentrations	of	
HEDS	(0.18,	0.37,	0.55	and	0.74	mM)	or	HEDS	was	varied	between	90	and	920	µM	at	fixed	
concentrations	of	GSH	(0.25,	0.5,	1	and	2	mM).	NADPH,	GSH	and	HEDS	were	mixed	and	pre-
incubated	for	exactly	120	s	before	a	baseline	was	recorded	for	30	s	after	the	addition	of	GR.	
During	 the	pre-incubation	 step,	 the	 formation	of	mixed	disulfides	between	HEDS	and	GSH	
takes	place	[123].	The	HEDS	assay	was	started	by	the	addition	of	ScGrx	or	PfGrx.	The	decrease	
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in	absorbance	was	normalized	against	a	reference	cuvette	measured	in	parallel	including	all	
components	except	the	investigated	enzyme.	The	kinetic	parameters	kcat
app	and	Km
app	were	
determined	by	non-linear	 regression	 according	 to	 the	Michaelis-Menten	 theory	 and	 linear	
regression	based	on	Lineweaver-Burk,	Eadie-Hofstee	and	Hanes	theory	with	SigmaPlot	12.5	
or	13	based	on	established	protocols	[112,	113,	123].		
	
Grx	assay	buffer	 	 	 	 0.1	M	Tris	
1	mM	EDTA	
pH	8.0	at	25°C	
	
2.5.10	Determination	of	the	thiol	pKa	values	
The	thiol	pKa	values	of	ScGrx7	wild-type	enzyme	and	selected	mutants	were	determined	to	
gain	further	insights	into	the	function	of	different	amino	acid	residues.	The	protocol	used	for	
the	determination	of	the	thiol	pKa	values	of	the	enzymes	was	modified	from	Mieyal	et	al.	[149]	
and	Gallogly	et	al.	[150].	It	is	based	on	the	pH-dependent	alkylation	of	the	cysteine	thiolate	of	
ScGrx7	by	iodoacetamide	(IAM),	followed	by	determination	of	the	residual	enzyme	activity	in	
a	standard	kinetic	assay.	Only	freshly	purified	protein	was	used	for	determination	of	the	thiol	
pKa	 values.	 The	 enzyme	was	 reduced	with	 NaBH4	 for	 2	 h	 on	 ice	 according	 to	 a	 previously	
established	protocol	resulting	in	304	µM	protein	solution	with	a	20-fold	molar	excess	of	BH4-	
over	protein	[138].	Subsequently,	6	µM	ScGrx7	or	mutant	enzyme	was	incubated	for	exactly	
180	s	with	150	µM	IAM	at	23°C	in	a	three-buffer	system	(Ellis	et	al.	[151])	containing	100	mM	
KCl,	50	mM	potassium	acetate,	50	mM	MES	and	100	mM	Tris	with	pH	values	varying	over	a	
range	from	3.5	to	8.5.	Each	assay	was	also	performed	with	a	mock	control	containing	ddH2O	
instead	 of	 IAM	 and	 the	 activity	 of	 the	 enzyme	 at	 each	 pH	 was	 normalized	 against	 the	
corresponding	mock	control.	A	standard	HEDS	assay	was	started	in	parallel	to	the	IAM	pre-
incubation	 step	 and	was	 subsequently	 carried	 out	 as	 described	 in	 the	 previous	 section	 to	
determine	 the	 residual	 enzyme	 activity.	 The	 remaining	 enzyme	 activity	 after	 alkylation	
calculated	in	per	cent	for	every	pH	value	was	plotted	as	a	sigmoidal	curve	(Hill,	4	parameter)	
in	SigmaPlot	13.	From	this	curve,	the	pKa	values	for	ScGrx7	and	the	different	mutants	were	
determined.	
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3	Results	
	
	
3.1	Mitochondrial	protein	import	
	
3.1.1	Endogenous	chemical	trapping	of	mixed	disulfide	intermediates	
Different	approaches	were	tested	for	the	chemical	trapping	of	a	mixed	disulfide	intermediate	
between	 endogenous	 LtErv	 and	 a	 potential	 Mia40	 adapter	 replacement	 in	 wild-type	 L.	
tarentolae	 parasites.	 Analogous	 experiments	 were	 performed	 for	 the	 other	 site	 of	 the	
reaction.	In	this	reaction,	a	mixed	disulfide	intermediate	between	the	model	substrate	LtsTim1	
and	a	potential	Mia40	adapter	replacement	candidate	should	be	trapped.	For	stabilizing	the	
mixed	disulfide	bonds	between	the	model	substrate	LtsTim1,	the	potential	adapter	and	LtErv	
in	vivo,	free	cysteine	residues	in	intact	cells	were	blocked	by	alkylation	with	N-ethylmaleimide	
(NEM)	or	S-methyl-methanethiosulfonate	(MMTS).	Another	approach	was	to	alter	the	redox	
state	and	therefore	possibly	shift	the	redox	equilibrium	by	adding	the	oxidizing	agent	diamide	
or	the	reducing	agent	DTT	in	combination	with	alkylation	by	NEM.	A	schematical	overview	for	
the	potential	outcome	of	the	different	trapping	experiments	is	shown	in	Figure	12.	
	
	
	
Figure	12	|	Schematic	overview	for	the	potential	outcome	of	the	trapping	experiments.	Under	non-reducing	
conditions	(-β-ME)	a	mixed	disulfide	intermediate	between	LtErv	and	a	potential	interaction	partner	(left	side)	
or	LtsTim1	and	a	potential	 interaction	partner	(right	side)	is	detected	in	addition	to	the	lower	band	reflecting	
monomeric	 LtErv	 or	 LtsTim1.	 After	 reduction	 of	 the	 sample	 (+β-ME)	 only	 the	 monomeric	 band	 should	 be	
detectable.	 Only	 one	 potential	 higher	 band	 indicating	 one	 specific	 interaction	 is	 shown	 for	 the	 sake	 of	
convenience	but	also	several	bands	or	a	smear	of	bands	that	reflect	several	potential	interactions	are	possible.	
b-ME:	b-mercaptoethanol.	
	
Endogenous	LtErv	
None	of	the	approaches	performed	with	L.	tarentolae	wild-type	cells	showed	specific	bands	
with	 a	 higher	molecular	weight	 that	might	 reflect	 a	 trapped	mixed	 disulfide	 intermediate	
between	LtErv	and	a	potential	Mia40	adapter	replacement	under	non-reducing	conditions	in	
western	blot	analyses.	The	NEM-concentration	was	varied	between	10	µM	and	100	mM	and	
each	sample	was	incubated	for	5	min	(Figure	13	A).	As	an	alternative	alkylating	agent	MMTS	
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was	used	and	the	result	of	this	experiment	is	shown	in	Figure	13	B.	A	specific	LtErv	antibody	
was	used	 for	 the	detection.	 In	another	experiment	 the	parasites	were	 treated	with	2	mM	
diamide	or	DTT	for	1min	to	120min	followed	by alkylation	with 100	mM	NEM	for	5min (Figure	
13,	C	and	D;	data	from	120	min	diamide-	or	DTT-treatment	are	not	shown).	Only	one	specific	
band	corresponding	to	the	calculated	molecular	mass	of	monomeric	LtErv	with	34.8	kDa	was	
detectable for	 all	 the	 conditions that	were	 tested and	 no	 disulfide	 intermediate	 could	 be	
enriched.		
	
	
	
Figure	 13	 |	 Chemical	 trapping	 of	 LtErv.	 Representative	 SDS-PAGE	 and	 western	 blot	 analysis	 with	 5	 ×	 107	
parasites/lane	under	reducing	and	non-reducing	conditions	(±β-ME).	The	primary	antibody	αLtErv	was	diluted	
1:500,	the	secondary	antibody	αRabbit	(BioRad)	was	used	1:5000.	The	calculated	molecular	mass	of	monomeric	
LtErv	is	34.8	kDa.	A:	NEM-trapping	of	LtErv.	L.	tarentolae	treated	for	5	min	with	different	concentrations	(10	µM	
up	to	100	mM)	of	NEM.	B:	MMTS-trapping	of	LtErv.	L.	tarentolae	treated	for	5	min	with	different	concentrations	
(10	µM	up	to	50	mM)	of	MMTS.	The	asterisk	indicates	unspecific	bands	that	were	also	observed	in	the	control.	
C:	Diamide-trapping	of	LtErv.	L.	tarentolae	treated	for	1-30	min	with	2	mM	diamide	followed	by	5	min	treatment	
with	100	mM	NEM.	D:	DTT-trapping	of	LtErv.	L.	tarentolae	treated	for	1-30	min	with	2	mM	DTT	followed	by	5	min	
treatment	with	100	mM	NEM.	For	all	conditions,	the	cells	were	lysed	in	5	×	Laemmli-buffer	(±β-ME)	after	the	
treatment.	 NEM:	 N-ethylmaleimide;	 DTT:	 dithiothreitol;	 MMTS:	 S-methyl-methanethiosulfonate;	 b-ME:	 b-
mercaptoethanol.	
	
In	 another	 experiment	 the	 treatment	 conditions	 shown	 above	 were	 combined	 with	
precipitation	of	the	samples	with	5%	trichloroacetic	acid	(TCA)	leading	to	an	immediate	pH	
drop	that	quenches	redox	reactions	and	unspecific	thiol	exchange	reactions	[152,	153].	The	
cells	were	treated	with	diamide	or	DTT	in	combination	with	NEM	before	centrifugation	and	
resuspension	of	the	cells	in	ice-cold	PBS	containing	5%	TCA.	The	solution	was	incubated	for	
30	min	on	ice	(longer	incubations	led	to	insolubility	of	the	resulting	pellet).	After	centrifugation	
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of	 the	 solution	 at	 10000	 ×	g	 for	 10	min,	 the	 pellet	was	washed	 three	 times	with	 ice-cold	
acetone.	In	all	TCA-precipitation	experiments	only	one	band	reflecting	monomeric	LtErv	was	
detectable	in	western	blot	analyses	with	the	LtErv-specific	antibody (Figure	14).	
Hence,	endogenous	LtErv	could	not	be	enriched	as	a	 trapped	mixed	disulfide	 intermediate	
under	the	chosen	conditions	including	varying	treatment	durations	and	concentrations	of	the	
alkylating	substances	NEM	or	MMTS	or	the	redox-active	chemicals	diamide	or	DTT.	
	
	
	
Figure	14	|	Chemical	trapping	of	LtErv	combined	with	TCA	precipitation.	SDS-PAGE	and	western	blot	analysis	
with	5	×	107	parasites/lane.	The	primary	antibody	αLtErv	was	diluted	1:500,	 the	secondary	antibody	αRabbit	
(BioRad)	was	used	1:5000.	The	calculated	molecular	mass	of	monomeric	LtErv	is	34.8	kDa.	A:	Diamide-trapping	
of	LtErv	combined	with	TCA	precipitation.	L.	tarentolae	 treated	for	1-30	min	with	2	mM	diamide	followed	by	
5	min	treatment	with	100	mM	NEM.	B:	DTT-trapping	of	LtErv	combined	with	TCA	precipitation.	L.	 tarentolae	
treated	 for	 1-30	min	 with	 2	 mM	 DTT	 followed	 by	 5	 min	 treatment	 with	 100	mM	 NEM.	 The	 samples	 were	
afterwards	precipitated	with	5%	TCA	and	analyzed	under	reducing	and	non-reducing	conditions	(±β-ME).	NEM:	
N-ethylmaleimide;	DTT:	dithiothreitol;	TCA:	trichloroacetic	acid;	b-ME:	b-mercaptoethanol.	
	
Endogenous	LtsTim1	
L.	tarentolae	wild-type	lysates	were	also	used	for	western	blot	analysis	with	a	specific	antibody	
against	 the	 model	 substrate	 LtsTim1.	 Endogenous	 LtsTim1	 and	 strains	 with	 upregulated	
LtsTim1	protein	levels	were	in	general	difficult	to	analyze	because	the	small	Tim	proteins	are	
highly	hydrophobic	and	tend	to	form	higher	molecular	oligomers.	There	was	a	strong	signal	in	
the	 upper	 part	 between	 the	 stacking	 and	 separating	 SDS-gel	 in	 all	 western	 blot	 analyses	
performed	with	the	LtsTim1-antibody	that	could	reflect	these	oligomers.	First,	different	types	
of	 gels	 recommended for	 small	 and	 hydrophobic	 proteins	 were	 tested	 to	 improve	 the	
migration	pattern	of	LtsTim1.	Urea	gels	 containing	8	M	urea,	a	precast	gel	 (BioRad,	16.5%	
Mini-PROTEAN™	 Tris-Tricine)	 and	 a	 Tris-Tricine	 buffer	 system	 according	 to	 a	 published	
protocol	by	Schägger	et	al. [154] did	not	help	to	decrease the	strong	signal.	Second,	various
protocols	 for	 the	preparation	of	 SDS-samples	were	 tested.	Different	 temperatures	 ranging	
from	RT	to	95°C,	incubation	times	from	10-30	min,	urea	in	concentrations	up	to	8	M	in	the	
sample	 and	 shearing	of	 the	DNA	did	not	 alter	 the	migration	pattern.	 The	 influence	of	 the	
incubation	temperature	and	the	addition	of	urea	to	the	SDS-samples	is	shown	in	Figure	15	as	
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a	 representative	 result.	 However,	 the	 LtsTim1	monomeric-specific	 signal	was	 variable	 and	
often	not	detectable	with	standardized	or	alternative	experimental	procedures.		
	
	
Figure	15	|	Migration	pattern	of	LtsTim1.	SDS-PAGE	and	western	blot	analysis	with	5	×	107	parasites/lane	under	
reducing	conditions.	The	SDS-samples	were	incubated	at	the	indicated	temperatures	for	10	min	and	one	portion	
of	 the	 samples	 was	 supplemented	 with	 4	 M	 urea.	 The	 primary	 antibody	 αLtsTim1	 was	 diluted	 1:250,	 the	
secondary	antibody	αRabbit	(BioRad)	was	used	1:5000.	The	calculated	molecular	mass	of	monomeric	LtsTim1	is	
11.5	kDa.	The	figure	is	representative	also	for	the	other	conditions	that	were	tested.	RT:	room	temperature.		
	
Nevertheless,	experiments	analogous	to	the	ones	with	L.	tarentolae	wild-type	cells	detecting	
endogenous	LtErv	in	western	blot	analyses	were	performed	with	the	LtsTim1-specific	antibody	
to	test	for	disulfide	bridged	intermediates	after	chemical	trapping	(Figure	16).	In	this	approach	
faint	bands	with	a	higher	molecular	weight	were	observed	under	non-reducing	conditions	that	
were	not	detectable	after	reduction	of	the	samples.	Hence,	these	bands	could	reflect	mixed	
disulfide	 intermediates	 between	 endogenous	 LtsTim1	 and	 potential	 Mia40	 adapter	
replacement	candidates.	Again,	a	strong	signal	was	detectable	in	the	upper	part	of	the	gel	and	
could	not	be	reduced.	In	order	to	enrich	the	potential	mixed	disulfide	intermediates	by	affinity	
chromatography,	different	LTsTIM1	overexpressing	strains	were	generated.		
	
	
Figure	16	|	Chemical	trapping	of	LtsTim1.	SDS-PAGE	and	western	blot	analysis	with	5	×	107	parasites/lane	under	
reducing	and	non-reducing	conditions	(±β-ME).	The	primary	antibody	αLtsTim1	was	diluted	1:250,	the	secondary	
antibody	αRabbit	(BioRad)	was	used	1:5000.	The	calculated	molecular	mass	of	monomeric	LtsTim1	is	11.5	kDa.	
A:	 Diamide-trapping	 of	 LtsTim1.	 L.	 tarentolae	 treated	 for	 1-120	min	with	 2	mM	 diamide	 followed	 by	 5	min	
treatment	with	100	mM	NEM.	B:	DTT-trapping	of	LtsTim1.	L.	tarentolae	treated	for	1-120	min	with	2	mM	DTT	
followed	 by	 5	 min	 treatment	 with	 100	 mM	 NEM.	 NEM:	 N-ethylmaleimide;	 DTT:	 dithiothreitol;	 b-ME:	 b-
mercaptoethanol.	
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In	another	experiment,	it	was	tested	if	the	higher	molecular	band	at	around	55	kDa	(Figure	
16)	could	reflect	a	heterodimer	between	LtErv	and	LtsTim1.	This	would	suggest	that	Erv	acts	
alone	as	recently	proposed [155]. The	membranes	showing	higher	molecular	bands	with	the	
LtsTim1	antibody	in	western	blot	analyses	were	stripped	and	subsequently	redecorated	with	
the	LtErv	antibody.	However,	only	the	monomeric	band	for	LtErv	and	no	bands	with	a	higher	
molecular	weight	were	detected (data	not	shown).	
3.1.2	Expression	of	bait	protein-encoding	genes	
Since	the	identification	of	potential	interaction	partners	with	endogenous	LtErv	levels	was	not	
possible	and	the	bands	observed	with	endogenous	LtsTim1	were	very	faint,	the	bait	proteins	
should	be	upregulated	in	L.	tarentolae	parasites	in	order	to	perform	pull-down	studies.	First,	
constructs	 encoding	 the	 two	 bait	 proteins	 and	 cysteine	 mutants	 that	 could	 lead	 to	 an	
enrichment	 of	 the	 disulfide	 complexes	 between	 the	 bait	 protein	 and	 potential	 interacting	
proteins	were	generated	and	are	shown	in	Figure	17.	All	constructs	were	cloned	in	the	newly	
designed	 vector	 termed	 “pX-backbone”	 for	 the	 expression	 in	 L.	 tarentolae.	 This	 vector	
encodes	 an	 N-terminal	 His8-tag	 and	 no	 further	 tags.	 Constructs	 without	 His8-tag	 were	
generated	in	parallel	and	served	as	negative	controls	for	pull-down	studies.	
	
	
Figure	17	|	Constructs	for	pull-down	experiments.	All	the	constructs	were	cloned	into	the	newly	designed	vector	
termed	 “pX-backbone”	 for	 expression	 in	 L.	 tarentolae.	 A:	 Constructs	 for	 production	 of	 wild-type	 LtErv	 and	
LtErvC63S	for	enrichment	of	disulfide	complexes	between	LtErv	and	the	unknown	adapter	replacement	candidate.	
B:	Constructs	for	production	of	wild-type	LtsTim1	and	the	mutants	LtsTim1C1-3S	or	LtsTim1C2-4S	for	enrichment	of	
disulfide	complexes	between	LtsTim1	and	the	unknown	adapter	replacement	candidate.	Constructs	without	His8-
tag	serve	as	a	negative	control	for	pull-down	studies.		
	
L.	tarentolae	was	transfected	with	each	of	the	constructs	shown	in	Figure	17	and	clonal	lines	
were	 generated.	 At	 least	 three	 independent	 clones	 for	 each	 construct	 were	 analyzed	
regarding	 their	 protein	 levels	 by	 western	 blot	 analyses	 with	 specific	 LtErv	 and	 LtsTim1	
antibodies.	 The	 lysates	 of	 L.	 tarentolae	 transfected	with	 pX/His8LTERV	were	 also	 analyzed	
under	 non-reducing	 conditions	 by	 western	 blotting	 to	 investigate	 if	 disulfide-bridged	
intermediates	could	be	enriched.	The	protein	level	of	LtErv	was	increased	compared	to	the	
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wild-type	control	in	all	of	the	four	analyzed	clones	(Figure	18).	Only	one	band	corresponding	
to	monomeric	His8-tagged	LtErv	was	detectable	and	no	bands	with	a	higher	molecular	weight	
were	visible with the	chosen	conditions.	Thus,	even	with	highly	enriched protein	levels	of	LtErv	
resulting	in	strong	signals	 in	western	blot	analysis,	no	band	with	a	higher	molecular	weight	
potentially	reflecting	an	interaction	between	LtErv	and	potential	interaction	partners	could	be	
detected.	The	upregulation of	the	LtErvC63S mutant	is	shown	in	Figure	20.	
	
	
Figure	18	|	L.	tarentolae	with	upregulated	His8LtErv	levels.	Representative	SDS-PAGE	and	western	blot	analysis	
with	5	×	107	parasites/lane	under	reducing	and	non-reducing	conditions	(±β-ME).	Four	clones	of	L.	tarentolae	
transfected	 with	 pX/His8LTERV
	 were	 analyzed.	 The	 cells	 were	 treated	 with	 100	 mM	 NEM	 for	 5	 min	 before	
harvesting.	The	primary	antibody	αLtErv	was	diluted	1:500,	the	secondary	antibody	αRabbit	(BioRad)	was	used	
1:5000.	The	calculated	molecular	mass	of	monomeric	LtErv	is	34.8	kDa.	wt:	wild-type;	b-ME:	b-mercaptoethanol.	
	
Protein	levels	of	LtsTim1	and	the	two	mutants	LtsTim1C1-3	and	LtsTim1C2-4S	were	also	increased	
compared	to	the	wild-type	control	 in	most	of	the	analyzed	clones	(Figure	19).	The	samples	
were	analyzed	on	different	gels	but	were	exposed	in	parallel	to	ensure	comparability.	Only	the	
clones	with	strongest	upregulation	were	used	for	the	following	experiments	(see	Figure	21).		
	
	
Figure	19	|	Expression	of	LtsTim1-bait	protein-encoding	genes.	SDS-PAGE	and	western	blot	analysis	with	5	×	107	
parasites/lane	under	reducing	conditions.	Four	clones	of	each	L.	tarentolae	strain	were	analyzed	regarding	their	
protein	levels.	The	primary	antibody	αLtsTim1	was	diluted	1:250,	the	secondary	antibody	αRabbit	(BioRad)	was	
used	1:5000.	The	calculated	molecular	mass	of	monomeric	LtsTim1	and	the	N-terminally	His8-tagged	version	is	
11.5	kDa	and	13	kDa,	respectively.	wt:	wild-type.	
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3.1.3	Trapping	of	mixed	disulfide	intermediates	with	mutated	LtErv	and	LtsTim1	
The	 two	 cysteine	 mutants	 of	 LTsTIM1	 with	 all	 but	 one	 cysteines	 mutated	 to	 a	 serine	
(LTsTIM1C1-3S	and	LTsTIM1C2-4S) were	previously	generated	by	Oren	Shatz	during	an	internship	
in	our	lab.	The	LtsTim1	mutants	and	the	single	cysteine	mutant	LtErvC63S	should	mechanistically	
trap	the	mixed	disulfide	intermediate	with	a	potential	Mia40	replacement	candidate.	Western	
blot	analyses	under	reducing	and	non-reducing	conditions	were	performed	with	cell	lysates	of	
the	transfected	L.	tarentolae	strains	after	alkylation	with	100	mM	NEM.		
	
Mutated	LtErv	
Three	to	five	clones	of	L.	tarentolae	transfected	with	pX/LTERVC63S	or	pX/His8LTERV
C63S	were	
analyzed	 regarding	 their	 protein	 levels	 and	 investigated	under	non-reducing	 conditions	 by	
western	blot	analysis.	Two	clones	of	 the	L.	 tarentolae	 strain	 transfected	with	pX/LTERVC63S	
only	 showed	 a	 minor	 upregulation	 of	 LtErv	 compared	 to	 the	 endogenous	 protein	 level	
observed	in	the	wild-type	sample	(Figure	20,	clone	2	and	clone	3).	These	clones	were	not	used	
for	further	experiments.	All	other	clones	of	L.	tarentolae	transfected	with	pX/LTERVC63S	or	the	
N-terminally	His8-tagged	version	of	the	protein	showed	a	strong	upregulation	of	the	protein.	
For	 all	 analyzed	 clones	of	 the	LtErvC63S	mutant	no	additional	 bands	 that	potentially	 reflect	
mixed	disulfide	intermediates	could	be	observed	under	non-reducing	conditions.		
	
	
Figure	20	|	L.	tarentolae	with	upregulated	LtErvC63S	levels.	Representative	SDS-PAGE	and	western	blot	analysis	
with	5	×	107	parasites/lane	under	 reducing	and	non-reducing	conditions	 (±β-ME).	Five	clones	of	L.	 tarentolae	
transfected	with	pX/LTERVC63S	and	three	clones	of	L.	tarentolae	transfected	with	pX/His8LTERV
C63S	were	analyzed	
regarding	their	protein	levels.	The	cells	were	treated	with	100	mM	NEM	for	5	min	before	harvesting.	The	primary	
antibody	αLtErv	was	diluted	1:500,	the	secondary	antibody	αRabbit	(BioRad)	was	used	1:5000.	The	calculated	
molecular	mass	of	monomeric	LtErv	and	LtErvC63S	is	34.8	kDa	and	35.9	kDa	for	the	tagged	version,	respectively.	
wt:	wild-type;	b-ME:	b-mercaptoethanol.	
	
Mutated	LtsTim1	
The	western	blot	analysis	of	lysates	from	L.	tarentolae	transfected	with	the	different	LTsTIM1	
mutants	 showed	 several	 bands	 with	 a	 higher	 molecular	 weight	 under	 non-reducing	
conditions.	These	bands	could	be	reduced	by	the	addition	of	β-ME	(Figure	21).	The	pattern	
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was	identical	to	the	one	observed	for	wild-type	LtsTim1	treated	with	different	alkylating	and	
redox	active	chemicals	(see	Figure	16).	Hence,	the	trapping	of	mixed	disulfide	intermediates	
of	 LtsTim1	 and	 a	 potential	Mia40	 adapter	 replacement	 could	 not	 be	 further	 enhanced	 by	
mutating	all	but	one	cysteines	of	LtsTim1	in	the	two	different	mutants.	For	the	C2-4S	mutant	
only	faint	bands	with	a	higher	molecular	weight	were	detectable.	Hence,	upregulated	wild-
type	LtsTim1	and the	C1-3S	mutant	were	selected for	further	experiments.	
	
	
Figure	21	 |	Potential	 interaction	partners	of	LtsTim1wt	and	LtsTim1	mutants.	Representative	SDS-PAGE	and	
western	blot	analysis	with	5	×	107	parasites/lane	under	reducing	and	non-reducing	conditions	(±β-ME).	One	of	
each	clones	of	L.	 tarentolae	 transfected	with	pX/His8LTsTIM1	 (LtsTim1),	pX/His8LTsTIM1
C1-3S	(LtsTim1C1-3S)	and	
pX/His8LTsTIM1
C2-4S	 (LtsTim1C2-4S)	 together	 with	 wild-type	 L.	 tarentolae	 lysates	 were	 analyzed	 by	 western	
blotting.	The	cells	were	treated	with	100	mM	NEM	for	5	min	before	harvesting.	The	primary	antibody	αLtsTim1	
was	diluted	1:250,	the	secondary	antibody	αRabbit	(BioRad)	was	used	1:5000.	The	calculated	molecular	mass	of	
monomeric	LtsTim1	and	the	N-terminally	His8-tagged	version	is	11.5	kDa	and	13	kDa,	respectively.	wt:	wild-type;	
b-ME:	b-mercaptoethanol.	
	
3.1.4	The	up-regulated	bait	proteins	are	correctly	localized	
The	localization	of	the	different	up-regulated	bait	proteins	in	L.	tarentolae	was	analyzed	by	
digitonin	 fractionation	 to	 test	 if	 the	 proteins	were	 correctly	 imported	 into	 the	 IMS	 of	 the	
mitochondria.	EF1α	served	as	a	cytosolic	marker	and	was	released	to	the	supernatant	already	
at	 low	 concentrations	 of	 digitonin.	 Even	 in	 the	 fractions	 without	 digitonin	 but	 after	
hypotonous	swelling	or	without	digitonin	and	without	hypotonous	swelling	EF1α	was	partially	
released	to	the	supernatant.	Wild-type	LtErv	and	LtsTim1	(Figure	22,	panel	A)	were	released	
to	the	supernatant	at	higher	concentrations	of	digitonin	compared	to	the	cytosolic	marker.	In	
several	independent	experiments	the	same	pattern	for	LtErv	and	LtsTim1	was	obtained	and	
therefore	this	was	used	as	a	control	pattern	for	the	mitochondrial	localization	of	mutant	LtErv	
and	LtsTim1.	LtErv	was	always	released	to	the	supernatant	at	around	100-150	µg	digitonin/108	
cells	 whereas	 LtsTim1	 was	 only	 solubilized	 with	 the	 highest	 concentration	 of	 2	 mg	
digitonin/108	 parasites	 or	 in	 the	 control	with	 2%	 Triton™	X-100.	 The	 L.	 tarentolae	mutant	
strains	 were	 also	 analyzed	 regarding	 their	 specific	 solubilization	 pattern	 by	 western	 blot	
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analysis.	In	contrast	to	cytosolic	EF1α,	the	proteins	appeared	to	be	correctly	localized	to	the	
mitochondria	of	L.	tarentolae	and	showed	a	similar	pattern	as	endogenous	LtErv.	No	protein	
was	observed	in	the	supernatant	fractions	without	or	with	low	concentrations	of	digitonin.	
The	 upregulated	 proteins	 of	 the	 LtsTim1	mutants	 containing	 only	 one	 cysteine	were	 also	
correctly	 localized	 to	 the	 IMS.	 This	 behavior	 is	 not	 self-explanatory	 because	 the	 mutant	
LtsTim1 cannot	form	internal	disulfide	bonds	anymore,	which	are	usually	a	prerequisite	for	
trapping	the	substrates	in	the	IMS.	Potential	reasons	for	this	behavior	are	discussed	in	section	
4.	Answering	the	question,	to	which	membrane	LtErv	is	associated	would	be	also	interesting	
but	will	require	the	use	of	additional	marker	antibodies	and	was	not	part	of	this	work.	
	
	
	
Figure	22	|	Differential	fractionation	of	whole	cell	lysates	of	L.	tarentolae.	Hypotonous	swelling	in	combination	
with	increasing	digitonin	concentrations	ranging	from	0-2	mg/108	cells	were	used	for	differential	fractionation	of	
the	cells.	Parasites	treated	with	2%	Triton™	X-100	served	as	a	positive	control	for	complete	solubilization.	A:	L.	
tarentolae	wild-type	lysates	showing	the	localization	of	endogenous	LtErv	and	LtsTim1	protein.	EF1α	served	as	a	
marker	 for	 cytosolic	 localization	 whereas	 LtErv	 and	 LtsTim1	 served	 as	 marker	 proteins	 for	 the	 IMS	 of	 the	
mitochondria.	 B-D:	 Differential	 fractionation	 of	 L.	 tarentolae	 strains	 expressing	 the	 indicated	 His8-tagged	
LtsTim1-	or	LtErv-proteins.	
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3.1.5	Enrichment	of	mixed	disulfide	intermediates	by	affinity	chromatography		
Only	a	small	proportion	of	the	bait	protein	is	probably	bound	as	a	mixed	disulfide	intermediate	
with	 its	 potential	 interaction	 partner	 and	 is	 therefore	 difficult	 to	 detect	 in	 western	 blot	
analyses	without	prior	protein	enrichment.	Thus,	affinity	chromatography	by	Ni-NTA	agarose	
with	 His8-tagged	 bait	 proteins	 was	 performed	 under	 native	 and	 denaturing	 conditions.	 A	
native	affinity	chromatography	with	LtErv as	the	bait	protein	led to	a	slight enrichment	of	the	
LtErv	 fraction,	 although	no	bands	with	 a	 higher	molecular	weight	were	 visible	 under	non-
reducing	conditions	(Figure	23).		
	
Figure	23	|	Native	pull-down	with	N-terminally	His8-tagged	LtErv.	Cell	lysis	was	done	by	hypotonous	swelling	
and	 shearing.	 The	 cells	 were	 treated	 with	 100	 mM	 NEM	 for	 5	 min	 prior	 to	 harvesting.	 All	 fractions	 were	
investigated	under	non-reducing	conditions	(-β-ME)	in	order	to	identify	mixed	disulfide	intermediates	between	
LtErv	and	a	potential	Mia40	adapter	replacement.	b-ME:	b-mercaptoethanol;	sn:	supernatant;	depl.:	depleted.		
	
A	denaturing	pull-down	with	LtErvC63S	using	8	M	urea	and	2%	Triton™	X-100	as	the	denaturing	
agents	led	to	a	stronger	enrichment	of	the	bait	protein	than	under	native	conditions,	but	also	
in	this	experiment	no	bands	with	a	higher	molecular	weight	were	visible	under	non-reducing	
conditions	by	western	blot	analysis	(Figure	24).	The	chance	to	identify	potential	interaction	
partners	 of	 LtErv	 in	mass	 spectrometry	 analysis	was	 therefore	 very	 little	 and	 a	 pull-down	
protocol	for	LtsTim1	should	be	established	as	the	next	step	because	for	this	bait	protein	faint	
bands	with	a	higher	molecular	weight	were	already	detectable	endogenously.	
	
	
Figure	24	|	Denaturing	pull-down	with	N-terminally	His8-tagged	LtErv
C63S.	Cell	lysis	and	denaturation	were	done	
with	a	lysis	buffer	containing	8	M	urea	and	2%	Triton™ X-100.	The	eluate	fraction	was	also	investigated	under	
non-reducing	conditions	(-β-ME)	in	order	to	identify	mixed	disulfide	intermediates	between	LtErv	and	a	potential	
Mia40	adapter	replacement.	b-ME:	b-mercaptoethanol.		
	
	 	 3	Results	
 
	
56 
The	protocol	for	denaturing	affinity	chromatography	was	also	used	for	the	L.	tarentolae	strains	
with	 upregulated	 LtsTim1C1-3S	 and	 LtsTim1C2-4S	 but	 did	 not	 lead	 to	 an	 enrichment	 of	 the	
mutated	bait	protein	even	with	altered	buffer	compositions	or	the	use	of	guanidine-HCl	as	the	
denaturing	agent,	thus	raising	the	question	of	stability	and	expression	levels.	For	all	protocols	
that	were	 tested	with	 all	 different	 LtsTim1-strains,	 no	 enrichment	 of	 the	 bait	 protein	was	
possible	in	the	eluate fraction	(data	not	shown).	Thus,	no	samples	of	these	trials	were	further	
analyzed	by	mass	spectrometry.		
	
3.1.6	Screening	for	a	defined	Leishmania	tarentolae	culture	medium	
For	the	identification	of	potential	interaction	partners	of	LtErv	and	LtsTim1,	a	SILAC	(=stable	
isotope	labeling	of	amino	acids	in	cell	culture)	approach	followed	by	mass	spectrometry	was	
initially	planned	to	discriminate	between	unspecific	bindings	and	actual	interaction	partners.	
Such	experiments	require	a	defined	culture	medium	to	ensure	a	labeling	efficiency	of	at	least	
95%.	 With	 a	 defined	 medium,	 the	 incorporation	 of	 heavy	 amino	 acids	 is	 not	 diluted	 by	
unlabeled	amino	acids.		
A	medium	screen	was	performed	with	six	different	media	 that	are	also	available	as	SILAC-
media	with	heavy	isoforms	of	arginine	and	lysine	with	different	supplements.	To	exclude	a	pH-
dependent	 effect	 on	 the	 cell	 survival,	 the	 pH	 of	 the	 different	media	was	 determined	 and	
revealed	comparable	values	between	7.0	and	7.39	and	a	pH	of	6.92	for	the	BHI	control.	The	
concentrations	of	folic	acid,	hemin	solution	and	FCS	were	titrated	resulting	in	a	total	number	
of	 216	 different	 media	 that	 were	 screened	 for	 their	 suitability	 as	 BHI-replacement	 for	
following	SILAC	experiments.	The	cells	were	visually	analyzed	under	the	microscope	and	RPMI-
1640,	DMEM	and	DMEM/F12	with	all	different	variants	of	supplements	could	be	excluded	for	
further	analyses	because	the	cells	completely	died	after	one	to	three	days,	which	is	not	long	
enough	for	sufficient	labeling	with	heavy	amino	acids	in	a	SILAC	experiment.		
Subsequently,	 selected	 compositions	 of	 IMDM,	 McCoy’s	 5A	 and	 MEM	 were	 further	
investigated	in	comparison	to	BHI	as	a	positive	control	in	a	growth	curve	analysis	(Figure	25).	
The	 cells	 showed	medium	 specific	 maximum	 growth	 rates	 and	 doubling	 times	 that	 were	
calculated	from	the	growth	curves	and	are	listed	in	Table	13.	The	highest	maximum	cell	density	
and	shortest	doubling	time	were	observed	in	McCoy’s	media	containing	10%	FCS.	The	cells	in	
this	culture	grew	even	better	than	in	the	BHI	control.	For	all	media,	the	growth	of	cells	was	
better	with	10%	FCS	compared	to	5%	FCS,	which	shows	that	addition	of	serum	is	necessary	
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when	using	a	defined	medium.	IMDM	supplemented	with	0.5%	AlbuMax™	as	a	serum-free	
alternative	confirmed	this	result	because	the	cells	did	not	grow	at	all.	
	
	
Figure	25	|	Growth	rates	of	L.	tarentolae	in	different	media.	L.	tarentolae	cells	were	cultivated	under	normal	
conditions	in	different	media.	The	cell	density	was	determined	every	24	h	by	counting.	The	data	was	analyzed	
with	SigmaPlot	13	using	a	sigmoidal	curve	fit.	All	data	points	represent	the	mean	±	standard	deviation	from	two	
independent	experiments.	FCS:	fetal	calf	serum.		
	
The	parasites	were	also	analyzed	regarding	their	cell	morphology	(Figure	26).	Cells	cultivated	
in	IMDM	supplemented	with	0.5%	AlbuMax™	as	a	serum-free	alternative	served	as	a	negative	
control	and	showed	aggregates	of	cells	with	reduced	motility.	Parasites	cultivated	in	IMDM,	
MEM	or	McCoy’s	5A	supplemented	with	10%	FCS	all	showed	a	normal	cell	morphology	and	a	
motility	comparable	to	the	positive	control	with	L.	tarentolae	cultivated	in	BHI.	
	
Table	 13	 |	 Growth	 parameters	 for	 L.	 tarentolae	 from	 Figure	 25.	 Comparison	 of	 growth	 parameters	 for	 L.	
tarentolae	in	different	defined	culture	media	in	comparison	to	BHI.	
	
Medium	 Maximum	cell	density	
	[107	cells/mL]	
Doubling	time			
[h]	
BHI	 12.08	 12.41	
IMDM	+	0.5%	AlbuMax™	 0.66	 N/A	
IMDM	+	5%	FCS	 5.09	 22.02	
IMDM	+	10%	FCS	 8.05	 17.85	
McCoy’s	+	5%	FCS	 10.44	 18.85	
McCoy’s	+	10%	FCS	 13.57	 9.42	
MEM	+	5%	FCS	 4.55	 13.02	
MEM	+	10%	FCS	 7.37	 9.80	
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Figure	26	|	Morphology	of	L.	 tarentolae	 in	different	media.	Light	microscopy	of	mid-log	phase	L.	 tarentolae	
promastigotes	in	A)	IMDM	+	0.5%	AlbuMax™,	B)	BHI,	C)	IMDM	+	10%	FCS,	D)	MEM	+	10%	FCS	or	E)	McCoy’s	5A	
+	10%	FCS.		
	
The	FCS	used	for	the	experiments	shown	above	also	contains	amino	acids	and	therefore	needs	
to	be	changed	to	dialyzed	FCS	to	avoid	dilution	of	the	labeling	efficiency	in	a	SILAC	experiment.	
Hence,	the	influence	of	dialyzed	FCS	on	the	parasite	growth	was	determined	and	cells	were	
cultivated	in	IMDM	supplemented	with	10%	dialyzed	FCS.	Cells	cultivated	with	BHI	and	cells	
cultivated	with	IMDM	supplemented	with	10%	non-dialyzed	FCS	served	as	positive	controls.	
All	media	were	supplemented	with	10	µg/ml	hemin	chloride.	Cells	cultivated	in	IMDM	with	
10%	dialyzed	FCS	died	within	24	h	whereas	the	positive	controls	showed	normal	growth	rates	
and	morphology.	Hence,	a	SILAC	experiment	with	L.	tarentolae	was	not	possible	because	no	
suited	 defined	 cultivation	medium	 that	might	 be	 used	 instead	 of	 undefined	 BHI	 could	 be	
identified	 in	 this	 work.	 Further	 testing	 of	 different	 supplements	 would	 be	 necessary	 to	
determine	a	defined	medium	for	the	use	in	a	SILAC	experiment.		
	
3.1.7	Identification	of	interaction	partners	with	BioID	
As	the	different	trials	of	trapping	a	mixed	disulfide	 intermediate	of	LtErv	or	LtsTim1	with	a	
potential	 Mia40	 adapter	 replacement	 were	 not	 successful,	 BioID	 should	 be	 tested	 as	 an	
independent	 approach	 for	 finding	 potential	 interaction	 partners	 of	 the	 two	 bait	 proteins.	
L.	tarentolae	was	transfected	with	the	constructs	shown	in	Figure	27	containing	a	Myc-tagged	
BirA*	fused	to	the	N-terminus	of	the	bait	protein.		
The	 parasites	 transfected	 with	 the	 BirA*-LTsTIM1	 construct	 were	 first	 analyzed	 by	
immunofluorescence	microscopy.	No	signal	for	Myc	and	Streptavidin	could	be	detected	after	
an	 unspecific	 binding	 of	 the	 secondary	 antibody	 was	 excluded	 by	 omitting	 the	 primary	
antibody.	Therefore,	the	success	of	the	transfection	should	first	be	confirmed	by	western	blot	
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analysis.	Only	unspecific	signals	for	the	Myc-antibody	could	be	detected	and	no	streptavidin-
signal	 was	 visible.	 The	 level	 of	 overexpression	 was	 difficult	 to	 elucidate	 because	 of	 the	
problems	with	the	LtsTim1-antibody	described	before.	Owing	to	that	difficulties,	the	strains	
transfected	with	the	BirA*-LTERV	construct	should	be	analyzed	instead.	Western	blot	analysis	
revealed	much	higher	 levels	 of	 LtErv	 in	 the	 control	 sample	 (L.	 tarentolae	 transfected	with	
pX/LTERV)	 compared	 to	 the	 strains	 with	 the	 BirA*-LtErv	 fusion	 protein.	 No	 signal	 was	
detectable	for	streptavidin,	which	showed	that	no	biotinylation	of	proteins	took	place	under	
the	used	experimental	conditions.	Therefore,	prolonged	incubation	times	with	150	µM	biotin	
for	48	h	or	72	prior	to	harvesting	were	also	tested	and	showed	the	same	results	than	a	24	h	
incubation	 (data	 not	 shown).	 In	 summary,	 the	 identification	 of	 a	 potential	Mia40	 adapter	
replacement	was	not	possible	in	this	work	using	BioID.	
	
	
	
Figure	 27	 |	 Constructs	 for	 BioID	 experiments.	 The	 constructs	were	 cloned	 into	 the	 pX-backbone	 vector	 for	
expression	in	L.	tarentolae.	The	proteins contain	a	Myc-tagged BirA*	fused	to	the	N-terminus of	LtErv	or	LtsTim1.	
The	strategy	is	based	on	the	publication	of	Roux	et	al.	2014	[74].	
	
3.1.8	Redox	state	of	Erv	in	Leishmania	tarentolae	
To	determine	the	redox	state	of	endogenous	LtErv,	a	mobility	shift	assay	was	performed.	A	
redox	mobility	shift	assay	using	alkylation	by	mm(PEG)24,	which	leads	to	a	mass	shift	of	1.2	
kDa	per	accessible	cysteine	residue,	was	therefore	established	in	this	work.	The	first	lane	in	
Figure	28	showed	reduced,	unmodified	LtErv	with	an	expected	molecular	mass	of	around	35	
kDa.	Lanes	2-6	showed	LtErv	signals	for	differently	treated	L.	tarentolae	samples	modified	by	
mm(PEG)24.	In	lane	2	the	physiological	redox	state	of	LtErv	was	elucidated.	There	were	mainly	
two	bands	detectable,	of	which	the	lower	one	corresponds	to	the	size	of	unmodified	LtErv	as	
shown	 in	 lane	1.	The	band	with	 the	higher	molecular	weight	 indicated	 the	modification	of	
probably	one	cysteine	residue	of	LtErv.	The	results	suggest	that	in	the	predominant	form	all	
but	one	of	 the	 cysteine	 residues	of	LtErv	are	either	oxidized	or	 inaccessible	 to	mm(PEG)24	
under	physiological	conditions.	The	next	lanes	showed	the	modification	of	mildly	(lane	3)	or	
strongly	(lane	4)	reduced	LtErv	by	TCEP	at	either	27°C	or	95°C.	A	shift	towards	higher	molecular	
weight	species	of	LtErv	 indicating	the	modification	of	reduced	cysteines	by	mm(PEG)24	was	
detectable.	For	the	strong	reduction	of	the	sample	only	one	band	reflecting	the	modification	
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of	all	cysteines	was	expected	in	theory.	In	this	experiment,	mainly	two	bands	with	a	higher	
molecular	weight	were	observed	indicating	that	either	not	all	cysteines	were	accessible	even	
after	 a	 theoretically	 complete	 reduction	 or	 that	 the	 concentration	 of	mm(PEG)24 was not	
sufficient	for	modification	of	all	cysteines.	The	second	possible	explanation	was	excluded	by	
titrating	the	concentration	of	the	alkylating	agent	leading	to	the	same	result.	With	the	samples	
analyzed	in	the	two	last	lanes	it	should	be	tested	if	the	concentration	of	NEM	is	sufficient	to	
alkylate	free	cysteines	in	living	L.	tarentolae	cells	as	it	was	done	for	several	other	experiments	
in	order	to	freeze	the	redox	state	of	the	cell	and	potentially	trap	mixed	disulfide	intermediates	
between	LtErv	or	LtsTim1	and	a	potential	Mia40	adapter	replacement.	A	shift	towards	lower	
molecular	 species	 of	 LtErv	 compared	 to	 lane	 2	 and	 3	 was	 observed	 indicating	 that	 the	
concentration	of	NEM	was	at	least	partially	sufficient	to	enter	the	cell	and	block	free	cysteines	
in	living	L.	tarentolae.	In	summary,	endogenous	LtErv	appears	to	be	mainly	oxidized	in	vivo.		
	
	
Figure	28	|	Evaluation	of	the	physiological	redox	state	of	LtErv	using	mm(PEG)24-redox	mobility	shift	assays.	
Leishmania	tarentolae	promastigotes	were	treated	with	or	without	100	mM	NEM	in	order	to	preserve	the	redox	
state	and	to	block	free	thiol	groups.	The	cells	were	lysed	in	SDS-sample	buffer	with	or	without	the	reducing	agent	
TCEP	 at	 27	 or	 95°C	 as	 indicated.	 Free	 thiols	were	 subsequently	 alkylated	with	mm(PEG)24,	which	 leads	 to	 a	
theoretical	mass	shift	of	1.2	kDa	per	accessible	cysteine	residue.	Lysates	containing	5	×	107	parasites	per	lane	
were	analyzed	by	SDS-PAGE	and	western	blotting	against	LtErv.	
	
3.1.9	Overexpression	of	the	gene	encoding	PfErv	in	Leishmania	tarentolae	
P.	 falciparum	ERV1	was	cloned	with	or	without	an	N-terminal	His8-tag	 in	 the	L.	 tarentolae	
vector	 pX-backbone.	 The	 protein-coding	 sequences	 of	 both	 plasmids	 were	 confirmed	 by	
sequencing	 before	 the	 transfection	 of	 L.	 tarentolae.	 The	 heterologous	 expression	 of	
recombinant	PFERV	was	confirmed	by	western	blot	analysis	of	L.	 tarentolae	 lysates	with	a	
PfErv-specific	antibody	(Figure	29).	Leishmania	tarentolae	and	P.	falciparum	wild-type	lysates	
served	as	a	negative	and	positive	controls,	respectively.	There	was	a	band	detectable	with	the	
expected	mass	for	His8-tagged	PfErv	at	around	17	kDa	(calculated	molecular	mass:	18.5	kDa)	
in	addition	to	an	unspecific	band	below	that	was	also	detected	in	the	negative	control.	The	
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upregulation	 of	 His8-tagged	PfErv	 appeared	 to	 be	 strongest	with	 10	 ×	 G418	 (1	mg/ml)	 at	
comparable	allover	protein	levels	shown	by	the	PonceauS-staining	of	the	membrane	(data	not	
shown).	This	G418-concentration	was	used	for	purification	trials	by	affinity	chromatography	
using	Ni-NTA	agarose	columns.	PfErv	should	be	purified	from	L.	tarentolae	because	different	
purification	 trials	with	E.	 coli	were	 not	 successful	 before	 and	 resulted	 in	 the	 formation	 of	
inclusion	bodies [38]. There	are	a	lot	of	examples	in	literature	with biologically	active,	natively	
processed	proteins	produced	 in	L.	 tarentolae	as	reviewed	by	Breitling	et	al.	2002	[60].	The	
resulting	eluate	fraction	was	planned	to	be	used	for	crystallization	trials	and	kinetic	analyses.		
	
	
Figure	29	|	Recombinant	expression	of	PFERV	in	L.	tarentolae.	Leishmania	tarentolae	and	P.	falciparum	wild-
type	lysates	(Lt	wt	and	Pf	wt)	served	as	negative	and	positive	controls,	respectively.	The	selection	marker	G418	
was	added	in	different	concentrations	to	parasites	producing	His8-tagged	PfErv.	The	calculated	molecular	mass	
of	His8-tagged	PfErv	is	18.5	kDa.	
	
Different	 protocols	 were	 tested	 for	 the	 purification	 of	 PfErv	 from	 L.	 tarentolae.	 The	 L.	
tarentolae	strains	producing	N-terminally	His8-tagged	PfErv	were	cultivated	in	1	liter	of	mid-
log	phase	cells.	In	a	first	trial	a	protocol	similar	to	the	one	used	for	the	purification	of	PfGR	
from	E.	coli	was	used	(see	section	2.5.1;	buffer	I	and	II	GR).	The	cell	lysis	was	performed	by	
sonication	 and	 the	 success	 of	 the	 lysis	 was	 checked	 under	 the	 microscope.	 A	 prolonged	
sonication	(10	cycles	with	each	10	sec)	was	necessary	to	lyse	the	parasites	and	the	column	
volume	was	reduced	to	100	µl	Ni-NTA	(protocol	a).	A	western	blot	analysis	was	performed	
with	the	PfErv-specific	antibody	and	a	signal	at	around	18	kDa	corresponding	to	the	molecular	
mass	of	PfErv	was	detected	in	the	input	and	pellet	fraction.	Only	a	faint	band	for	PfErv	was	
visible	 in	 all	 the	 other	 fractions	 including	 the	 eluate	 fraction	 showing	 that	 under	 these	
conditions	no	enrichment	of	PfErv	was	possible.		
To	increase	the	solubility	of	the	protein,	different	other	protocols	were	tested	with	the	same	
negative	 result.	 A	 disruption	 buffer	 containing	 0.25%	 (v/v)	 Tween	 20,	 20	 mM	 imidazole,	
300	mM	NaCl	and	50	mM	sodium	phosphate	with	a	pH	of	8.5	at	4°C	combined	with	sonication	
was	 tested	with	 two	 rounds	 of	 lysis	 (protocol	 b).	 In	 another	 protocol,	 a	 hypotonic	 buffer	
containing	1	mM	Tris/HCl	with	pH	7.9	at	4°C	combined	with	sonication	in	two	rounds	of	lysis	
was	tested	(protocol	c).	Furthermore,	the	pellet	resulting	from	protocol	b	was	solubilized	with	
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250	µg	digitonin	per	108	cells.	This	approach	also	did	not	lead	to	an	enrichment	of	PfErv	in	the	
eluate	 fraction.	Taken	together	PfErv	could	be	successfully	produced	 in	L.	 tarentolae	but	a	
native	purification	for	further	studies	was	not	possible	under	the	chosen	conditions.	
	
	
Figure	30	|	Native	pull-down	with	a	L.	tarentolae	strain	producing	N-terminally	His8-tagged	PfErv.	Cell	lysis	was	
done	according	to	protocol	a)	by	sonication.	The	different	fractions	were	analyzed	by	western	blotting	and	the	
result	is	representative	also	for	the	other	purification	trials	with	altered	conditions.		
	
3.1.10	Detection	of	potential	interaction	partners	of	PfErv	
Potential	interaction	partners	of	PfErv	in	P.	falciparum	3D7	trophozoite	lysates	were	analyzed	
by	 western	 blotting under	 reducing	 and	 non-reducing	 conditions	 with	 a	 PfErv-specific	
antibody	[38].	The	parasites	were	treated	with	or	without	100	mM	NEM	for	5	min	to	stabilize	
potential	disulfide-bridged	interaction	partners.	Figure	31	shows	a	strong	PfErv-specific	signal	
with the	expected	mass for	the	monomeric	isoform	at	around	17	kDa	for	all	conditions.	There	
are	three	additional	bands	visible	in	the	sample	treated	with	100	mM	NEM	that	was	analyzed	
under	 non-reducing	 conditions.	 The	 protein	 detected	 with	 the	 highest	molecular	mass	 at	
around	 34	 kDa	 might	 indicate	 a	 dimeric	 isoform	 of	 PfErv.	 This	 band	 is	 not	 visible	 under	
reducing	conditions	as	expected	for	disulfide-bridged	protein	interactions.	Band	2	at	around	
26	kDa	could	indicate	a	potential	interaction	partner	of	PfErv	might	be	also	disulfide-bridged	
because	it	disappears	under	reducing	conditions.	Band	3	runs	below	the	monomeric	isoform	
of	 PfErv	 between	 10	 and	 17	 kDa	 and	might	 indicate	 a	 monomeric	 isoform	 of	 PfErv	 with	
intramolecular	disulfide-bridges	that	are	stabilized	by	the	alkylating	agent	NEM	because	this	
band	 is	not	 visible	 in	 the	 sample	 that	was	analyzed	under	 reducing	 conditions	after	NEM-
treatment.		
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Figure	31	|	Identification	of	potential	interaction	partners	of	PfErv.	P.	falciparum	3D7	trophozoites	were	treated	
with	or	without	100	mM	NEM	as	indicated.	Parasite	lysates	containing	107	parasites	per	lane	were	analyzed	by	
(non-)reducing	SDS-PAGE	and	western	blotting.	M,	monomeric	PfErv	(with	a	calculated	molecular	mass	of	17.2	
kDa).	Bands	1	and	2	might	 indicate	either	disulfide-bonded	dimeric	PfErv	or	potential	 interaction	partners	of	
PfErv.	
	
	
3.2	Glutaredoxins	
The	 second	 objective	 of	 this	 PhD	 was	 to	 analyze	 the	 general	 applicability	 of	 the	 results	
obtained	 from	prior	 analysis	 of	 ScGrx7,	which	 revealed	 a	 distinct	 glutathione	 scaffold	 and	
activator	site	during	the	MD	thesis	of	Patricia	Begas.	Thus,	PfGrx	was	analyzed	as	a	non-related	
model	 system	 and	 the	 results	 were	 published	 in	 Nature	 Communications	 with	 the	 title	
“Glutaredoxin	catalysis	requires	two	distinct	glutathione	interaction	sites”	by	Begas	et	al.	2017	
[116].	Additional	residues	of	ScGrx7	that	might	be	part	of	the	glutathione	activator	site	were	
analyzed	to	gain	more	insights	into	the	exact	structure-function	relationships	of	Grx	and	to	
define	the	substrate	binding	sites	in	more	detail.		
	
3.2.1	Selection	of	residues	of	PfGrx	and	ScGrx7	mutants	
First,	homologous	residues	of	the	proposed	glutathione	activator	and	glutathione	scaffold	site	
in	S.	cerevisiae	were	selected	in	Grx	from	the	non-related	parasite	P.	falciparum.	Lys26	from	
PfGrx	is	corresponding	to	Lys105	of	ScGrx7	and	is	shown	in	Figure	32	as	residue	1	in	strand	1.	
This	residue	is	conserved	in	many	Grx	[106,	112,	113,	156].	Furthermore,	the	positive	charge	
of	this	amino	acid	could	help	to	bind	the	substrate	GSH	as	GS-.	The	acidic	residue	Asp90	of	
PfGrx	was	chosen	as	the	homolog	of	residue	Glu170	in	ScGrx7	and	is	shown	as	residue	6	in	
Figure	32.	This	residue	could	contribute	to	a	strong	 ionic	glutathione	 interaction	due	to	 its	
charge.	 Furthermore,	 residue	 6	 is	 conserved	 in	 enzymatically	 active	 in	 contrast	 to	
enzymatically	inactive	Grx.	Alanine	mutants	of	both	residues	of	PfGrx	were	generated	by	side-
directed	mutagenesis.	The	correct	mutations	were	confirmed	by	sequencing.		
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For	a	potential	further	mapping	of	the	glutathione	activator	site,	several	ScGrx7	mutants	were	
selected	 and	 subsequently	 analyzed	 in	 GSSCys	 or	 HEDS	 steady-state	 kinetic	 assays.	 First,	
Tyr110	 in	 the	 CPYS-motif	 in	 helix	 2	 of	 ScGrx7	 was	 selected	 as	 a	 potential	 glutathione	
interaction	residue.	The	hydroxyl	group	of	the	conserved	residue	Tyr110	could	contribute	to	
the	glutathione	activator	site	because	it	is	replaced	in	enzymatically	inactive	Grx	[112,	113]	
and	sticks	out	on	the	protein	surface.	Phe,	His	and	Ala	mutants	were	generated	of	residue	
Tyr110	and	subsequently	analyzed	 in	GSSCys	and	HEDS	assays.	The	two	acidic	amino	acids	
Asp144	and	Glu147	in	helix	3	(residue	r3*	in	Figure	32)	were	selected	as	potential	glutathione	
activator	 residues	 because	 of	 geometric	 reasons	 and	 Glu147	 is	 also	 conserved	 in	 many	
enzymatically	active	Grx.	As	another	potential	residue	that	could	contribute	to	the	glutathione	
activator	 site	 Arg153	 in	 the	 loop	was	 chosen	 (residue	 3,	 Figure	 32).	 Charge	 inversion	 and	
alanine	mutants	of	Asp144,	Glu147	and	Arg153	were	generated	and	subsequently	analyzed	in	
a	GSSCys	assay.		
	
 
	
 
Figure	 32	 |	 Sequence	 alignment	 of	 different	 members	 of	 the	 thioredoxin	 superfamily.	 The	 sequences	 of	
different	 glutaredoxin	 isoforms	were	 compared	with	 other	members	 of	 the	 thioredoxin	 superfamily	 from	A.	
thaliana	(At),	S.	cerevisiae	(Sc),	Homo	sapiens	(Hs),	P.	falciparum	(Pf),	E.	coli	(Ec)	and	C.	glutamicium	(Cg).	The	
alignment	was	done	manually	based	on	structural	overlays.	The	figure	was	adapted	from	Begas	et	al.	[116].	The	
numbering	of	the	residues	r1-7	as	potential	glutathione-interacting	amino	acids	is	based	on	previous	publications	
[106,	 112].	 The	 residues	 marked	 with	 orange	 boxes	 and	 arrows	 were	 analyzed	 as	 potential	 glutathione-
interacting	amino	acids	in	this	work.	
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3.2.2	Purification	of	recombinant	PfGrx	and	ScGrx	mutants	
The	different	mutants	of	ScGrx7	and	PfGrx	were	purified	by	Ni-NTA	affinity	chromatography	
for	kinetic	characterization.	The	obtained	eluate	fractions	were	analyzed	regarding	their	purity	
on	a	SDS-gel.	Figure	33	shows	gels	with	representative	eluate	fractions.	The	observed	size	for	
PfGrx	fits	to	the	calculated	molecular	mass	of	13.6	kDa.	ScGrx7	(calculated	molecular	mass	of	
20.2	kDa)	runs	above	25	kDa	as	observed	before [112] and	shows	only	a	minor	 fraction	of	
degradation	 product	 or	 contamination.	 The	 protein	 concentrations	 were	 determined	 by	
Bradford	 assays.	 Average	 yields	 from	 up	 to	 seven	 independent	 protein	 purifications	 of	
PfGrxC32S/C88S, PfGrxC32S/C88S/K26A and PfGrxC32S/C88S/D90A were	8.8±3.8,	31±10	and	5.1±1.9	mg	of	
recombinant	protein	per	liter	of	E.	coli	culture,	respectively.	Average	yields	from	up	to	seven	
independent	 protein	 purification	 experiments	 for	 each	 ScGrx7	mutant	 were	 highly	 repro-
ducible	and	ranged	from	12.6±4.1	to	16.4±7.7	mg	of	recombinant	protein	per	liter	of	E.	coli	
culture	depending	on	the	mutant.		
 
 
 
Figure	33	|	Purification	of	recombinant	wild-type	and	mutant	ScGrx7	and	PfGrx	enzymes.	The	eluate	fractions	
of	representative	Grx	purifications	by	Ni-NTA	affinity	chromatography	are	shown	on	a	15%	SDS-gel.	A:	Mutants	
of	the	double	cysteine	mutant	PfGrxC32S/C88S	run	according	to	the	calculated	molecular	mass	of	13.6	kDa.	DM:	
PfGrxC32S/C88S,	K26A:	PfGrxC32S/C88S/K26A,	D90A:	PfGrxC32S/C88S/D90A.	B:	Tyr110-mutants	of	ScGrx7.	C:	Asp144,	Glu147	
and	Arg153	mutants	 of	ScGrx7.	 The	 calculated	molecular	mass	of	ScGrx7	 is	 20.2	 kDa.	WT:	ScGrx7	wild-type,	
Y110A:	 ScGrx7Y110A,	 Y110H:	 ScGrx7Y110H,	 Y110F:	 ScGrx7Y110F,	 D144E:	 ScGrx7D144E,	 D144A:	 ScGrx7D144A,	 D144K:	
ScGrx7D144K,	E147A:	ScGrx7E147A,	E147K:	ScGrx7E147K,	R153A:	ScGrx7R153A,	R153E:	ScGrx7R153E.	Panel	A	was	adapted	
from	Begas	et	al.	2017	[116].	
	
3.2.3	Kinetics	of	PfGrx	mutants	in	the	GSSCys	assay	confirm	a	conserved	mechanism	
It	was	tested	if	the	results	obtained	from	kinetic	characterization	of	ScGrx7	mutants	indicate	
a	 general	 catalysis	mechanism	with	 two	distinct	 glutathione	 interaction	 sites	 as	previously	
suggested	 [106,	 116].	 Therefore,	 corresponding	 point	 mutants	 of	 the	 non-related	 P.	
falciparum	 enzyme	 PfGrx	 were	 analyzed	 in	 Grx	 steady-state	 kinetic	 assays.	 The	 mutants	
PfGrxC32S/C88S/K26A	 and	 PfGrxC32S/C88S/D90A	 were	 generated	 in	 the	 monothiol	 double	 mutant	
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PfGrxC32S/C88S,	which	has	only	one	cysteine	to	avoid	side	reactions	that	might	complicate	the	
interpretation	of	the	kinetics	[138].		
Recombinant	mutants	obtained	from	affinity	chromatography	were	subsequently	analyzed	in	
a	GSSCys	and	HEDS	assay	with	PfGrxC32S/C88S	as	 a	 control.	 In	a	 first	 set	of	experiments,	 the	
effects	 of	 the	 mutations	 were	 analyzed	 in	 steady-state	 assays	 with	 variable	 GSH	
concentrations	at	fixed	GSSCys	concentrations	or	variable	GSSCys	concentrations	with	fixed	
GSH	concentrations,	respectively.	Both	mutants,	as	well	as	the	control,	revealed	ping-pong	
kinetics	shown	by	parallel	lines	for	the	different	substrate	concentrations	in	the	Lineweaver-
Burk	 blots (Supplementary	 figure	 1,	 panel	 b,	 c,	 e and	 f).	 This	 indicates that	 a	 general	
mechanism	with	separated	oxidative	and	reductive	half-reaction	as	it	was	observed	before	for	
the	ScGrx7	mutants	was	not	affected	by	the	mutations	[116].	The	activity	of	PfGrxC32S/C88S/K26A	
in	the	GSSCys	assay	was	strongly	reduced	and	the	final	concentration	of	that	mutant	had	to	
be	increased	by	factor	10,	whereas	the	activity	of	PfGrxC32S/C88S/D90A	was	similar	to	the	control	
(Supplementary	figure	1,	panel	a	and	d)	and	the	final	concentration	of	PfGrxC32S/C88S/D90A	in	the	
assay	was	the	same	as	used	for	the	control.	The	enzyme-specific	apparent	parameters	Km
app	
and	kcat
app	were	derived	from	analysis	according	to	Michaelis-Menten,	Lineweaver	Burk,	Eadie	
Hofstee	and	Hanes	theory	and	showed	high	similarities	for	all	analyses.	Supplementary	table	
1	lists	selected	kinetic	constants	from	non-linear	regression	analysis	of	the	Michaelis-Menten	
plots	of	Supplementary	figure	1.	In	Figure	34	the	apparent	kinetic	constants	are	visualized	as	
bar	charts	(panel	A,	B	and	C).	The	replacement	of	Lys26	in	PfGrx	by	an	alanine	led	to	a	decrease	
of	the	kcat
app	of	68-95%	for	both	substrates	indicating	a	role	of	this	residue	for	the	oxidative	
half-reaction	with	GSSCys	as	well	as	the	reductive	half-reaction	with	GSH	(Figure	34,	panel	A).	
Furthermore,	PfGrxC32S/C88S/K26A	showed	increased	Km
app	(GSSCys)	values	and	decreased	Km
app	
(GSH)	values	compared	to	the	control.	The	observed	effects	on	the	kcat
app	and	Km
app	are	mostly	
significant	(statistical	analyses	are	listed	in	Supplementary	table	8	A).	The	catalytic	efficiencies	
defined	by	the	ratio	kcat
app/Km
app	were	decreased	by	62-67%	for	the	reductive	half-reaction	
with	GSH	and	95%	for	the	oxidative	half-reaction	with	GSSCys	for	PfGrxC32S/C88S/K26A	(Figure	34,	
panel	C).		
The	replacement	of	Asp90	in	PfGrx	by	an	alanine	affected	the	kinetic	parameters	to	a	smaller	
extent	than	the	Lys26	mutant.	The	PfGrxC32S/C88S/D90A	mutant	showed	slightly	reduced	kcat
app	
and	 Km
app	 values	 for	 GSH	whereas	 the	 kcat
app	 and	 Km
app	 values	 for	 GSSCys	 were	 increased	
(Figure	34,	panel	A	and	B;	Supplementary	table	1).	The	catalytic	efficiencies	kcat
app/Km
app	for	
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GSSCys	were	reduced	by	around	20%	in	contrast	to	the	catalytic	efficiencies	for	GSH	that	were	
increased	to	125-144%	(Figure	34,	panel	C;	Supplementary	table	1).		
For	further	analyses	of	the	kinetic	properties	of	the	two	alanine	mutants, secondary	plots	were	
generated	(Supplementary	figure	2).	The	values	for	Km
app	and	kcat
app	were	obtained	from	the	
Michaelis-Menten	plots	 in	Supplementary	figure	1.	These	plots	allow	the	estimation	of	the	
true	kcat value	from	the	y-axis	intercept	(1/kcat)	and	the	true	Km value	from	the	x-axis	intercept	
(-1/Km).	The	estimated	true	kinetic	parameters	are	listed	in	Table	14.	Both	of	the	mutants	as	
well	as	the	control	tended	to	have	infinite	true	kcat	and	Km	values	as	shown	before	for	ScGrx7	
[116].	This means that	the	enzymes	are	not	saturated	by	both	of	the	substrates.	The	equation
[E]/V	 =	F1/[GSSCys]	 +	F2/[GSH]	 can	be	used	 to	describe	 the	 velocity	 of	 such	 a	ping-pong	
reaction.	The	Dalziel	coefficient	F1	is	the	slope	of	the	secondary	plot	for	kcatapp	(GSH),	whereas	
the	Dalziel	coefficient	F2	is	the	slope	of	the	secondary	plot	for	kcatapp	(GSSCys).	The	reciprocal	
Dalziel	 coefficient	 1/F1	 can	 be	 interpreted	 as	 the	 apparent	 rate	 constant	 koxapp	 for	 the	
oxidative	half-reaction	with	GSSCys,	whereas	1/F2	can	be	 interpreted	as	the	apparent	rate	
constant	kred
app	 for	the	reductive	half-reaction	with	GSH.	These	values	 for	PfGrxC32S/C88S/K26A	
and	PfGrxC32S/C88S/D90A	 as	well	 as	 for	 the	 corresponding	 control	 are	 listed	 in	 Table	 14.	 Both	
reciprocal	 Dalziel	 coefficients	 were	 highly	 similar	 to	 the	 corresponding	 apparent	 catalytic	
efficiencies	 as	 it	was	 also	 observed	before	 for	 the	 homologous	ScGrx7	mutants	 [116].	 For	
PfGrxC32S/C88S/K26A,	 both	 values	 were	 decreased	 by	 up	 to	 one	 or	 two	 orders	 of	magnitude,	
whereas	 for	 PfGrxC32S/C88S/D90A	 only	 1/F1	 was	 slightly	 reduced	 in	 contrast	 to	 the	 second	
reciprocal	Dalziel	coefficient	1/F2	(Figure	34,	panel	D	and	Table	14).		
	
Table	14	|	Kinetic	constants	for	PfGrx	mutants	in	the	GSSCys	assay.	Estimated	true	kinetic	constants	kcat,	Km	and	
Dalziel	coefficients	of	PfGrxC32S/C88S	and	the	mutants	K26A	and	D90A	 in	the	GSSCys	assay.	The	constants	were	
obtained	from	Supplementary	figure	2.	DM:	PfGrxC32S/C88S;	K26A:	PfGrxC32S/C88S/K26A;	D90A:	PfGrxC32S/C88S/D90A.	The	
data	was	already	published	in	Begas	et	al.	2017	[116].	
	
           1/F1  1/F2 kcat       Km (GSH) Km (GSSCys)  
PfGrx  (M-1s-1)  (M-1s-1) (s-1)  (mM) (mM) 
         
   DM  1.3 ´ 106  1.2 ´ 105 ¥  ¥ ¥ 
K26A  6.9 ´ 104  5.0 ´ 104 34 - ¥  0.7 - ¥ 1.2 - ¥ 
                  DM  1.4 ´ 106  1.2 ´ 105 289 - ¥  2.2 - ¥ 0.4 - ¥ 
D90A  1.0 ´ 106  1.7 ´ 105 ¥  ¥ ¥ 
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In	summary,	the	role	of	residue	r1	(Figure	32)	as	a	GSH	and	enzyme	activator	for	Grx	catalysis	
in	the	GSSCys	assay	could	be	confirmed	using	PfGrx	from	the	non-related	apicomplexan	P.	
falciparum.	 The	 determined	 kinetic	 constants	 of	 PfGrxC32S/C88S/K26A	 revealed	 extreme	
similarities	 to	 the	 homologous	 mutant	 ScGrx7K105A	 in	 the	 GSSCys	 assay	 and	 support	 a	
conserved	catalytic	mechanism.	The	same	is	true	for	the	role	of	residue	r6	with	highly	similar	
results	for	PfGrxC32S/C88S/D90A	compared	to	the	homologous	mutant ScGrx7E170A.	Both	mutants	
decelerated	the	reaction	with	GSSCys	as	a	substrate	in	the	GSSCys	assay	but	not	with	GSH.	In	
summary,	also	the	role	of	residue	r6	(Figure	32)	as	a	scaffold	site	in	the	GSSCys	assay	could	be	
confirmed	using	PfGrx.	
 
Figure	34	|	Relevance	of	Lys26	and	Asp90	of	PfGrx	in	the	GSSCys	assay.	A:	Selected	kcat
app	values	of	the	PfGrx	
mutants	 for	 GSSCys	 and	 GSH	 obtained	 from	 Supplementary	 figure	 1.	 B:	 Selected	Km
app	 values	 for	 the	 PfGrx	
mutants	for	GSSCys	and	GSH	obtained	from	Supplementary	figure	1.	C:	The	catalytic	efficiencies	for	GSSCys	and	
GSH	were	calculated	from	panels	A	and	B.	D:	The	reciprocal	Dalziel	coefficients	were	obtained	from	the	slopes	
of	the	secondary	plots	in	Supplementary	figure	2.	E:	Summary	of	the	kinetic	parameters	from	panels	A,	B	and	C.	
DM:	PfGrxC32S/C88S;	K26A:	PfGrxC32S/C88S/K26A;	D90A:	PfGrxC32S/C88S/D90A.	Adapted	from	Begas	et	al.	2017	[116].		
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3.2.4	Kinetics	of	PfGrx	mutants	in	the	HEDS	assay	confirm	a	conserved	mechanism	
It	was	tested	if	the	generalized	catalytic	mechanism	is	also	observed	in	the	HEDS	assay.	The	
primary	analyses	of	the	PfGrx	mutants	in	the	HEDS	assay	are	shown	in Supplementary	figure	
3,	the	apparent	rate	constants	are	listed	in	Supplementary	table	2	and	secondary	plots	are	
shown	in	Supplementary	figure	4.	Statistical	analyses	can	be	found	in	Supplementary	table	
8 B.	As observed	for	the	ScGrx7	mutants	analyzed	in	the	HEDS	assay,	all	PfGrx	mutants	showed	
a	sequential	kinetic	pattern	in	the	Lineweaver-Burk	plots	with	a	common	x	axis	interception.	
Replacement	of	Lys26	to	alanine	resulted	in	a	decrease	of	the	kcat
app	for	both	substrates	of	89-
96%,	whereas	the	Km
app for	GSH	stayed	rather	constant	and	the	Km
app for	HEDS	increased	to	
203-270%	resulting	in	a	decrease	of	the	apparent	catalytic	efficiencies	kcat
app/Km
app	by	91-96%	
for	both	substrates.		
The	 effect	 of	 the	 replacement	 of	 Asp90	 to	 an	 alanine	 were	 not	 as	 drastic	 as	 for	
PfGrxC32S/C88S/K26A	 in	 accordance	 with	 the	 previous	 results	 for	 the	 corresponding	 ScGrx7	
mutant.	For	both	substrates,	the	kcat
app	dropped	to	53-99%	with	mostly	increased	Km
app	values	
resulting	 in	 catalytic	 efficiencies	 that	 were	 reduced	 to	 41-72%	 (Figure	 35,	 panel	 C).	 The	
variation	in	the	Km
app	values	were	mostly	not	statistically	significant	and	the	changes	in	the	
catalytic	efficiencies	were	therefore	mainly	influenced	by	a	change	of	the	kcat
app	values.		
Again,	secondary	plots	were	generated	to	gain	further	insights	on	the	catalytic	mechanisms	of	
the	 analyzed	 mutants.	 The	 true	 kcat	 value	 obtained	 from	 the	 secondary	 plots	 seemed	 to	
decrease	 for	 PfGrxC32S/C88S/K26A	 with	 intercepts	 close	 to	 the	 origin.	 Both	 reciprocal	 Dalziel	
coefficients	 1/f1	and	 1/f2	were	drastically	 decreased.	 The	 effects	 on	 the	 reciprocal	 Dalziel	
coefficient	 1/f1	 were	 more	 than	 one	 order	 of	 magnitude,	 whereas	 the	 reciprocal	 Dalziel	
coefficient	1/f2	dropped	to	a	value	of	round	37%	of	the	PfGrxC32S/C88S	(DM)	value.	The	effects	
of	 a	 replacement	 of	 Asp90	 to	 an	 alanine	 on	 the	 reciprocal	 Dalziel	 coefficients	 was	 less	
pronounced.	The	mutation	mainly	influenced	the	reciprocal	Dalziel	coefficient	1/f1	that	was	
decreased	to	37%	of	the	DM	value.		
Again,	 the	 effects	 of	 both	mutations	 on	 the	 kinetic	 parameters	were	 highly	 similar	 to	 the	
effects	observed	before	with	the	homologous	ScGrx7	mutant in	the	HEDS	assay	pointing	to	a	
conserved	 catalytic	 mechanism	 with	 a	 separated	 glutathione	 activator	 and	 glutathione	
scaffold	 site.	 In	 summary,	 the	 role	 of	 r1	 as	 a	 glutathione	 activator	 residue	 and	 r6	 as	 a	
glutathione	 scaffold	 site	 residue	 could	 be	 confirmed	 using	 PfGrx	 as	 a	 non-related	 model	
enzyme	also	for	the	HEDS	assays.		
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Table	15	|	Kinetic	constants	for	PfGrx	mutants	in	the	HEDS	assay.	Estimated	true	kinetic	constants	kcat,	Km	and	
Dalziel	coefficients	of	PfGrxC32S/C88S	and	the	mutants	K26A	and	D90A	in	the	HEDS	assay.	aEstimated	kcat	values	and	
Dalziel	 coefficients	 were	 obtained	 from	 Supplementary	 figure	 4.	 bEstimated	 Km	 values	 were	 obtained	 from	
supplementary	figure	3	and	4.	DM:	PfGrxC32S/C88S;	K26A:	PfGrxC32S/C88S/K26A;	D90A:	PfGrxC32S/C88S/D90A.	The	data	was	
already	published	in	Begas	et	al.	2017	[116].	
	
           1/F1 a  1/F2 a kcat 
a       Km (GSH) 
b Km (HEDS) 
b  
PfGrx  (M-1s-1)  (M-1s-1) (s-1)  (mM) (mM) 
         
         DM  2.2 ´ 105  8.3 ´ 104 ¥  ¥ ¥ 
K26A  1.4 ´ 104  3.1 ´ 104 22 - ¥  2.5 - ¥ 2.1 - ¥ 
                  DM  2.7 ´ 105  7.1 ´ 104 ¥  ¥ ¥ 
D90A  1.0 ´ 105  5.3 ´ 104 ¥  ¥ ¥ 
         
                  	
 
Figure	35	|	Relevance	of	Lys26	and	Asp90	of	PfGrx	in	the	HEDS	assay.	A:	Selected	kcat
app	values	of	the	PfGrx	
mutants	for	HEDS	and	GSH	obtained	from	Supplementary	figure	3.	B:	Selected	Km
app	values	for	the	PfGrx	mutants	
for	HEDS	and	GSH	obtained	from	Supplementary	figure	3.	C:	The	catalytic	efficiencies	for	HEDS	and	GSH	were	
calculated	 from	panels	 A	 and	 B.	 D:	 The	 reciprocal	 Dalziel	 coefficients	were	 obtained	 from	 the	 slopes	 of	 the	
secondary	plots	in	Supplementary	figure	4.	E:	Summary	of	the	kinetic	parameters	from	panels	A,	B	and	C.	DM:	
PfGrxC32S/C88S;	K26A:	PfGrxC32S/C88S/K26A;	D90A:	PfGrxC32S/C88S/D90A.	Adapted	from	Begas	et	al.	2017	[116].		
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3.2.5	Kinetics	of	further	potential	activator	site	mutants	of	ScGrx7		
Additional	residues	of	ScGrx7	that	could	form	an	 interaction	site	 for	GSH	were	analyzed	 in	
steady-state	kinetic	assays.	Different	mutants	of	the	residues	Asp144	and	Glu147	in	helix	3,	
residue	Arg153	and	the	conserved	Tyr110	were	generated	and	analyzed	regarding	their	kinetic	
parameters	in	standard	enzymatic	assays	for	a	better	understanding	of	the	structure-function	
relationship	of	Grx	and	to	further	decipher	the	glutathione	interaction	site.	
3.2.5.1	Kinetics	of	ScGrx7Y110X	mutants	in	the	GSSCys	assay		
First,	different	ScGrx7Y110X	mutants	were	analyzed	in	the	GSSCys	assay	to	elucidate	the	role	of	
the	hydroxyl	group	of	this	residue	which	is	absent	in	enzymatically	inactive	Grx	(Figure	32).	
The	primary	analyses	of	ScGrx7Y110X	in	the	GSSCys	assay	according	to	Michaelis-Menten	and	
Lineweaver-Burk	are	shown	in	Supplementary	figure	5,	the	apparent	rate	constants	are	listed	
in	Supplementary	table	3	and	secondary	plots	are	shown	in	Supplementary	figure	6.	Statistical	
analyses	can	be	found	in	Supplementary	table	8	C.		
The	mutation	of	Tyr110	to	a	phenylalanine,	histidine	or	alanine	did	not	alter	the	general	ping-
pong	kinetics	visualized	by	the	parallel	lines	in	the	Lineweaver-Burk	plots.	ScGrx7Y110A	revealed	
the	most	drastic	effects	with	kcat
app	values	that	were	reduced	for	both	substrates	to	12-20%	of	
the	 wild-type	 values.	 The	 effects	 of	 ScGrx7Y110A	 on	 the	 Km
app	 values	 were	 mostly	 not	
significantly	 for	both	substrates	whereas	 the	effects	on	the	kcat
app	values	were	significantly	
altered.	The	catalytic	efficiency	kcat
app/Km
app	for	ScGrx7Y110A	was	therefore	mainly	influenced	
by	the	changes	of	the	kcat
app	values	and	showed	a	decrease	to	18-23%	of	the	wild-type	value	
for	GSH	as	a	substrate	and	9-15%	of	the	wild-type	value	for	GSSCys.		
ScGrx7Y110F	only	showed	minor	effects	on	the	apparent	catalytic	parameters.	The	kcat
app	and	
Km
app	values	for	GSH	were	mostly	not	significantly	altered	whereas	the	kcat
app	value	for	GSSCys	
was	 mainly	 significantly	 increased	 with	 unchanged	 Km
app	 values	 for	 GSSCys	 resulting	 in	 a	
slightly	 improved	 catalytic	 efficiency	kcat
app/Km
app	 (GSSCys)	with	 110-126%	of	 the	wild-type	
values.	Please	note	that	most	of	the	changes	of	the	apparent	catalytic	parameters	for	GSSCys	
for	 ScGrx7Y110F	 were	 not	 statistically	 significant	 but	 nevertheless	 consistent	 for	 different	
substrate	concentrations.		
For	ScGrx7Y110H	only	the	catalytic	efficiency	kcat
app/Km
app	for	GSSCys	was	drastically	reduced	to	
29-33%	of	the	wild-type	value	mainly	because	of	significantly	decreased	kcat
app	and	increased	
Km
app	 values	 for	 GSSCys.	 The	 catalytic	 efficiency	 kcat
app/Km
app	 of	 ScGrx7Y110H	 for	 GSH	 was	
effected	 to	 a	 much	 lesser	 extent	 because	 both	 the	 kcat
app	 and	 the	 Km
app	 for	 GSH	 were	
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significantly	 reduced	 to	 a	 value	 of	 24-43%	of	 ScGrx7wt	 resulting	 in	 an	 unchanged	 catalytic	
efficiency	for	GSH.		
Again,	 secondary	 plots	 should	 further	 elucidate	 the	 catalytic	mechanisms	 of	 the	 different	
ScGrx7Y110X	 mutants	 and	 were	 generated	 as	 described	 above.	 Estimated	 true	 kinetic	
parameters	and	the	reciprocal	Dalziel	coefficients	for	ScGrx7Y110X	obtained	from	the	GSSCys	
assay	are	 listed in Table	16.	The	 true	kcat and	Km value	obtained	 from	the	 secondary	plots	
seemed	to	increase	for	both	substrates	of	ScGrx7Y110F.	For	the	other	two	mutants	ScGrx7Y110H	
and	ScGrx7Y110A,	 the	kcat	values	for	both	substrates	decreased	with	more	drastic	effects	 for	
ScGrx7Y110A.	The	Km for	GSH	was	also	reduced	whereas	the	Km for	GSSCys	was	slightly	increased	
for	ScGrx7Y110H	and	ScGrx7Y110A.	An	effect	on	the	reciprocal	Dalziel	coefficient	1/f1	was	mainly	
shown	 by	 ScGrx7Y110A	 with	 a	 decrease	 by	 approximately	 factor	 10.	 The	 reciprocal	 Dalziel	
coefficient	1/f1	for	ScGrx7Y110F	was	slightly	increased	and	decreased	by	75%	for	ScGrx7Y110H.	
Only	 ScGrx7Y110A	 showed	 an	 effect	 on	 the	 reciprocal	 Dalziel	 coefficient	 1/f2,	 which	 was	
reduced	almost	by	factor	5.	The	reciprocal	Dalziel	coefficient	1/f2	for	the	other	mutants	was	
not	altered	in	the	GSSCys	assay	compared	to	ScGrx7wt.		
In	 summary,	 the	 experimental	 data	 of	 different	 ScGrx7Y110X	 mutants	 in	 the	 GSSCys	 assay	
revealed	that	the	hydroxyl	group	of	this	residue	is	probably	not	taking	part	in	the	glutathione	
activator	site	as	it	was	expected	before.	Potential	catalytic	mechanisms	that	could	explain	the	
results	are	discussed	in	section	4.	
	
Table	16	|	Kinetic	constants	for	ScGrx7Y110X	mutants	in	the	GSSCys	assay.	Estimated	true	kinetic	constants	kcat,	
Km	and	Dalziel	coefficients	of	ScGrx7
wt	and	the	mutants	Y110F,	Y110H	and	Y110A	in	the	GSSCys	assay.	aEstimated	
kcat	values	and	Dalziel	coefficients	were	obtained	from	Supplementary	figure	6.	WT:	ScGrx7	wild-type;	Y110F:	
ScGrx7Y110F;	Y110H:	ScGrx7Y110H;	Y110A:	ScGrx7Y110A.	This	data	was	in	parts	(WT	and	Y110A)	already	published	in	
Begas	et	al.	2017	[116].	
	
                    GSSCys assay  
    
     1/Φ1 
a 1/Φ2 
a kcat (GSH)
 a kcat (GSSCys)
 a Km (GSH)
 a Km (GSSCys)
 a 
ScGrx7 (M-1s-1) (M-1s-1) (s-1) (s-1) (µM) (µM) 
        
        WT 7.2 x 105 2.2 x 105 219 380 762 292 
Y110F 7.7 x 105 2.5 x 105 346 554 1067 784 
Y110H 1.8 x 105 2.2 x 105 154 74 422 375 
Y110A 9.2 x 104 4.7 x 104 36 35 426 332 
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Figure	36	|	The	hydroxyl	group	of	Tyr110	in	ScGrx7	does	not	act	as	a	specific	activator	site	in	the	GSSCys	assay.	
A:	Selected	kcat
app	values	of	ScGrx7Y110X	for	GSSCys	and	GSH	obtained	from	Supplementary	figure	5.	B:	Selected	
Km
app	 values	 for	 ScGrx7Y110X	 for	 GSSCys	 and	 GSH	 obtained	 from	 Supplementary	 figure	 5.	 C:	 The	 catalytic	
efficiencies	for	GSSCys	and	GSH	were	calculated	from	panels	A	and	B.	D:	The	reciprocal	Dalziel	coefficients	were	
obtained	from	the	slopes	of	the	secondary	plots	in	Supplementary	figure	6.	E:	Summary	of	the	kinetic	parameters	
from	panels	A,	B	and	C.	WT:	ScGrx7	wild-type;	Y110F:	ScGrx7Y110F;	Y110H:	ScGrx7Y110H;	Y110A:	ScGrx7Y110A.	This	
data	was	in	parts	(WT	and	Y110A)	already	published	in	Begas	et	al.	2017	[116].	
	
3.2.5.2	Kinetics	of	ScGrx7Y110X	mutants	in	the	HEDS	assay		
The	different	ScGrx7Y110X mutants	were	also	analyzed	in	a	HEDS	assay	to	further	elucidate	the	
catalytic	mechanism.	The	analyses	of	these	mutants	in	the	HEDS	assay	according	to	Michaelis-
Menten	 and	 Lineweaver-Burk	 are	 shown	 in	 Supplementary	 figure	 7,	 the	 apparent	 rate	
constants	 are	 listed	 in Supplementary	 table	 4 and	 secondary	 plots	 are	 shown	 in
Supplementary	figure	8.	Statistical	analyses	can	be	found	in	Supplementary	table	8	D.		
As	observed	for	ScGrx7wt	and	previously	analyzed	mutants	in	the	HEDS	assay,	the	ScGrx7Y110X	
mutants	all	showed	a	sequential	kinetic	pattern	in	the	Lineweaver-Burk	plots	with	a	common	
x	 axis	 interception.	 ScGrx7Y110A	 showed	 the	most	 drastic	 effects	 on	 the	 apparent	 catalytic	
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values	for	both	substrates.	The	kcat
app	of	ScGrx7Y110A	for	both	substrates	decreased	statistically	
significant	to	3-8%	of	the	wild-type	values,	whereas	the	Km
app	values	for	both	substrates	were	
not	 significantly	 altered.	 The	 strongly reduced	kcat
app in	 combination	with	 a	 constant	Km
app
resulted	 in	 a	 drastically	 decreased	 catalytic	 efficiency	 kcat
app/Km
app	 of	 ScGrx7Y110A	 for	 both	
substrates	to	4-7%	of	the	wild-type	values	(Figure	37,	panel	C).		
The	ScGrx7Y110H mutant also	showed	strong	effects	on	the	apparent	catalytic	values	but	to	a	
lesser	extent	than	the	ScGrx7Y110A	mutant.	Here,	again	the	Km
app	values	for	both	substrates	
were	 not	 significantly	 changed	 compared	 to	 ScGrx7wt,	 whereas	 the	 kcat
app	 values	 for	 both	
substrates	were	significantly	reduced.	The	kcat
app value	for	GSH	decreased	by	78-85%	and	the	
kcat
app	value	for	HEDS	by	70-78%	for	ScGrx7Y110H.	These	changes	resulted	in	a	decrease	of	the	
catalytic	efficiency	for	both	substrates	to	12-15%	of	the	value	obtained	for	ScGrx7wt.		
The	ScGrx7Y110F	mutant	showed	the	least	drastic	effects	on	the	catalytic	efficiencies.	The	Km
app	
for	GSH	and	for	HEDS	were	mainly	not	significantly	altered.	The	kcat
app	for	HEDS	was	mainly	
not	 significantly	 altered,	whereas	 the	kcat
app	 for	GSH	was	mostly	 significantly	 reduced.	 The	
combination	of	these	effects	led	to	catalytic	efficiencies	for	ScGrx7Y110F	with	kcat
app/Km
app	(GSH)	
of	58-72%	of	the	wild-type	enzyme	and	kcat
app/Km
app	(HEDS)	of	44-47%.		
Again,	 secondary	 plots	 should	 further	 help	 to	 elucidate	 the	 catalytic	 mechanism	 of	 the	
analyzed	mutants.	The	true	kcat	values	from	the	secondary	plots	can	be	found	in	Table	17	and	
seemed	to	increase	for	both	substrates	for	ScGrx7Y110F.	However,	for	the	other	two	mutants	
ScGrx7Y110H	and	ScGrx7Y110A,	the	estimated	true	kcat	values	both	seemed	to	decrease.	The	true	
Km	values	seemed	to	be	rather	constant	for	the	different	mutants	compared	to	ScGrx7
wt.	Both	
reciprocal	 Dalziel	 coefficients	 1/f1	 and	 1/f2	 decreased	 for	 all	 of	 the	mutants.	 Only	 minor	
effects	were	observed	for	ScGrx7Y110F,	intermediate	effects	for	ScGrx7Y110H	with	a	decrease	of	
up	to	one	order	of	magnitude	and	even	more	drastic	effects	for	ScGrx7Y110A	with	a	decrease	
of	almost	two	orders	of	magnitude.		
As	observed	before	in	the	GSSCys	assay,	kinetic	constants	of	the	different	ScGrx7Y110X	mutants	
in	the	HEDS	assay	show	that	the	hydroxyl	group	of	this residue	is	probably	not	taking	part	in	
the	glutathione	activator	site	as	it	was	expected	before	because	the	hydroxyl	group	is	absent	
in	enzymatically	inactive	Grx.	Potential	catalytic	mechanisms	that	could	explain	the	role	of	this	
residue	are	discussed	in	section	4.	
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Table	17	|	Kinetic	constants	for	ScGrx7Y110X	mutants	in	the	HEDS	assay.	Estimated	true	kinetic	constants	kcat,	Km	
and	Dalziel	coefficients	of	ScGrx7wt	and	the	mutants	Y110F,	Y110H	and	Y110A	in	the	HEDS	assay.	aEstimated	kcat	
values	and	Dalziel	coefficients	were	obtained	from	Supplementary	figure	8a.	bEstimated	Km	values	were	averaged	
from	Supplementary	figure	7.	WT:	ScGrx7	wild-type;	Y110F:	ScGrx7Y110F;	Y110H:	ScGrx7Y110H;	Y110A:	ScGrx7Y110A.	
This	data	was	in	parts	(WT	and	Y110A)	already	published	in	Begas	et	al.	2017	[116].	
	
                   HEDS assay  
    
     1/Φ1 
a 1/Φ2 
a kcat (GSH)
 a kcat (HEDS)
 a Km (GSH)
 b Km (HEDS)
 b 
ScGrx7 (M-1s-1) (M-1s-1) (s-1) (s-1) (mM) (mM) 
        
       WT 2.4 x 105 1.5 x 105 136     185 1.3 ± 0.8 
  
1.3 ± 0.3 
Y110F 1.2 x 105 1.2 x 105 275 485 
  
2.1 ± 0.9 
  
1.5 ± 0.2 
Y110H 2.9 x 104 3.7 x 104 92 43 
  
1.8 ± 0.3 
  
1.7 ± 0.2 
Y110A 9.5 x 103 4.6 x 103 15 30 
  
0.7 ± 0.2 
  
1.4 ± 0.3 
              
	
	
Figure	37	|	Replacement	of	Tyr110	in	ScGrx7	slows	down	the	turnover	of	both	substrates	in	the	HEDS	assay.	A:	
Selected	kcat
app	values	of	the	ScGrx7	Y110X	mutants	for	HEDS	and	GSH	obtained	from	Supplementary	figure	7.	B:	
Selected	Km
app	values	for	the	ScGrx7	mutants	for	HEDS	and	GSH	obtained	from	Supplementary	figure	7.	C:	The	
catalytic	efficiencies	for	HEDS	and	GSH	were	calculated	from	panels	A	and	B.	D:	The	reciprocal	Dalziel	coefficients	
were	obtained	 from	 the	 slopes	of	 the	 secondary	plots	 in	 Supplementary	 figure	8.	 E:	 Summary	of	 the	 kinetic	
parameters	 from	 panels	 A,	 B	 and	 C.	 WT:	 ScGrx7	 wild-type;	 Y110F:	 ScGrx7Y110F;	 Y110H:	 ScGrx7Y110H;	 Y110A:	
ScGrx7Y110A.	This	data	was	in	parts	(WT	and	Y110A)	already	published	in	Begas	et	al.	2017	[116].	
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3.2.5.3	Kinetics	of	ScGrx7D144X	mutants	in	the	GSSCys	assay		
An	aspartate	 at	 position	144	 in	helix	 3	of	ScGrx7	was	 analyzed	as	 a	 further	potential	GSH	
activator	site because	it	sticks	out on the enzyme surface.	The	replacement	of	Asp144	by	an	
alanine	or	a	lysine	as	charge	inversion	mutation	were	analyzed	in	a	GSSCys	assay.	For	the	sake	
of	convenience,	 the	primary	plots	are	shown	 in	Supplementary	 figure	9,	 the	apparent	rate	
constants	 are	 listed	 in Supplementary	 table	 5 and	 secondary	 plots	 are	 shown	 in
Supplementary	figure	10.	Statistical	analyses	can	be	found	in	Supplementary	table	8	E.		
Again,	the	general	ping-pong	kinetics	were	not	altered	by	the	mutations.	In	general,	the	effects	
of	the	mutated Asp144	was	much	more	subtle than	for	the	PfGrxC32S/C88S/K26A	or	ScGrx7Y110X
mutants.	The	kcat
app	 (GSH)	for	ScGrx7D144A	was	slightly,	but	significantly	decreased,	whereas	
the	Km
app	(GSH)	was	not	significantly	altered.	This	led	to	a	catalytic	efficiency	kcat
app/Km
app	(GSH)	
for	ScGrx7D144A	that	was	reduced	to	77-89%	compared	to	the	control	values.	The	changes	for	
the	apparent	catalytic	values	of	ScGrx7D144A	for	GSSCys	were	mainly	not	statistically	significant,	
but	 for	 all	 concentrations	 of	 GSH	 a	 reduced	 catalytic	 efficiency	 kcat
app/Km
app	 (GSSCys)	 was	
observed.		
For	the	charge	inversion	mutant	ScGrx7D144K,	the	observed	effects	were	more	significant.	The	
kcat
app	(GSH)	was	reduced	by	14-33%	with	Km
app	(GSH)	of	37-56%	of	the	control	value.	This	led	
to	an	increased	catalytic	efficiency	kcat
app/Km
app	(GSH)	for	ScGrx7D144K	to	151-202%.	The	kcat
app	
(GSSCys)	 and	 Km
app	 (GSSCys)	 for	 ScGrx7D144K	 were	 significantly	 increased,	 leading	 to	 a	
decreased	catalytic	efficiency	kcat
app/Km
app	(GSSCys)	for	ScGrx7D144K	to	66-75%	of	the	wild-type	
value.		
Again,	secondary	plots	were	generated	to	gain	further	insights	into	the	catalytic	mechanism	
of	 the	 analyzed	 residue.	 Estimated	 true	 kinetic	 parameters	 and	 the	 reciprocal	 Dalziel	
coefficients	for	the	ScGrx7D144X	mutants	of	ScGrx7	in	the	GSSCys	assay	are	listed	in	Table	18.	
The	effects	on	 the	estimated	 true	kinetic	 constants	were	 in	general	 very	 subtle.	 The	most	
interesting	result	was	the	increase	of	the	reciprocal	Dalziel	coefficient	1/f2	for	ScGrx7D144K	by	
almost	factor 2.	The	replacement	of	Asp144	in	helix	3	with	a	positively	charged	amino	acid	
therefore	seems	to	accelerate	the	reductive	half-reaction.		
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Figure	38	|	The	replacement	of	D144	in	ScGrx7	with	a	positively	charged	amino	acid	accelerates	the	reductive	
half-reaction.	A:	Selected	kcat
app	values	of	ScGrx7D144X	for	GSSCys	and	GSH	obtained	from	Supplementary	figure	
9.	B:	Selected	Km
app	values	 for	ScGrx7D144X	 for	GSSCys	and	GSH	obtained	from	Supplementary	 figure	9.	C:	The	
catalytic	 efficiencies	 for	 GSSCys	 and	 GSH	 were	 calculated	 from	 panels	 A	 and	 B.	 D:	 The	 reciprocal	 Dalziel	
coefficients	were	obtained	from	the	slopes	of	the	secondary	plots	in	Supplementary	figure	10.	E:	Summary	of	
the	kinetic	parameters	from	panels	A,	B	and	C.	WT:	ScGrx7	wild-type;	D144A:	ScGrx7D144A;	D144K:	ScGrx7D144K.	
	
3.2.5.4	Kinetics	of	ScGrx7E147X	mutants	in	the	GSSCys	assay		
As	 another	 residue	 of	 helix	 3	 that	 could	 form	 a	 potential	 GSH	 activator	 site,	 Glu147	was	
selected	because	of	geometric	reasons.	Again,	the	residue	was	replaced	by	an	alanine	or	a	
charge	inversion	mutation	(ScGrx7E147K)	and	the	different	mutants	were	analyzed	in	a	GSSCys	
assay	with	 ScGrx7wt	 as	 a	 control.	 The	 primary	 analyses	 are	 summarized	 in	 Supplementary	
figure	 11,	 the	 apparent	 rate	 constants	 are	 listed	 in	 Supplementary	 table	 6,	 the	 secondary	
analyses	 can	 be	 found	 in	 Supplementary	 figure	 12	 and	 statistical	 analyses	 are	 shown	 in	
Supplementary	table	8	F.		
As	observed	before,	mutation	of	ScGrx7E147	did	not	alter	the	ping-pong	kinetics.	In	general,	the	
effects	observed	for	the	ScGrx7E147X	mutants	were	highly	similar	to	the	other	investigated	helix	
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3	residue	Asp144.	The	kcat
app	(GSH)	for	ScGrx7E147A	was	only	slightly,	but	mainly	significantly	
decreased,	whereas	the	Km
app	(GSH)	was	in	most	of	the	cases	not	significantly	altered.	This	led	
to	an	altered	catalytic	efficiency	kcat
app/Km
app (GSH)	for	the	ScGrx7E147A that	was	reduced	to	86-
91%	of	 the	control	values.	The	changes	 for	 the	apparent	catalytic	values	of	ScGrx7E147A	for	
GSSCys	were	not	statistically	significant.		
For	 the	charge	 inversion	mutant	ScGrx7E147K,	 the	observed	effects	were	more	pronounced.
The	kcat
app	(GSH)	for	this	mutant	was	increased	to	105-122%	with	Km
app	(GSH)	of	58-73%	of	the	
control	value.	This	led	to	an	increased	catalytic	efficiency	kcat
app/Km
app	(GSH)	for	ScGrx7E147K	to	
156-195%.	The	kcat
app (GSSCys)	and	Km
app (GSSCys)	for	ScGrx7E147K were	significantly	increased,	
leading	to	a	mainly	unchanged	catalytic	efficiency	kcat
app/Km
app	(GSSCys)	for	ScGrx7E147K	with	
87-103%	of	ScGrx7wt.		
Again,	secondary	plots	were	generated	to	gain	further	insights	into	the	catalytic	mechanism	
of	 the	 analyzed	 residue.	 Estimated	 true	 kinetic	 parameters	 and	 the	 reciprocal	 Dalziel	
coefficients	for	the	Glu147	mutants	of	ScGrx7	in	the	GSSCys	assay	are	listed	in	table	18.	The	
effects	on	the	estimated	true	kinetic	constants	were	in	general	very	subtle.	As	observed	before	
for	the	other	investigated	helix	3	residue	Asp144,	the	reciprocal	Dalziel	coefficient	1/f2	for	the	
charge	inversion	mutant	ScGrx7E147K	was	increased	by	more	than	factor	2.		
In	summary,	the	effects	of	the	two	analyzed	mutants	of	helix	3	both	showed	that	a	positively	
charged	amino	acid	in	helix	3	seems	to	accelerate	the	reductive	half-reaction.	Moreover,	the	
positively	charged	amino	acids	in	the	mutants	presumably	influence	the	glutathione	activator	
site.		
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Figure	39	|	The	replacement	of	E147	in	ScGrx7	with	a	positively	charged	amino	acid	accelerates	the	reductive	
half-reaction.	A:	Selected	kcat
app	values	of	ScGrx7E147X	for	GSSCys	and	GSH	obtained	from	Supplementary	figure	
11.	B:	Selected	Km
app	values	for	ScGrx7E147X	for	GSSCys	and	GSH	obtained	from	Supplementary	figure	11.	C:	The	
catalytic	 efficiencies	 for	 GSSCys	 and	 GSH	 were	 calculated	 from	 panels	 A	 and	 B.	 D:	 The	 reciprocal	 Dalziel	
coefficients	were	obtained	from	the	slopes	of	the	secondary	plots	in	Supplementary	figure	12.	E:	Summary	of	
the	kinetic	parameters	from	panels	A,	B	and	C.	WT:	ScGrx7	wild-type;	E147A:	ScGrx7E147A;	E147K:	ScGrx7E147K.	
	
3.2.5.5	Kinetics	of	ScGrx7R153X	mutants	in	the	GSSCys	assay		
Residue	Arg153	of	ScGrx7	was	analyzed	 in	a	GSSCys	assay	as	a	potential	GSH	activator	site	
because	it	was	previously	proposed	to	be	involved	in	the	glutathione	binding	by	Mesecke	et	
al.	[112].	The	residue	was	replaced	by	an	alanine	or	a	charge	inversion	mutation	(ScGrx7R153E).	
The	primary	analyses	can	be	found	in	Supplementary	figure	13,	the	apparent	rate	constants	
are	listed	in	Supplementary	table	7,	the	secondary	analyses	are	summarized	in	Supplementary	
figure	14	and	statistical	analyses	are	shown	in	Supplementary	table	8	G.		
As	for	all	other	analyzed	mutants	of	ScGrx7,	the	ping-pong	kinetics	were	not	changed.	The	
kcat
app	 and	Km
app	 for	GSH	of	ScGrx7R153A	was	 significantly	decreased	 to	 values	of	 41-52%	of	
ScGrx7wt.	This	resulted	in	a	catalytic	efficiency	kcat
app/Km
app	(GSH)	that	was	not	altered	much	
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with	values	of	84-96%	of	the	wild-type	enzyme.	However,	the	catalytic	efficiency	kcat
app/Km
app	
for	GSSCys	was	reduced	to	35-43%,	determined	by	mainly	unchanged	kcat
app	(GSH)	values	in	
combination	with	significantly	increased	Km
app (GSH)	values.	
For	 the	 charge	 inversion	 mutant	 ScGrx7R153E,	 the	 observed	 effects	 were	 in	 general	 more	
pronounced.	The	kcat
app	(GSH)	for	this	mutant	was	significantly	decreased	to	22-25%	and	the	
Km
app (GSH)	was 40-53%	of	ScGrx7wt.	This	led	to	a decreased	catalytic	efficiency	kcat
app/Km
app
(GSH)	for	ScGrx7R153E	to	47-53%.	The	kcat
app	(GSSCys)	for	ScGrx7R153E	was	significantly	decreased	
to	values	of	43-61%	of	the	control	and	the	Km
app	(GSSCys)	values	were	significantly	increased	
to	192-290%,	 leading	 to	a	 reduced	catalytic	efficiency	kcat
app/Km
app (GSSCys)	 for	ScGrx7R153E
with	20-23%	of	ScGrx7wt.		
As	a	next	step,	secondary	plots	were	generated	to	further	elucidate	the	catalytic	mechanism	
of	 the	 analyzed	 residue.	 Estimated	 true	 kinetic	 parameters	 and	 the	 reciprocal	 Dalziel	
coefficients	for	ScGrx7R153X	in	the	GSSCys	assay	are	listed	in	table	18.	The	mutation	of	Arg153	
to	alanine	resulted	in	a	decrease	of	the	reciprocal	Dalziel	coefficient	1/f1	by	more	than	factor	
2.	Even	stronger	effects	were	observed	 for	 the	charge	 inversion	mutant	ScGrx7R153E	with	a	
reciprocal	Dalziel	coefficient	1/f1	that	was	decreased	by	around	factor	5.	The	reciprocal	Dalziel	
coefficient	1/f2	was	not	altered	for	ScGrx7R153A,	but	reduced	by	50%	for	ScGrx7R153E.		
Taken	together,	residue	Arg153	seems	to	play	a	role	mainly	for	the	oxidative	half-reaction	in	
the	GSSCys	assay	in	accordance	with	the	glutathione	scaffold	model.		
	
Table	18	|	Kinetic	constants	for	ScGrx7	Asp144,	Glu147	and	Arg153	mutants	in	the	GSSCys	assay.	Estimated	
true	kinetic	constants	kcat,	Km	and	Dalziel	coefficients	of	ScGrx7
wt	and	the	mutants	D144A,	D144K,	E147A,	E147K,	
R153A	and	R153E	 in	 the	GSSCys	assay.	 aEstimated	kcat,	Km values	and	Dalziel	 coefficients	were	obtained	 from	
Supplementary	figure	10a	(D144X),	Supplementary	figure	12a	(E147X)	and	Supplementary	figure	14a	(R153X).	
WT:	ScGrx7	wild-type;	D144A:	ScGrx7D144A;	D144K:	ScGrx7D144K;	E147A:	ScGrx7E147A;	E147K:	ScGrx7E147K;	R153A:	
ScGrx7R153A;	R153E:	ScGrx7R153E.	
	
                    GSSCys assay  
    
     1/Φ1 
a 1/Φ2 
a kcat (GSH)
 a kcat (GSSCys)
 a Km (GSH)
 a Km (GSSCys)
 a 
ScGrx7 (M-1s-1) (M-1s-1) (s-1) (s-1) (µM) (µM) 
                WT 7.1 x 105 2.8 x 105 206 213 744 257 
       D144A 5.7 x 105 3.0 x 105 151 161 488 250 
D144K 5.9 x 105 4.7 x 105 161 591 590 760 
       
E147A 7.1 x 105 2.9 x 105 370 259 926 314 
E147K 7.6 x 105 7.0 x 105 332 263 300 280 
       
R153A 2.8 x 105 2.7 x 105 168 125 293 404 
R153E 1.4 x 105 1.4 x 105 113 72 807 491 
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Figure	40	|	Arg153	in	ScGrx7	is	mainly	important	for	the	oxidative	half	reaction	in	the	GSSCys	assay.	A:	Selected	
kcat
app	values	of	ScGrx7R153X	for	GSSCys	and	GSH	obtained	from	Supplementary	figure	13.	B:	Selected	Km
app	values	
for	 ScGrx7R153X	 for	 GSSCys	 and	GSH	 obtained	 from	 Supplementary	 figure	 13.	 C:	 The	 catalytic	 efficiencies	 for	
GSSCys	and	GSH	were	calculated	from	panels	A	and	B.	D:	The	reciprocal	Dalziel	coefficients	were	obtained	from	
the	slopes	of	the	secondary	plots	in	Supplementary	figure	14.	E:	Summary	of	the	kinetic	parameters	from	panels	
A,	B	and	C.	WT:	ScGrx7	wild-type;	R153A:	ScGrx7R153A;	R153E:	ScGrx7R153E.	
	
3.2.6	Influence	of	selected	point	mutations	of	ScGrx7	on	the	pKa	value	
Different	residues	of	ScGrx7	should	be	analyzed	regarding	their	influence	on	the	thiol	pKa	value	
of	 the	active	site	cysteine.	The	 two	residues	Lys105	and	Glu170	were	analyzed	acting	as	a	
glutathione	 activator	 and	 glutathione	 scaffold,	 respectively	 [116].	 As	 another	 mutant	
ScGrx7Y110A	was	analyzed	because	this	mutant	also	showed	a	strong	effect	in	the	GSSCys	assay	
that	might	be	influenced	by	an	altered	pKa	value.	Additionally	to	the	alanine	mutants	of	these	
residues,	 ScGrx7K105E	 was	 analyzed	 as	 a	 control,	 because	 this	 mutation	 showed	 the	 most	
drastic	effect	of	all	the	analyzed	mutants	in	previous	kinetic	analyses	[116].		
The	results	are	shown	in	Figure	41.	The	analysis	revealed	a	pKa	value	for	ScGrx7
wt	of	4.34	±	
0.10.	This	value	was	not	significantly	altered	for	ScGrx7Y110A	(4.50	±	0.03),	ScGrx7K105A	(4.45	±	
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0.02)	and	ScGrx7E170A	(4.35	±	0.13).	Only	the	pKa	value	of	ScGrx7
K105E	was	significantly	increased	
compared	 to	 ScGrx7wt	 and	 all	 other	 analyzed	mutants	 to	 a	 value	 of	 4.97	 ±	 0.08.	Of	 note,	
samples	with	iodoacetamide	(IAM) were	in	general	apparently	more	stable	at	lower	pH	values	
resulting	in	remaining	activities	>	100%.	Taken	together,	point	mutations	of	ScGrx7	only	had	a	
minor	influence	on	the	pKa	value	of	the	active	site	cysteine.		
	
	
	
Figure	41	|	Point	mutations	of	ScGrx7	only	have	a	minor	influence	on	the	pKa	value	of	the	active	site	cysteine.	
Freshly	reduced	ScGrx7	(black	circles)	and	selected	mutants	 (colored	circles)	were	 incubated	for	180	seconds	
with	150	µM	iodoacetamide	(IAM)	at	23°C	in	a	three-buffer	system	with	different	pH	values	varying	from	3.5	to	
8.5.	 The	 residual	 enzyme	 activity	was	measured	 in	 a	 standard	HEDS	 assay	 and	 normalized	 against	 a	 control	
incubated	 without	 IAM.	 Symbols	 represent	 the	mean	 ±	 SD	 of	 three	 independent	 determinations	 of	 ScGrx7	
activity.	The	sigmoidal	curve	fit	(Hill,	4	parameter)	for	ScGrx7	and	mutants	are	represented	as	full	and	dashed	
lines,	respectively.	A:	Only	the	pKa	value	for	the	ScGrx7
K105E	mutant	is	statistically	different	from	all	other	mutants	
and	ScGrx7wt.	There	is	no	statistically	significant	difference	between	the	other	mutants	and	wild-type	enzyme.	B:	
The	 pKa	 value	 of	 ScGrx7
wt	 and	 ScGrx7Y110A	 is	 4.34	 ±	 0.10	 and	 4.50	 ±	 0.03,	 respectively.	 C:	 The	 pKa	 value	 of	
ScGrx7K105A	and	ScGrx7K105E	is	4.45	±	0.02	and	4.97	±	0.08,	respectively.	D:	The	pKa	value	of	ScGrx7
E170A	is	4.35	±	
0.13.	Samples	with	IAM	were	apparently	more	stable	at	lower	pH	values	resulting	in	remaining	activities	>	100%.	
P-values	from	one	way	ANOVA	analysis	followed	by	a	Holm-Sidak	test	were	calculated	in	SigmaPlot	13	(P	>	0.05:	
ns;	P	≤	0.001:	***).	
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4	Discussion	
	
	
4.1	Mitochondrial	protein	import	into	the	IMS	of	Leishmania	tarentolae	
	
4.1.1	A	potential	replacement	for	Mia40	in	protists	remains	to	be	elucidated		
The	major	objective	of	this	thesis	was	the	identification	of	a	Mia40	adapter	replacement	
for	 the	 mitochondrial	 protein	 import	 into	 the	 IMS	 of	 the	 kinetoplastid	 parasite	 L.	
tarentolae.	The	model	organism	might	be	representative	also	for	other	eukaryotes	without	
an	identified	Mia40	homolog.	Unraveling	the	mechanism	of	mitochondrial	protein	import	
into	the	IMS	of	early	eukaryotes	is	a	hot	topic	in	the	field	because	of	its	potential	to	find	
new	 targets	 for	 drug	 design.	 Furthermore,	 it	 could	 help	 to	 gain	more	 insights	 into	 the	
evolution	of	eukaryotes.	The	two	known	components	of	mitochondrial	protein	import	into	
the	IMS	of	L.	infantum	(LiErv	and	LisTim1)	seem	to	be	essential	for	parasite	survival	[157].	
Erv	 from	 the	 closely	 related	 parasite	T.	 brucei	was	 also	 shown	 to	 be	 essential	 by	 RNAi	
studies	[37,	155,	158].	Therefore,	the	missing	link	–	the	putative	Mia40	adapter	replace-
ment	–	is	likely	to	be	essential	as	well	and	may	be	a	promising	target	for	drug	development.	
An	 appropriate	 drug	 would	 interfere	 only	 with	 the	 parasite	 specific	 Mia40	 adapter	
replacement,	but	not	with	the	MIA	pathway	of	the	host	cell.	
In	 this	work,	different	 strategies	 for	endogenous	chemical	 trapping	of	a	mixed	disulfide	
intermediate	 between	 LtErv	 and	 the	 unknown	 protein	 were	 applied	 using	 various	
alkylating,	reducing	and	oxidizing	compounds.	None	of	these	experiments	revealed	mixed	
disulfides	in	western	blot	analyses	(Figure	13	and	Figure	14).	Moreover,	trapping	attempts	
with	an	upregulated	cysteine	mutant	of	LtErv	with	the	aim	to	stabilize	a	mixed	disulfide	
between	LtErv	and	the	unknown	Mia40	replacement did	not	lead	to	the	identification	of	
an	 interacting	 protein	 (Figure	 20).	 Even	 with	 highly	 enriched	 LtErv	 protein	 levels	 after	
denaturing	 (Figure	 24)	 or	 native	 pull-down	 experiments	 (Figure	 23),	 no	mixed	 disulfide	
intermediate	was	detectable. Hence,	LtErv	could	not	be	enriched	as	a	trapped	intermediate
with	the	unknown	interaction	partner	under	the	conditions	being	tested	and	no	further	
analysis	by	mass	spectrometry	was	possible.	These	results	do	not	support	the	direct	Erv-
substrate	interaction	model	that	was	previously	proposed	[155,	159].		
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Trapping	 attempts	 with	 the	 model	 substrate	 LtsTim1	 showed	 several	 disulfide-bridged	
intermediates	 that	 could	 potentially	 reflect	 heterodimers	 between	 LtsTim1	 and	Mia40	
adapter	 replacement	 candidates	 (Figure	 16	 and	 Figure	 21).	However,	 an	 enrichment	 of	
these	 intermediates	by	affinity	chromatography	was	not	possible	because	of	systematic	
problems	 with	 western	 blot	 analyses	 of	 LtsTim1.	 The	 protein	 is	 known	 to	 be	 highly	
hydrophobic [160] and	tends	to	form	oligomers	that	are	visible	as	strong	signals	between	
the	 separating	 and	 stacking	 gel	 of	 the	 SDS-PAGE	 gel	 in	 western	 blot	 analyses.	 These	
oligomers	could	not	be	eliminated	using	various	protocols	(Figure	15).		
Taken	 together,	 neither	 trapping	 attempts	 with	 LtsTim1	 as	 a	 model	 substrate	 for the	
oxidative	folding	pathway	 in	the	 IMS,	nor	with	LtErv	 led	to	the	 identification	of	a	stable	
disulfide-bonded	 interaction	partner.	The	correct	 localization	of	 the	bait	proteins	 to	the	
mitochondria	of	L.	 tarentolae	were	confirmed	 (Figure	22).	Hence,	 the	 results	 cannot	be	
explained	by	mislocalized	bait	proteins.	However,	a	non-covalent	or	transient	interaction	
with	a	Mia40	adapter	replacement	cannot	be	excluded.	All	experiments	were	based	on	the	
assumption	 that	 the	 interaction	 between	 LtErv	 or	 LtsTim1	 and	 the	 unknown	 adapter	
replacement	is	linked	via	disulfide	bonds.	Hence,	non-covalent	interactions	would	not	be	
detectable	with	the	approaches	used	in	this	work.	Transient	interactions	are	also	difficult	
to	enrich	and	detect.	It	is	known	that	ScMia40	forms	intermolecular	disulfide	species	with	
its	 substrate	 that	 are	 stable	 for	 several	 seconds	 to	minutes	 [159,	161].	 This	behavior	 is	
rather	 unusual	 compared	 to	 other	 oxidoreductases	 such	 as	 members	 of	 the	 protein	
disulfide	 isomerase	 (PDI)	 that	 catalyze	 very	 fast	 oxidative	 protein	 folding	 in	 the	
endoplasmatic	 reticulum	 [162].	 It	 is	 possible	 that	 the	 Mia40	 adapter	 replacement	 in	
kinetoplastida	is	also	a	highly	specific	and	efficient	enzyme	and	would	hence	be	missed	in	
the	analyses	because	of	very	transient	interactions.		
BioID	 is	 a	 method	 that	 might	 overcome	 these	 problems	 because	 also	 very	 transient	
interactions	can	potentially	be	detected	as	the	biotinylated	interacting	proteins	accumulate	
over	time	[84].	Moreover,	the	interaction	partner	does	not	necessarily	have	to	be	linked	
via	 disulfide	 bonds.	 However,	 in	 this	 work,	 no	 Mia40	 adapter	 replacement	 could	 be	
detected	by	the	help	of	BioID.	The	failure	was	probably	due	to	technical	problems	because	
even	the	bait	protein	itself	did	not	show	biotinylation.	However,	a	biotinylated	protein	as	
a	positive	control	was	not	included	in	the	western	blot	analyses.	Hence,	it	is	possible	that	
the	streptavidin-HRP	did	not	work	for	L.	tarentolae.	Such	a	control	needs	to	be	included	in	
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the	future.	An	alternative	method	to	BioID	is	APEX	that	was	already	successfully	used	for	
mitochondrial	proteins	in	the	IMS	with	faster	biotinylation	rates	than	BioID	[83,	163]	and	
could	be	used	 for	 further	 studies.	However,	 these	methods	are	not	 specific	and	usually	
result	in	long	lists	of	potential	interacting	proteins.		
An	interaction	partner	may	also	have	been	missed	in	this	work	if	early	eukaryotes	do	not	
possess	a	Mia40	homolog	and	rather	have	an	Erv-only-system	that	directly	catalyze	 the	
oxidation	of	the	substrates	as	proposed	by	Peleh	et	al.	[159].	The	authors	could	show	that	
in	plants	Mia40	is	not	essential	and	substrate	oxidation	can	occur	in	a	Mia40-independent	
manner.	From	this	result,	they	propose	an	evolutionary	scenario	starting	with	an	Erv1-like	
oxidase	 and	 hypothesize	 that	 a	 similar	 situation	 might	 still	 be	 found	 in	 some	 protists	
(starting	from	eukaryote	B	and	taking	route	4	in	the	evolutionary	model	in	Figure	42).	Might	
LtErv	with	its	additional	kinetoplastida-specific	second	(KISS)	domain	functionally	replace	
Mia40	 in	 kinetoplastida?	 This	 would	 imply	 an	 alternative	 pathway	 in	 apicomplexan	
parasites	because	they	do	not	possess	a	KISS	domain.	Even	if	LtErv	would	operate	alone	
with	a	 simplified	oxidative	 folding	machinery	 as	proposed	by	Haindrich	et	al.	 [155]	and	
Peleh	et	al.	[159],	a	direct	interaction	between	LtErv	and	the	substrate	LtsTim1	should	be	
detectable	with	appropriate	experimental	methods.	 In	this	case,	LtErv	should	be	able	to	
directly	oxidize	substrates	of	the	oxidative	folding	pathway.	This	direct	interaction	was	not	
observed	 in	 this	 work.	 According	 to	 the	 hypothesis	 of	 a	 simplified	 oxidative	 folding	
machinery,	LtErv	should	also	be	able	to	complement	the	function	of	ScMia40	in	yeast	due	
to	 the	 evolutionary	 conservation	 of	 the	 import	 signals	 of	 IMS	 proteins	 in	 different	
eukaryotic	supergroups	[24].	There	is	no	evidence	for	such	a	simplified	oxidative	folding	
machinery	because	neither	LtErv	nor	PfErv	were	able	to	complement	the	loss	of	ScMia40	
in	yeast	[157].	Moreover,	oxidative	folding	assays	with	TbErv	in	vitro	were	not	successful	
[37].	Taken	together,	these	results	rather	point	to	the	existence	of	an	adapter	replacement	
for	Mia40	 in	 kinetoplastida	 (protein	 Z	 in	 the	 evolutionary	 scenario	 proposed	 before	 by	
Eckers	et	al.	2012	[24],	see	Figure	42)	that	still	remains	elusive.	
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Figure	42	|	Evolution	of	mitochondrial	protein	import	into	the	intermembrane	space.	In	general,	there	are	
three	possibilities	existing	for	the	evolution	of	mitochondrial	protein	import	into	the	intermembrane	space	
of	Excavata	and	Chromalveolata.	Primitive	eukaryotes	either	had	a	Mia40	and	Erv	ancestor	(eukaryote	A),	
only	an	Erv	ancestor	(eukaryote	B)	or	an	Erv	ancestor	as	well	as	an	unknown	additional	protein	Z	(eukaryote	
C).	The	current	knowledge	points	to	an	evolutionary	scenario	starting	from	eukaryote	B	or	C	and	producing	
protists	containing	Erv	and	protein	Z.	The	evolutionary	model	was	taken	from	Eckers	et	al.	2012	[24].		
	
What	can	be	done	to	overcome	the	systematic	problems	with	LtsTim1	to	further	analyze	
the	reaction	from	the	substrate	side?	LtsTim1	is	only	one	model	substrate	of	the	oxidative	
folding	pathway	in	the	IMS	and	alternative	substrates	may	be	tested	that	are	potentially	
less	hydrophobic.	The	recently	published	list	of	putative	substrates	of	the	oxidative	folding	
pathway	 of	 the	 IMS	 by	 Peikert	 et	 al.	 in	 T.	 brucei	 [158]	 was	 therefore	 used	 to	 select	
alternative	substrates	that	could	serve	as	bait	proteins	 for	 further	 investigations	 (Figure	
43).	What	 characterizes	 a	 protein	 from	 this	 list	 as	 a	 suited	model	 substrate	 for	 further	
analyses?	 First,	 proteins	 were	 selected	 according	 to	 their	 mass	 that	 should	 be	 around	
20	kDa	to	be	different	enough	from	LtErv	around	35	kDa	and	not	as	small	as	the	model	
substrate	LtsTim1.	Second,	the	list	was	checked	for	the	sequence	coverage	and	proteins	
with	a	value	below	20%	were	subsequently	excluded.	Third,	 the	proteins	were	selected	
according	to	the	number	and	motifs	of	their	cysteines.	Proteins	with	too	many	cysteines	
were	excluded	because	of	a	too	complicated	subsequent	workflow	for	generating	different	
trapping	mutants	analogous	to	this	work.	The	conservation	of	the	proteins	in	apicomplexan	
parasites	 and	opisthokonts	was	also	 considered	because	 this	 list	 could	also	 contain	 the	
potential	Mia40	 adapter	 replacement,	which	 is	 presumably	 conserved	 in	 apicomplexan	
parasites	but	not	in	opisthokonts	(or	if	it	can	also	be	found	in	opisthokonts,	it	will	probably	
not	be	essential).	In	total,	four substrates	were	selected	as	potential	bait	proteins,	including	
Tb927.9.7980/substrate	1	and	Tb927.10.15790/substrate	3	with	classical	twin	Cx9C-motifs,	
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as	 well	 as	 two	 proteins	 with	 less	 characteristic	motifs	 (Tb927.10.4280/substrate	 2	 and	
Tb927.11.13510/substrate	4).	Three	of	 them	also	 fulfill	 the	 last	 criterion	 (Tb927.9.7980,	
Tb927.10.4280	and	Tb927.11.13510).	The	corresponding	proteins	from	L.	tarentolae	were	
recently	cloned	by	Mirko	Höhn	and	Sandra	Specht.	Cysteine	mutants	for	the	stabilization	
of	mixed	disulfide	intermediates	were	generated	with	substrate	2	and	4	according	to	the	
workflow	with	LtsTim1 shown	in	this	work.	The	proteins	have already	been	expressed	in	L.	
tarentolae	by	Sandra	Specht	and	are	going	to	be	further	characterized	by	another	student	
in	the	lab	analogous	to	the	experiments	with	LtErv	and	LtsTim1	described	in	this	thesis.		
	
Figure	43	|	Selection	of	new	substrates	of	the	oxidative	folding	pathway.	Putative	substrates	of	the	oxidative	
protein	folding	pathway	of	the	IMS	were	recently	identified	by	Peikert	et	al.	by	comparing	induced	versus	
uninduced	TBERV	knockdown	cultures	[158].	Four	new	substrates	for	analysis	in	L.	tarentolae	were	selected	
based	on	the	published	list	with	25	downregulated	proteins.	Adapted	from	Peikert	et	al.	2017	[158].		
	
A	rather	unexpected	result	was	observed	when	the	correct	localization	of	the	bait	proteins	
was	analyzed	(Figure	22).	The	two	mutated	LtsTim1	isoforms	containing	only	one	cysteine	
seem	to	correctly	 localize	to	the	mitochondria	of	L.	tarentolae.	This	behavior	 is	not	self-
explanatory	because	these	proteins	cannot	form	internal	disulfide	bonds	anymore,	which	
are	usually	a	prerequisite	for	trapping	of	the	substrates	in	the	IMS	according	to	the	folding	
trap	mechanism	[164,	165].	What	could	explain	the	correct	import	of	mutated	LtsTim1	with	
only	one	 cysteine	 residue	 left?	 In	 yeast,	 a	 cysteine-free	mutant	of	 the	Mia40	 substrate	
Atp23	was	shown	to	be	efficiently	imported	into	isolated	mitochondria	[166].	The	import	
required	 Mia40,	 but	 not	 the	 formation	 of	 mixed	 disulfide	 bonds	 with	 the	 adapter.	
Moreover,	in	the	list	of	putative	substrates	of	the	oxidative	protein	folding	pathway	of	the	
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IMS	published	by	Peikert	et	al.,	there	are	several	proteins	without	the	classical	twin	Cx3C	or	
Cx9C	motif,	one	protein	with	only	one	cysteine	and	another	one	without	cysteines	[158].	
However,	these	proteins	are	presumably	imported	in	an	Erv-dependent	manner	because	
they	are	significantly	downregulated	after	TBERV	knockdown.	This	points	to	the	presence	
of	an	altered	pathway	that	is	dependent	on	Mia40	or	the	unknown	adapter	replacement	
but	does	not	necessarily	rely on	the	formation	of	mixed	disulfide	intermediates.	Another	
possible	explanation	for	the	behavior	of	the	single-cysteine	mutants	of	LtsTim1	might	be	
that	they	accumulate	in	inclusion	bodies	because	of	the	strong	upregulation	and	are	only	
solubilized and	transferred to	the	supernatant	with	high	digitonin	concentrations.	
Initially,	 it	 was	 planned	 to	 perform	 pull-down	 experiments	 for	 the	 identification	 of	 a	
potential	Mia40	adapter	replacement	coupled	with	a	SILAC	approach.	An	advantage	of	this	
method	is	that	it	can	discriminate	between	unspecific	hits	and	actual	interaction	partners	
as	 explained	 in	 the	 introduction.	 Several	 cultivation	 media	 combined	 with	 different	
supplements	 were	 tested	 in	 order	 to	 identify	 a	 defined	 medium	 for	 cultivation	 of	 L.	
tarentolae	as	a	prerequisite	 for	a	SILAC	approach.	Even	 in	an	extensive	search	with	216	
different	compositions	no	completely	defined	medium	could	be	determined	for	the	use	in	
a	 SILAC	 experiment.	Moreover,	 a	 defined	medium	 that	was	 published	 for	 the	 use	 in	 L.	
infantum	was	not	suited	for	the	cultivation	of	the	close	relative	L.	tarentolae	[71,	72].	The	
needs	of	these	parasites	seem	to	be	very	specific	and	to	differ	even	among	closely	related	
strains.	Thus,	much	more	experiments	would	be	needed	to	determine	a	defined	medium	
for	the	cultivation	of	L.	tarentolae.	Instead,	the	new	substrates	may	be	analyzed	with	label-
free	mass	spectrometry	as	a	cheaper	alternative	for	SILAC	[73].		
	
4.1.2	Redox	state	of	LtErv	
The	native	redox	state	of	LtErv	as	an	important	component	of	the	mitochondrial	protein	
import	machinery	into	the	IMS	was	unknown	so	far.	Therefore,	a	redox	mobility	shift	assay	
was	used	to	elucidate	the	redox	state	and	to	gain	further	insights	into	the	altered	import	
machinery	 of	 kinetoplastida	 (Figure	 28).	 LtErv	 seems	 to	 be	 mainly	 oxidized	 under	
physiological	 conditions.	 The	 structural	 disulfide	 bonds	 in	 LtErv	 are	 stable	 against	
treatment	with	TCEP	as	a	reductant	at	low	temperature,	and	even	at	high	temperature	the	
reduction	was	not	complete.	Recently,	a	study	was	published	investigating	the	redox	state	
of	the	mammalian	Mia40	homolog	CHCHD4	[167].	Erdogan	et	al.	could	show	that	under	
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basal	 conditions,	 the	 protein	 is	 predominantly	 oxidized.	 Oxidative	 protein	 folding	 is	
impaired	when	the	redox	state	of	Mia40	is	shifted	to	a	more	reduced	state.	Therefore,	the	
redox	state	of	Mia40/CHCHD4	is	mainly	controlled	by	Erv	and	the	glutathione	content	of	
the	IMS	[168].	This	is	either	induced	by	Erv	depletion	or	glutaredoxin	overexpression	[168,	
169].	We	could	previously	 show	 in	 collaboration	with	Kai	Hell’s	 group	 that	 an	 impaired	
protein	import	mediated	by different	chimeras	of	Erv	can	be	presumably	explained	by	the	
altered	ratio	between	reduced	and	oxidized	ScMia40	[157].	Moreover,	a	reduced	Erv	may	
impair	the	import	of	IMS	substrates	because	it	can	only	recover	Mia40	efficiently,	when	Erv	
is	mainly	present	in	an	oxidized	state.	This	might also	be	the	case	in	kinetoplastida	if	there	
is	a	Mia40	adapter	replacement	or	if	Erv	directly	oxidizes	the	substrates.	
The	mobility	shift	assay	that	I	established	in	our	lab	for	the	determination	of	the	redox	state	
of	LtErv	might	be	used	in	the	future	for	the	investigation	of	other	redox	regulated	proteins	
or	 to	 further	 analyze	different	mutants	of	 LtErv	 in	 order	 to	 gain	more	 insights	 into	 the	
structure-function	relationships	of	this	protein.		
	
4.1.3	Recombinant	expression	and	identification	of	interaction	partners	of	PfErv	
As	explained	in	the	introduction,	L.	tarentolae	can	be	used	as	an	expression	system	for	the	
recombinant	 production	 of	 biologically	 active	 and	 natively	 processed	 proteins	 [60].	
Therefore,	L.	 tarentolae	was	used	 in	 this	work	to	obtain	recombinant	P.	 falciparum	Erv,	
which	 could	 not	 be	 purified	 from	 E.	 coli	 [38].	 The	 successful	 production	 of	 PfErv	 in	 L.	
tarentolae	was	confirmed	using	a	specific	antibody	(Figure	29).	However,	different	native	
purification	trials	failed	and	no	further	characterization	of	PfErv	was	possible	(Figure	30).	A	
possible	reason	for	this	outcome	may	be	the	formation	of	 insoluble	aggregates	of	PfErv	
because	of	a	strong	upregulation.	A	potential	strategy	to	overcome	this	problem	might	be	
the	use	of	the	inducible	L.	tarentolae	Lexsy	system	that	is	currently	being	established	in	our	
lab	[170].	Nevertheless,	the	L.	tarentolae	strain	with	upregulated	PfErv	protein	levels	may	
be	 useful	 for	 further	 investigations.	 For	 example,	 it	 might	 be	 tested,	 if	 the	 protein	 is	
transported	into	the	IMS	of	L.	tarentolae	mitochondria.	This	may	help	to	further	elucidate	
the	oxidative	folding	pathway	for	mitochondrial	protein	import	 into	the	IMS	of	different	
protists.		
As	the	identification	of	a	Mia40	adapter	replacement	in	L.	tarentolae	did	not	succeed,	it	
was	 also	 investigated	 if	 disulfide-bonded	 intermediates	 of	 PfErv	 can	 be	 observed	 in	 P.	
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falciparum.	 Western	 blot	 analyses	 revealed	 three	 additional	 bands	 to	 the	 one	
corresponding	 to	 the	 monomeric	 isoform	 of	 PfErv	 after	 NEM	 treatment	 under	 non-
reducing	 conditions	 (Figure	 31).	 The	 two	 upper	 bands	 may	 reflect	 mixed	 disulfide	
intermediates	 between	 PfErv	 and	 a	 potential	 interaction	 partner.	 However,	 the	 band	
observed	 at	 34	 kDa	might	 also	 reflect	 dimeric	 PfErv.	 The	 band	 at	 around	 26	 kDa	may	
indicate	an	interaction	with	a	protein	with	a	mass	of	around	9	kDa, which	is	a	typical	size
for	small	Tim	proteins	as	substrates	of	the	oxidative	folding	pathway	[17].	There	was	also	
one	band	detectable	below	the	monomeric	isoform	of	PfErv,	which	could	be	a	degradation	
product	or	unspecific	interaction	of	the	antibody.	However,	this	band	was	only	observed	
for	 the	 sample	 treated	 with	 NEM	 under	 non-reducing	 conditions.	 Hence,	 most	 likely	
intramolecular	 disulfide	 bonds	 of	 PfErv	 were	 stabilized	 by	 alkylation	 with	 NEM	 and	
represent	 this	 band.	 In	 order	 to	 perform	 pull-down	 analyses	 with	 PfErv	 and	 further	
characterize	the	potential	interaction	partners,	PfErv	could	be	endogenously	tagged	using	
the	CRISPR/Cas9	technology	for	future	analyses.		
	
4.1.3	Conclusion	1:	Investigation	of	oxidative	protein	folding	in	protist	mitochondria	
Taken	 together,	 a	 potential	 replacement	 for	 Mia40	 in	 parasitic	 protists	 remains	 to	 be	
identified	and	the	oxidative	folding	machinery	in	the	IMS	of	kinetoplastida	and	apicomplexa	
could	 not	 be	 unraveled	 during	 this	 PhD	 project.	 However,	 various	 protocols	 including	
trapping	of	potential	mixed	disulfide-bonded	interaction	partners,	native	and	denaturing	
pull-downs	and	redox	mobility	shift	assays	were	established	in	this	work.	These	techniques	
might	 in	 the	 future	be	helpful	 to	 find	a	Mia40	adapter	 replacement	 (or	 to	 show	 that	 a	
comparable	 replacement	 does	 not	 exist)	 and	 to	 further	 elucidate	 the	 oxidative	 protein	
folding	 machinery.	 First	 results	 with	 PfErv	 already	 showed	 mixed	 disulfide-bonded	
interactions	 and	 can	 be	 characterized	 in	 future	 by	 endogenous	 tagging	 using	 the	
CRISPR/Cas9	technology.	Moreover,	initial	results	with	the	four	newly	designed	cysteine-
containing	 substrates	 of	 the	 oxidative	 protein	 folding	 pathway	 of	 the	 IMS	 were	 quite	
promising	and	could	lead	to	a	rather	fast	breakthrough	in	another	PhD	project.		
As	the	results	of	the	first	project	on	oxidative	protein	folding	in	protist	mitochondria	were	
not	conclusive,	a	backup	project	was	started	after	about	1.5	years.	The	second,	unrelated	
project	on	the	elucidation	of	 the	catalytic	mechanism	of	glutaredoxins	 led	 to	numerous	
results,	which	are	discussed	in	the	following	sections.		
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4.2	Glutaredoxins	
	
4.2.1	Kinetics	of	PfGrx	mutants	confirm	a	conserved	catalysis	mechanism	
How	exactly	 is	 the	 substrate	preference	 for	one	of	 the	 two	 substrates	of	 glutaredoxins	
determined	 by	 different	 enzyme	 residues?	 It	 was	 shown	 that	 the	 preference	 of	
glutaredoxins	 for	GSSR	and	GSH	depends	on	the	γ-glutamyl	moiety	of	glutathione	 [171-
173].	However,	the	conventional	model	of	Grx	catalysis	does	not	explain	the	exact	binding	
of	 the	 different	 substrates.	 Therefore,	 I	 further	 investigated	 the	 interaction	 of	 specific	
enzyme	 areas	 with	 the	 substrates	 and	 the	 general	 mechanisms	 of	 Grx	 catalysis	 in	 the	
second	project	of	my	thesis	[106,	116].		
First,	 the	 applicability	 of	 the	 mechanistic	 model	 proposing	 two	 distinct	 glutathione	
interaction	 sites	 in	 ScGrx7	was	 tested	 using	 the	 non-related	 enzyme	PfGrx.	 The	mainly	
conserved	residue	Lys26	of	PfGrx	was	analyzed	in	analogy	to	ScGrx7K105	(Figure	32).	Kinetic	
parameters	determined	by	GSSCys	and	HEDS	assays	were	highly	similar	to	the	respective	
mutant	 ScGrx7K105A	 analyzed	 by	 Patricia	 Begas	 during	 her	 MD	 thesis	 [116].	 The	
PfGrxC32S/C88S/K26A	mutant	 revealed	a	decelerated	oxidative	and	 reductive	half-reaction	 in	
both	assays,	which	is	in	accordance	with	the	glutathione	activator	model	as	shown	before	
for	the	ScGrx7K105X	mutants	[116].		
Analyses	of	the	analogous	residue	in	human	Grx	revealed	a	decrease	of	the	apparent	Vmax	
for	HsGrxK19L	 and	HsGrxK19Q	 by	 70-80%	 compared	 to	 the	 control.	 Jao	et	 al.	 assumed	 an	
impaired	interaction	of	GSH	and	the	glutathionylated	mutant	enzyme	being	responsible	for	
the	decrease	of	Vmax	[174].	These	observations	are	in	agreement	with	our	data	determined	
for	residue	1	in	Figure	32	from	ScGrx7	and	PfGrx	[116].		
Residue	Asp90	of	PfGrx	mostly	affected	the	interaction	with	the	first	substrate	during	the	
oxidative	half-reaction	while	the	reductive	half-reaction	with	GSH	remained	rate-limiting	
as	observed	for	the	control.	The	impaired	oxidative	half-reaction	is	in	accordance	with	the	
results	 obtained	 from	 analysis	 of	 the	 homologous	 ScGrx7	 residue	 and	 the	 proposed	
glutathione-scaffold	model	 [116].	Again,	 the	determined	kinetic	parameters	were	highly	
similar.	 For	 a	 detailed	 discussion	 of	 the	 results	 mainly	 obtained	 from	 ScGrx7	mutants,	
especially	regarding	the	size	and	charge	dependent	effects,	please	also	note	the	publication	
by	Begas	et	al.	2017	[116].	
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Which	is	the	rate-limiting	step	for	glutaredoxin	catalysis?	PfGrxC32S/C88S	shows	typical	ping-
pong	kinetics	with	the	substrates	GSSCys	and	GSH	as	previously	observed	for	ScGrx7	[116].	
Moreover,	the	enzyme	tends	to	have	infinite	true	kcat	and	Km	values,	which	is	in	accordance	
with	results	obtained	from	analyses	of	human	dithiol	Grx	or	poplar	GrxS12	[122,	175].	The	
rate	constants	for	PfGrxC32S/C88S	and	the	mutants	were	 in	the	range	of	104-106	M-1s-1	and	
indicate	a short-lived	enzyme-substrate	 interaction with a	rate-limiting	re-orientation of	
the	substrate.	The	reductive	half-reaction	with	GSH	is	rate-limiting	with	a	rate	constant	of	
1.2	×	105	M-1s-1	and	10	times	slower	than	the	oxidation	by	GSSCys	with	a	rate	constant	of	
1.3	 ×	 106 M-1s-1.	 However,	 when	 Lys26	 was	 replaced	 by	 an	 alanine residue,	 the	 ratio	
between	the	rate	constants	 for	the	oxidative	and	reductive	half-reaction	decreased	and	
both	reaction	revealed	similar	rate	constants.	The	stronger	deceleration	of	the	oxidative	
half-reaction	supports	the	dual	activator	function	for	Lys26	of	PfGrx	as	also	observed	for	
ScGrx7K105	 [116].	 The	 obtained	 rate	 constants	 are	 in	 accordance	 with	 analyses	 of	
mammalian	glutaredoxins	and	poplar	GrxS12	that	revealed	rate	constants	between	2.5	×	
104	 and	 2	 ×	 106	M-1s-1.	 These	 results	 also	 support	 the	 hypothesis	 of	 the	 reductive	 half-
reaction	as	the	rate-limiting	step	[150,	156,	174,	175].	The	different	rate	constants	for	the	
oxidative	and	reductive	half-reaction	may	be	explained	by	different	transition	states	 for	
both	substrates.	The	formation	of	the	transition	state	between	GSSCys	and	the	reduced	
enzyme	seems	to	be	more	efficient	than	the	formation	of	the	transition	state	between	GSH	
and	the	glutathionylated	enzyme.	A	possible	explanation	therefore	could	be	a	reorientation	
of	Lys26	towards	GS-.	This	reorientation	may	result	 in	a	destabilization	of	the	active	site	
thiolate	 as	 the	 leaving	 group.	 The	modeling	 of	 transition	 states	 will	 help	 to	 prove	 the	
proposed	mechanism	and	will	be	done	in	collaboration	with	Holger	Gohlke	to	gain	further	
insights	into	the	exact	structure-function	relationship	of	glutaredoxins.		
In	summary,	I	confirmed	two	distinct	substrate	interaction	sites	(r1	with	Lys26	of	PfGrx;	r6	
with	 Asp90	 of	PfGrx,	 Figure	 32)	 and	 a	 conserved	mechanism	 for	 glutaredoxin	 catalysis	
investigating	the	non-related	enzyme	PfGrx.	The	kinetic	parameters	of	mutant	ScGrx7	[116]	
and	the	respective	PfGrx	mutants	were	highly	similar.	Therefore,	the	results	obtained	for	
the	 PfGrx	 mutants	 support	 a	 general	 applicability	 of	 our	 mechanistic	 model	 with	 a	
glutathione-scaffold	site	interacting	with	GSSR	and	a	glutathione	activator	site	interacting	
with	GSH	[116].	Moreover,	 the	results	show	that	PfGrx	is	an	excellent	model	enzyme	to	
study	glutaredoxin	catalysis.		
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In	general,	our	study	helps	to	understand	the	differences	between	enzymatically	active	and	
inactive	glutaredoxins.	Furthermore,	this	knowledge	might	be	used	for	the	generation	of	
glutaredoxin-coupled	fluorescent	redox	sensors	or	specific	transition-state	inhibitors	[116].	
Two	 distinct	 residues	 of	 two	 non-related	 Grx	were	 assigned	 as	 part	 of	 the	 glutathione	
activator	 and	 glutathione	 scaffold	 site.	 Nevertheless,	 the	 prediction	 of	 the	 complete	
glutathione	activator	site	without	transition-state	analogous	is	difficult	because	of	instable	
GSH	 interactions	 [122].	 Therefore,	 additional	 residues	 that	 could	 take	 part	 in	 the	
glutathione	activator	site	were	experimentally	investigated	in	this	work.	
4.2.2	Further	mapping	of	the	activator	site	of	ScGrx7	
A	structure-based	assignment	of	the	glutathione	activator	site	 is	difficult	because	of	the	
labile	GSH	interaction	[116].	However,	in	Begas	et	al.	2017,	we	proposed	several	possible	
residues	[116].	These	candidates	are	described	in	section	3	and	were	analyzed	as	potential	
activator	site	residues	in	this	work.		
The	dimension	of	the	kinetic	parameters	obtained	from	analyses	of	ScGrx7	in	this	work	is	
in	 accordance	 with	 our	 previous	 results	 [116].	 Nevertheless,	 for	 a	 reliable	 comparison	
between	the	parameters	of	different	mutants,	ScGrx7wt	was	measured	in	parallel.		
In	this	work,	I	showed	that	the	hydroxyl	group	of	Tyr110	in	ScGrx7	most	probably	does	not	
contribute	to	the	glutathione	activator	site.	The	effect	of	ScGrx7Y110A	on	the	oxidative	and	
reductive	 half-reaction	 in	 the	 GSSCys	 and	 HEDS	 assay	 can	 be	 explained	 by	 geometric	
influences	due	to	the	reduced	size	of	this	residue.	This	effect	might	point	to	a	dual	function	
of	this	residue	for	the	interaction	with	both	substrates.	Another	explanation	could	be,	that	
the	decreased	oxidative	half-reaction	indirectly	affects	the	reductive	half-reaction	with	GSH	
because	 of	 a	 potential	 “sandwich-like”	 arrangement	 of	 the	 two	 different	 substrate	
interaction	sites.	This	would	imply	that	the	effects	also	of	other	mutations	on	the	oxidative	
half-reaction	cannot	be	strictly	separated	from	the	reductive	half-reaction.	The	behavior	
could	 in	 general	 also	 be	 explained	 by	 an	 influence	 on	 the	 reactivity	 of	 the	 active	 site	
cysteine.	However,	the	pKa	value	of	this	mutant	is	not	significantly	altered	compared	to	the	
control	(see	next	section)	and	therefore	the	first	explanation	is	more	likely.	The	reductive	
half-reaction	is	not	rate-limiting	for	ScGrx7Y110H	in	the	GSSCys	assay	as	well	as	in	the	HEDS	
assay	in	contrast	to	the	control.	Both	reactions	show	approximately	the	same	reaction	rate.	
In	 the	 HEDS	 assay,	 all	 ScGrx7Y110X	 mutants	 showed	 an	 influence	 on	 the	 oxidative	 and	
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reductive	 half-reaction	 in	 contrast	 to	 the	 GSSCys	 assay,	 in	 which	 only	 the	 ScGrx7Y110A	
mutant	affected	the	reductive	half-reaction	with	GSH.	Comparing	the	results	of	the	HEDS	
assay	of	the	ScGrx7Lys105	mutants	and	ScGrx7Y110X	mutants,	parameters	are	quite	similar	and	
could	also	point	to	a	contribution	of	Tyr110	to	the	activator	site.	Again,	this	indicates	the	
existence	of	two	distinct	glutathione	interaction	sites.	As	already	discussed	in	Begas	et	al.,	
the	reciprocal	Dalziel	coefficient	2	most	likely	reflects	the	GSH-dependent	reduction	of	a	
mixed	disulfide	intermediate	between	the	glutaredoxin	and	β-ME	[116].	
Why	is	Tyr110	of	ScGrx7	not	replaced	by	a	phenylalanine	in	nature?	ScGrx7Y110F	revealed	
increased	catalytic	efficiencies	compared	to ScGrx7wt	in	the	GSSCys	assay.	The	monothiol	
glutaredoxins	AtGrxS15,	ScGrx3-5,	HsGrx5	and	EcGrx4	are	inactive	in	standard	enzymatic	
assays	and	have	a	phenylalanine	at	the	same	position	(Figure	32)	[106,	109,	116,	176].	Thus,	
a	 replacement	 at	 this	 position	 by	 phenylalanine	 does	 not	 necessarily	 lead	 to	 a	 higher	
enzymatic	 activity.	Regulation	of	 the	enzyme	by	posttranslational	modifications	 such	as	
phosphorylation	could	play	a	role	for	the	different	preferences	 in	various	glutaredoxins.	
Sequence	 analysis	 of	 all	 three	 human	 Grx	 by	 Gallogly	 et	 al.	 revealed	 several	 putative	
phosphorylation	sites	with	a	probability	score	≥	0.6.	However,	these	phosphorylation	sites	
were	not	experimentally	validated	yet	[122].	The	probability	score	for	the	phosphorylation	
of	Tyr110	was	determined	using	the	NetPhos	3.1	server	[177]	and	revealed	a	much	lower	
value	of	0.513,	which	shows	that	a	phosphorylation	of	this	residue	is	not	very	likely.	To	the	
best	 of	my	 knowledge,	 the	 only	 evidence	 for	 a	 phosphorylation	 of	 a	 glutaredoxin	 was	
published	by	Peggion	et	al.	showing	the	phosphorylation	of	ScGrx4	by	the	kinase	Bud32p	
[178].	 Taken	 together,	 it	 seems	 rather	 unlikely	 that	 a	 potential	 phosphorylation	 is	 the	
reason	for	a	tyrosine	(potentially	leading	to	a	reduced	activity)	instead	of	a	phenylalanine	
at	position	110	in	ScGrx7.	A	potential	reason	for	a	tyrosine	at	position	110	in	ScGrx7	could	
be	the	possible	formation	of	hydrogen	bonds	between	the	hydroxyl	group	of	the	Tyr110	
and	a	substrate	or	another	protein.		
Taken	together,	the	hydroxyl	group	of	Tyr110	in	ScGrx7	is	most	probably	not	part	of	the	
glutathione	 activator	 site	 but,	 nevertheless,	 the	 residue	 seems	 to	 be	 important	 for	
catalysis.		
Mutants	of	the	two	potential	activator	site	residues	in	helix	3,	Asp144	and	Glu147,	showed	
very	similar	effects	in	the	GSSCys	assay.	In	both	cases,	the	replacement	of	the	residues	with	
a	 positively	 charged	 amino	 acid	 accelerated	 the	 reductive	 half-reaction	with	 GSH.	 This	
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suggests	that	a	positively	charged	amino	acid	in	helix	3	is	beneficial	for	the	recruitment	of	
GS-.	In	this	case,	the	reductive	half-reaction	is	not	longer	rate-limiting	and	both	reactions	
have	 similar	 rate-constants.	 The	 “gain-of-function”	mutants	 ScGrx7D144K	 and	 ScGrx7E147K	
indeed	seem	to	affect	the	glutathione	activator	site.	This	may	presumably	be	explained	by	
an	altered	electrostatic	complementarity	of	the	mutated	helix	3	of	ScGrx7	and	the	second	
substrate	GSH.	The	electrostatic	complementarity	was	shown	to	play	an	important	role	for	
the	substrate	specificity	[179]	
The	homologous	residue	of	ScGrx7,	Glu147,	is	replaced	by	a	positively	charged	lysine	in	the	
catalytically	 active	 glutaredoxins	 ScGrx6	 and	 PfGrx.	 However,	 a	 replacement	 of	 the	
homologs	of	Asp144	of	ScGrx7	is	not	always	beneficial.	In	nature,	this	residue	is	replaced	
by	a	positively	charged	amino	acid	 in	several	glutaredoxins	that	are	 inactive	 in	standard	
kinetic	 assays	 or	 only	 show	 a	 low	 activity	 such	 as	 ScGrx8	 (Figure	 32)	 [113,	 180].	 Taken	
together,	the	two	analyzed	residues	in	helix	3,	previously	proposed	as	potential	activator	
site	residues,	are	not	part	of	the	glutathione	activator	site	but	have	a	negative	effect	on	the	
reductive	half-reaction	because	of	their	acidic	side	chains.	A	replacement	of	these	residues	
by	an	amino	acid	with	a	positively	charged	side	chain	leads	to	a	gain	of	function	and	these	
mutants	indeed	seem	to	contribute	to	the	glutathione	activator	site.		
Mutations	of	Arg153	 in	ScGrx7	mainly	effected	 the	oxidative	half-reaction	with	GSSCys.	
However,	the	charge	inversion	mutation	also	decreased	the	reductive	half-reaction	with	
GSH.	Thus,	the	charge	but	not	the	size	of	this	residue	seems	to	have	an	influence	on	the	
recruitment	of	GS-.	Tang	et	al.	analyzed	two	residues	in	ScGrx8	(Asn80	and	Leu81)	that	are	
next	to	the	homolog	of	ScGrx7R153	in	the	loop	of	Grx	(corresponding	to	Thr154	and	Val155)	
[180].	They	could	show	that	these	two	residues	contribute	to	the	low	activity	of	ScGrx8	in	
the	HEDS	assay.	However,	 residue	153	 in	ScGrx7	 that	was	 analyzed	 in	 this	work,	 is	 not	
replaced	in	ScGrx8	(Arg79)	and	therefore	does	not	explain	the	difference	between	active	
and	 inactive	Grx.	 Further	experiments	might	address	 the	question,	whether	Thr154	and	
Val155	are	part	of	 the	glutathione	activator	site.	Taken	 together,	 residue	153	 in	ScGrx7	
does	not	seem	to	act	as	a	specific	activator	site	 residue	but	seems	to	contribute	 to	 the	
scaffold	site.		
Modeling	of	transition	states	will	be	done	in	collaboration	with	Holger	Gohlke	and	together	
with	analyses	by	roGFP	(redox-sensitive	GFP)	assays	of	the	different	mutants	shown	in	this	
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work	in	collaboration	with	Bruce	Morgan,	this	may	help	to	understand	the	role	of	these	
and	other	mutants	in	more	detail.		
	
4.2.3	Mutations	of	ScGrx7	only	have	a	minor	influence	on	the	thiol	pKa	value	
The	interaction	of	Grx	with	its	second	substrate	GSH	during	the	reductive	half-reaction	is	
the	most	important	step	for	catalysis	according	to	the	glutathione	activator	model	[113].	
The	 reductive	half-reaction	 is	 critical	 and	often	 rate-limiting	presumably	because	of	GS-	
nucleophile	 formation	and	 for	 the	stability	of	 the	 thiolate	 leaving	group	 [107,	113,	116,	
180].	Therefore,	a	low	pKa value	could	accelerate	the	reaction	or	vice	versa.	In	this	work,	I
investigated	how	the	different	enzymatic	activities	of	selected	ScGrx7	mutants	correlate	
with	the	pKa	value	of	their	active	site	cysteine.		
The	determination	of	the	effects	of	selected	point	mutants	of	ScGrx7	on	the	thiol	pKa	value	
of	the	active	site	cysteine	revealed	only	a	minor	influence	(Figure	41).	ScGrx7wt	showed	a	
pKa	value	of	4.34	±	0.1,	which	is	in	accordance	with	other	studies	showing	that	the	thiol	
group	 of	 the	 active	 site	 cysteine	 in	 various	Grx-isoforms	 is	 quite	 acidic	with	 pKa	 values	
between	3.2	and	5.5	[107,	108,	127,	149,	150,	175].	An	exception	is	ScGrx8	with	a	pKa	value	
of	7.1	±	0.1	as	reported	by	Tang	et	al.	corresponding	to	the	low	enzymatic	activity	of	this	
enzyme	[180].	Often,	a	high	pKa	value	of	the	active	site	cysteine	comes	along	with	absent	
or	reduced	enzymatic	activities	because	of	the	altered	stability	of	the	leaving	group	[106-
108].	However,	 the	pKa	value	does	not	always	correlate	with	the	activity	as	shown	by	a	
comparison	of	ScGrx1	and	ScGrx2	revealing	similar	pKa	values	of	the	active	site	cysteine	but	
differences	 in	 the	 activity	 [127].	 Jao	 et	 al.	 analyzed	 the	 influence	 of	 residue	 1	 (Lys19;	
homologous	to	Lys105	of	ScGrx7)	on	the	thiol	pKa	value	of	the	active	site	cysteine	in	human	
Grx	[174].	The	predicted	increase	of	the	pKa	value	for	enzymes	carrying	mutations	of	this	
residue,	 determined	 by	 modeling	 of	 the	 NMR	 structure,	 could	 not	 be	 experimentally	
confirmed	 and	 therefore	 does	 not	 fully	 account	 for	 the	 differences	 in	 the	 enzymatic	
activity.		
A	similar	result	was	also	observed	in	this	work.	Most	of	the	analyzed	mutants	did	not	show	
a	 significantly	 altered	pKa	 value	despite	 reduced	enzymatic	 activities	 in	 the	GSSCys	 and	
HEDS	 assay.	 The	different	 enzymatic	 activities	 of	 the	 alanine	mutants	 of	 the	 confirmed	
glutathione	activator	site	in	ScGrx7K105A,	the	scaffold	site	in	ScGrx7E170A	and	ScGrx7Y110A	did	
not	correlate	with	the	pKa	value	of	the	active	site	cysteine.	Only	the	pKa	value	of	the	active	
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site	 cysteine	 in	ScGrx7K105E,	which	also	 revealed	 the	most	drastically	 reduced	enzymatic	
activity	in	previous	studies	[116],	was	significantly	increased	from	4.34	to	4.97.		
Taken	 together,	 the	 contribution	 of	 both	 factors	 –	 GS-	 nucleophile	 formation	 and	 the	
stability	of	the	leaving	group	–	have	different	influences	on	the	enzyme	activity.	In	the	case	
of	ScGrx7K105A,	the	GS-	nucleophile	formation	might	be	the	crucial	factor.		
4.2.4	Conclusion	2:	Elucidation	of	the	catalytic	mechanism	of	glutaredoxins	
Taken	together,	the	existence	of	two	distinct	glutathione	interaction	sites	in	glutaredoxins	
as	it	was	shown	before	by	Begas	et	al. could	be	confirmed	using PfGrx	as	a	model	enzyme	
from	the	non-related	parasite	P.	falciparum	[116].	Moreover,	four	additional	residues	that	
were	suggested	to	also	contribute	to	the	glutathione	activator	site	were	analyzed	in	this	
work.	However,	for	these	residues	a	role	as	glutathione	activators	could	not	be	confirmed	
although	all	residues	seem	to	affect	substrate	interactions.	In	contrast,	Arg153	of	ScGrx7	
seem	to	contribute	to	the	glutathione	scaffold	site.	In	addition,	I	could	show	that	the	two	
charge	inversion	mutants	of	the	helix	3	residues	Asp144	and	Glu147	in	ScGrx7	enhanced	
the	interaction	with	the	second	substrate	GSH.	Hence,	helix	3	of	these	“gain-of-function”	
mutants	indeed	seems	to	affect	the	glutathione	activator	site.	Furthermore,	the	influence	
of	the	pKa	value	of	the	active	site	cysteine	was	determined	for	different	mutants	of	ScGrx7	
that	 previously	 showed	 a	 decreased	 activity	 in	 standard	 enzymatic	 assays.	Here,	 it	was	
shown	that	the	introduced	mutations	influenced	the	pKa	value	of	ScGrx7	only	to	a	minor	
degree.		
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6	Supplementary	Data	
	
6.1	Kinetics	of	PfGrx	mutants	in	the	GSSCys	assay	
6.1.1	Steady-state	kinetics	of	PfGrx	mutants	in	the	GSSCys	assay	
 
 
 
Supplementary	figure	1	|	Steady-state	kinetics	of	PfGrx	mutants	 in	the	GSSCys	assay.	 (a)	Michaelis-Menten	
plots	showing	 the	GSH-dependent	 reaction	velocity	at	different	 fixed	GSSCys-concentrations.	 (b)	Lineweaver-
Burk	plots	of	 the	data	shown	 in	 (a)	 reveal	ping-pong	kinetics.	 (c)	Lineweaver-Burk	plots	showing	the	GSSCys-
dependent	reaction	velocity	at	four	selected	fixed	GSH	concentrations.	(d)	Michaelis-Menten	plots	showing	the	
GSSCys-dependent	reaction	velocity	at	different	fixed	GSH-concentrations.	(e)	Lineweaver-Burk	plots	of	the	data	
shown	in	(d)	reveal	ping-pong	kinetics.	(f)	Lineweaver-Burk	plots	showing	the	GSH-dependent	reaction	velocity	
at	four	selected	fixed	GSSCys-concentrations.	All	data	points	represent	the	mean	±	standard	deviation	from	at	
least	 three	 independent	experiments.	DM:	PfGrxC32S/C88S;	K26A:	PfGrxC32S/C88S/K26A;	D90A:	PfGrxC32S/C88S/D90A.	The	
figure	was	taken	from	Begas	et	al.	2017	[116].	
	 	 6	Supplementary	Data	
 
	
109 
6.1.2	Apparent	rate	constants	of	PfGrx	mutants	in	the	GSSCys	assay	
 
Supplementary	table	1	|	Apparent	rate	constants	of	PfGrx	mutants	in	the	GSSCys	assay.	Selected	kcat
app	and	
Km
app	values	of	the	GSSCys	assays	with	the	PfGrx	mutants	obtained	from	supplementary	figure	1.	aMean±SD	from	
Michaelis-Menten	 plots	 of	 supplementary	 figure	 1	 of	 at	 least	 three	 independent	 protein	 purifications.	
Percentages	are	relative	to	PfGrxC32S/C88S.	DM:	PfGrxC32S/C88S;	K26A:	PfGrxC32S/C88S/K26A;	D90A:	PfGrxC32S/C88S/D90A.	This	
data	was	already	published	in	Begas	et	al.	2017	[116].	
	
           [GSSCys]  kcat
app
(GSH) 
a  Km
app
(GSH) 
a  kcat
app/Km
app
(GSH) 
PfGrx (µM) (s-1) (µM) (mM-1s-1) 
         
               DM  25  30.4  ± 0.4  100 %  206 ± 10 100 %  147  100 %  
K26A 25 1.7  ± 0.1  6 % 31.2  ± 2.0  15 % 55 37 %  
D90A  25  25.1 ± 0.7 83 %  119 ± 19 58 %  211 144 %
               
               DM  50  56.8  ± 1.1  100 %  403 ± 25  100 %  141 100 %  
K26A  50  3.3  ± 0.1  6 %  61.6  ± 3.6  15 %  53 38 %  
D90A  50  47.8  ± 2.0  84 %  262  ± 41  65 %  182  129 %  
               
               DM  100  88.3  ± 0.9  100 %  591 ± 17  100 %  149 100 %  
K26A  100  6.6  ± 0.1  7 %  134  ± 6.9  23 %  49 33 %  
D90A  100  90.9  ± 3.2  103 %  488 ± 47  83 %  186 125 %  
               
               DM  150  160 ± 5.6  100 %  1157 ± 84  100 %  138  100 %  
K26A  150  8.1  ± 0.2  5 %  156  ± 14  13 %  52  38 %  
D90A  150  136  ± 4.0  85 %  723  ± 51  62 %  189 137 %  
               
                          [GSH]  kcat
app
(GSSCys) 
a  Km
app
(GSSCys) 
a  kcat
app/Km
app
(GSSCys) 
PfGrx  (µM)  (s-1)  (µM)  (mM-1s-1) 
         
               DM  300  33.3 ± 0.4  100 %  25.3 ± 1.2  100 %  1399 100 %  
K26A  300  10.3 ± 0.9 31 %  139 ± 21  549 %  74 5 %  
D90A  300  50.4 ± 1.0  151 %  45.6 ± 2.8  180 %  1105 79 %  
               
               DM 500 56.4 ± 0.6  100 % 42.8 ± 1.4  100 % 1351 100 %  
K26A  500  17.2 ± 2.4 30 %  235 ± 48 549 %  73 5 %
D90A  500  84.9 ± 5.1  151 %  84.6 ± 12  198 %  1003 74 %  
               
               DM  1000  98.2 ± 2.5  100 %  73.1 ± 4.7  100 %  1316 100 %  
K26A  1000  25.2 ± 4.5 26 %  361 ± 86 494 %  70 5 %  
D90A  1000  168 ± 7.9 171 %  167 ± 14  228 %  1004 76 %  
               
               DM  2000  112 ± 2.4  100 %  82.9 ± 4.0  100 %  1311 100 %  
K26A 2000 36.1 ± 7.4 32 % 516 ± 130  1622 % 70 5 %  
D90A  2000  265 ± 15 237 %  260 ± 22 314 %  1019 78 %
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6.1.3	Secondary	plots	for	the	PfGrx	mutants	in	the	GSSCys	assay	
	
 
 
Supplementary	figure	2	|	Secondary	plots	for	the	PfGrx	mutants	obtained	from	the	GSSCys	assay.	Values	for	
Km
app	and	kcat
app	were	obtained	from	the	Michaelis-Menten	plots	in	supplementary	figure	1.	(a)	Secondary	plots	
of	the	kcat
app	values	at	different	concentrations	of	GSSCys	(left	side)	and	GSH	(right	side).	(b)	Secondary	plots	of	
the	Km
app	values	at	different	concentrations	of	GSSCys	(left	side)	and	GSH	(right	side).	Outliers	based	on	the	r2	
values	 (in	 brackets)	were	 omitted	 from	 the	 linear	 regression	 analysis.	 All	 data	 points	 represent	 the	mean	 ±	
standard	 deviation	 from	 at	 least	 three	 independent	 experiments.	 DM:	PfGrxC32S/C88S;	 K26A:	PfGrxC32S/C88S/K26A;	
D90A:	PfGrxC32S/C88S/D90A.	The	figure	was	taken	from	Begas	et	al.	2017	[116].	
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6.2	Kinetics	of	PfGrx mutants	in	the HEDS	assay
6.2.1	Steady-state	kinetics	of	PfGrx	mutants	in	the	HEDS	assay	
 
 
 
 
Supplementary	figure	3	|	Steady-state	kinetics	of	PfGrx	mutants	in	the	HEDS	assay.	(a)	Michaelis-Menten	plots	
showing	the	GSH-dependent	reaction	velocity	at	different	fixed	HEDS-concentrations.	(b)	Lineweaver-Burk	plots	
of	 the	 data	 shown	 in	 (a)	 reveal	 sequential	 kinetic	 patterns.	 (c)	 Lineweaver-Burk	 plots	 showing	 the	 HEDS-
dependent	reaction	velocity	at	seven	fixed	GSH	concentrations.	(d)	Michaelis-Menten	plots	showing	the	HEDS-
dependent	reaction	velocity	at	different	fixed	GSH-concentrations.	(e)	Lineweaver-Burk	plots	of	the	data	shown	
in	(d)	reveal	sequential	kinetic	patterns.	(f)	Lineweaver-Burk	plots	showing	the	GSH-dependent	reaction	velocity	
at	seven	fixed	HEDS-concentrations.	All	data	points	represent	the	mean	±	standard	deviation	from	at	least	three	
independent	experiments.	DM:	PfGrxC32S/C88S;	 K26A:	PfGrxC32S/C88S/K26A;	D90A:	PfGrxC32S/C88S/D90A.	 The	 figure	was	
taken	from	Begas	et	al.	2017	[116].	
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6.2.2	Apparent	rate	constants	of	PfGrx	mutants	in	the	HEDS	assay	
 
Supplementary	table	2 | Apparent	rate	constants	of	PfGrx	mutants	in	the	HEDS	assay.	Selected	kcat
app and	Km
app
values	 of	 the	 HEDS	 assays	 with	 the	 PfGrx	 mutants	 obtained	 from	 supplementary	 figure	 3.	 aMean±SD	 from	
Michaelis-Menten	 plots	 of	 supplementary	 figure	 3	 of	 at	 least	 three	 independent	 protein	 purifications.	
Percentages	are	relative	to	PfGrxC32S/C88S.	DM:	PfGrxC32S/C88S;	K26A:	PfGrxC32S/C88S/K26A;	D90A:	PfGrxC32S/C88S/D90A.	This	
data	was	already	published	in	Begas	et	al.	2017	[116].	
	
 [HEDS]  kcat
app
(GSH) 
a  Km
app
(GSH) 
a  kcat
app/Km
app
(GSH)
PfGrx  (mM)  (s-1)  (mM)  (mM-1s-1) 
         
               DM  0.18  37.1  ± 2.0  100 %  1.84 ± 0.20 100 %  20.2  100 %  
K26A  0.18  2.3  ± 0.1  6 %  1.96  ± 0.24  107%  1.2 6 %  
D90A  0.18  19.8  ± 1.5  53 %  1.37  ± 0.19  74 %  14.5  72 %  
               
               
DM  0.37  66.7  ± 3.0  100 %  1.86 ± 0.17  100 %  35.9 100 %  
K26A  0.37  4.5  ± 0.3  7 %  2.12  ± 0.23  114 %  2.1 6 %  
D90A  0.37  36.7  ± 3.5  55 %  1.51  ± 0.26  81 %  24.3  68 %  
               
               
DM  0.55  96.0  ± 2.1  100 %  2.08 ± 0.09  100 %  46.2 100 %  
K26A  0.55  6.5  ± 0.3  7 %  2.38  ± 0.19  114 %  2.7 6 %  
D90A  0.55  65.6  ± 8.8  68 %  2.27 ± 0.49  109 %  28.8 62 %  
               
               
DM  0.74  134 ± 9.1  100 %  2.86 ± 0.31  100 %  46.9  100 %  
K26A  0.74  7.2  ± 0.3  5 %  1.72  ± 0.17  60 %  4.2  9 %  
D90A  0.74  101  ± 10  75 %  3.29  ± 0.48  115 %  30.8 66 %  
               
                          [GSH]  kcat
app
(HEDS) 
a  Km
app
(HEDS) 
a  kcat
app/Km
app
(HEDS) 
PfGrx  (mM)  (s-1)  (mM)  (mM-1s-1) 
         
               DM  0.25  20.1 ± 1.0  100 %  0.51 ± 0.05  100 %  39.3 100 %  
K26A  0.25  2.1 ± 1.1 11 %  1.30 ± 0.86  253 %  1.7 4 %  
D90A  0.25  13.6 ± 0.7  68 %  0.68 ± 0.06  133 %  20.0 51 %  
               
               DM  0.5  40.6 ± 0.7  100 %  0.57 ± 0.02  100 %  71.2 100 %  
K26A  0.5  3.7 ± 1.5 9 %  1.16 ± 0.91  203 %  3.2 4 %  
D90A  0.5  23.6 ± 0.6  58 %  0.61 ± 0.03  108 %  38.4 54 %  
               
               DM  1.0  78.2 ± 2.0  100 %  0.75 ± 0.03  100 %  105 100 %  
K26A  1.0  8.5 ± 2.4 11 %  1.80 ± 0.98 241 %  4.7 4 %  
D90A  1.0  58.3 ± 2.6 75 %  1.02 ± 0.07  137 %  57.1 55 %  
               
               DM  2.0  130 ± 7.4  100 %  0.76 ± 0.08  100 %  170 100 %  
K26A  2.0  14.8 ± 3.9 11 %  2.06 ± 0.80  1270 %  7.2 4 %  
D90A  2.0  129 ± 18 99 %  1.83 ± 0.35 241 %  70.2 41 %  
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6.2.3	Secondary	plots	for	the	PfGrx	mutants	in	the	HEDS	assay	
 
 
 
Supplementary	figure	4	|	Secondary	plots	for	the	PfGrx	mutants	obtained	from	the	HEDS	assay.	Values	for	Km
app	
and	kcat
app	were	obtained	from	the	Michaelis-Menten	plots	in	supplementary	figure	3.	(a)	Secondary	plots	of	the	
kcat
app	values	at	different	concentrations	of	HEDS	(left	side)	and	GSH	(right	side).	(b)	Secondary	plots	of	the	Km
app	
values	 at	 different	 concentrations	 of	 HEDS	 (left	 side)	 and	 GSH	 (right	 side).	 Outliers	 at	 the	 lowest	 substrate	
concentration	based	on	 the	 r2	values	 (in	brackets)	were	omitted	 from	the	 linear	 regression	analysis.	All	data	
points	represent	the	mean	±	standard	deviation	from	at	least	three	independent	experiments.	DM:	PfGrxC32S/C88S;	
K26A:	PfGrxC32S/C88S/K26A;	D90A:	PfGrxC32S/C88S/D90A.	The	figure	was	taken	from	Begas	et	al.	2017	[116].	
	
  
	 	 6	Supplementary	Data	
 
	
114 
6.3 Kinetics	of	ScGrx7Y110X mutants	in	the	GSSCys	assay
6.3.1	Steady-state	kinetics	of	ScGrx7Y110X	mutants	in	the	GSSCys	assay	
 
 
 
Supplementary	 figure	 5	 |	 Steady-state	 kinetics	 of	 ScGrx7Y110X	 mutants	 in	 the	 GSSCys	 assay.	 (a)	Michaelis-
Menten	 plots	 showing	 the	 GSH-dependent	 reaction	 velocity	 at	 different	 fixed	 GSSCys-concentrations.	 (b)	
Lineweaver-Burk	 plots	 of	 the	 data	 shown	 in	 (a)	 reveal	 ping-pong	 kinetic	 patterns.	 (c)	 Lineweaver-Burk	 plots	
showing	the	GSSCys-dependent	reaction	velocity	at	different	fixed	GSH	concentrations.	All	data	points	represent	
the	mean	±	standard	deviation	from	three	independent	experiments.	WT:	ScGrx7	wild-type;	Y110F:	ScGrx7Y110F;	
Y110H:	ScGrx7Y110H;	Y110A:	ScGrx7Y110A.		
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6.3.2	Apparent	rate	constants	of	ScGrx7Y110X	mutants	in	the	GSSCys	assay		
 
Supplementary	table	3	|	Apparent	rate	constants	of	ScGrx7Y110X	mutants	in	the	GSSCys	assay.	Selected	kcat
app	
and	 Km
app	 values	 of	 the	 GSSCys	 assays	 with	 the	 ScGrx7wt	 enzyme	 and	 Y110X	 mutants	 obtained	 from	
supplementary	figure	5.	aMean±SD	from	Michaelis-Menten	plots	of	supplementary	figure	5	of	three	independent	
protein	 purifications.	 Percentages	 are	 relative	 to	ScGrx7wt.	WT:	ScGrx7	wild-type;	 Y110F:	 ScGrx7Y110F;	 Y110H:	
ScGrx7Y110H;	Y110A:	ScGrx7Y110A.	
	
           [GSSCys]  kcat
app
(GSH) 
a  Km
app
(GSH) 
a  kcat
app/Km
app
(GSH) 
ScGrx7  (µM)  (s-1)  (µM)  (mM-1s-1) 
         
               WT  25  18.8  ± 0.3  100 %  104 ± 7.6 100 %  180  100 %  
Y110F  25  17.9  ± 0.2  95 %  68.1  ± 4.2  65 %  264  147 %  
Y110H  25  4.8  ± 0.1  26 %  24.8  ± 3.8  24 %  198  110 %  
Y110A  25  2.4  ± 0.0  13 %  58.2  ± 4.5  56 %  41  23 %  
               
               
WT  50  31.1  ± 1.1  100 %  128 ± 16.8  100 %  243 100 %  
Y110F  50  36.6  ± 0.5  118 %  141  ± 7.7  110 %  259 107 %  
Y110H  50  8.4  ± 0.0  27 %  42.8  ± 0.9  33 %  196  81 %  
Y110A  50  4.1  ± 0.1  13 %  100  ± 5.7  78 %  41 17 %  
               
               WT  100  52.3  ± 2.2  100 %  215 ± 28.5  100 %  243 100 %  
Y110F  100  60.7  ± 1.0  116 %  216  ± 10.8  101 %  280 115 %  
Y110H  100  16.9  ± 5.0  32 %  93.0  ± 5.0  43 %  181 74 %  
Y110A  100  7.2  ± 0.1  14 %  159  ± 7.1 74 %  46 19 %  
               
               WT  150  75.2 ± 1.6  100 %  291 ± 17.6  100 %  258  100 %  
Y110F 150 82.5  ± 2.0  110 % 302  ± 20.1  104 % 273  106 %  
Y110H  150  21.6  ± 0.3  29 %  105  ± 6.4  36 %  204 79 %  
Y110A  150  10.1  ± 0.1  13 %  219  ± 9.6 75 %  46  18 %  
               
                          [GSH]  kcat
app
(GSSCys) 
a  Km
app
(GSSCys) 
a  kcat
app/Km
app
(GSSCys) 
ScGrx7  (µM)  (s-1)  (µM)  (mM-1s-1) 
         
               WT  50  12.6 ± 0.5  100 %  19.7 ± 3.8  100 %  639 100 %  
Y110F  50  13.9 ± 0.03 110 %  19.6 ± 0.2  99 %  712 111 %  
Y110H  50  9.4 ± 0.5  75 %  50.4 ± 6.4  256 %  187 29 %  
Y110A  50  2.5 ± 0.1 20 %  42.8 ± 6.5  217 %  60 9 %  
               
               WT  100  21.2 ± 1.5  100 %  34.2 ± 6.4  100 %  621 100 %  
Y110F  100  23.9 ± 1.2 113 %  32.0 ± 5.2  94 %  746 120 %  
Y110H  100  17.0 ± 0.6  80 %  90.3 ± 6.1  264 %  188 30 %  
Y110A  100  4.1 ± 0.2  19 %  48.9 ± 6.7 143 %  84 14 %  
               
               WT  200  40.4 ± 5.2  100 %  64.7 ± 19.7  100 %  624 100 %  
Y110F  200  49.1 ± 2.4 122 %  68.6 ± 7.6 106 %  716 115 %  
Y110H  200  24.2 ± 1.1 60 %  116 ± 10.3  180 %  207 33 %  
Y110A  200  7.5 ± 0.7  19 %  85.9 ± 15.9  133 %  87 14 %  
               
               
WT 1000 163 ± 54.8  100 % 266 ± 129  100 % 612 100 %  
Y110F  1000  142 ± 13.7 87 %  184 ± 28.3  169 %  771 126 %  
Y110H  1000  63.1 ± 16.3 39 %  319 ± 113 120 %  198 32 %  
Y110A  1000  19.2 ± 1.9  12 %  204 ± 30.7  77 %  94 15 %  
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6.3.3	Secondary	plots	for	the	ScGrx7Y110X	mutants	in	the	GSSCys	assay	
 
 
 
Supplementary	figure	6	|	Secondary	plots	for	the	ScGrx7Y110X	mutants	obtained	from	the	GSSCys	assay.	Values	
for	Km
app	and	kcat
app	were	obtained	from	the	Michaelis-Menten	plots	 in	supplementary	figure	5.	(a)	Secondary	
plots	of	the	kcat
app	values	at	different	concentrations	of	GSSCys	(left	side)	and	GSH	(right	side).	(b)	Secondary	plots	
of	the	Km
app	values	at	different	concentrations	of	GSSCys	(left	side)	and	GSH	(right	side).	Outliers	based	on	the	r2	
values	 (in	 brackets)	were	 omitted	 from	 the	 linear	 regression	 analysis.	 All	 data	 points	 represent	 the	mean	 ±	
standard	 deviation	 from	 three	 independent	 experiments.	 WT:	 ScGrx7	 wild-type;	 Y110F:	 ScGrx7Y110F;	 Y110H:	
ScGrx7Y110H;	Y110A:	ScGrx7Y110A.	
	
	
 
 
 
 
	 	
	 	 6	Supplementary	Data	
 
	
117 
6.4	Kinetics	of	ScGrx7Y110X	mutants	in	the	HEDS	assay	
6.4.1	Steady-state	kinetics	of	ScGrx7Y110X	mutants	in	the	HEDS	assay	
 
 
 
Supplementary	figure	7	|	Steady-state	kinetics	of	ScGrx7Y110X	mutants	in	the	HEDS	assay.	(a)	Michaelis-Menten	
plots	showing	the	GSH-dependent	reaction	velocity	at	different	fixed	HEDS-concentrations.	(b)	Lineweaver-Burk	
plots	of	the	data	shown	in	(a)	reveal	ping-pong	kinetic	patterns.	(c)	Lineweaver-Burk	plots	showing	the	HEDS-
dependent	reaction	velocity	at	different	fixed	GSH	concentrations.	All	data	points	represent	the	mean	±	standard	
deviation	from	three	independent	experiments.	WT:	ScGrx7	wild-type;	Y110F:	ScGrx7Y110F;	Y110H:	ScGrx7Y110H;	
Y110A:	ScGrx7Y110A.		
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6.4.2	Apparent	rate	constants	of	ScGrx7Y110X	mutants	in	the	HEDS	assay	
 
Supplementary	table	4	|	Apparent	rate	constants	of	ScGrx7Y110X	mutants	in	the	HEDS	assay.	Selected	kcat
app	and	
Km
app	values	of	 the	HEDS	assays	with	the	ScGrx7wt	enzyme	and	Y110X	mutants	obtained	from	supplementary	
figure	 7.	 aMean±SD	 from	 Michaelis-Menten	 plots	 of	 supplementary	 figure	 7	 of	 three	 independent	 protein	
purifications.	Percentages	are	relative	to	ScGrx7wt.	WT:	ScGrx7	wild-type;	Y110F:	ScGrx7Y110F;	Y110H:	ScGrx7Y110H;	
Y110A:	ScGrx7Y110A.	
	
           [HEDS]  kcat
app
(GSH) 
a  Km
app
(GSH) 
a  kcat
app/Km
app
(GSH) 
ScGrx7  (mM)  (s-1)  (mM)  (mM-1s-1) 
         
               WT  0.18  32.1  ± 1.4  100 %  1.55 ± 0.12 100 %  20.7  100 %  
Y110F  0.18  19.7  ± 2.5  61 %  1.64  ± 0.38  106 %  12.0  58 %  
Y110H  0.18  4.9  ± 0.2  15 %  1.52  ± 0.10  98 %  3.2  15 %  
Y110A  0.18  1.6  ± 0.1  5 %  1.64  ± 0.12  106 %  0.9  4 %  
               
               
WT  0.37  58.6  ± 2.4  100 %  1.60 ± 0.12  100 %  36.7 100 %  
Y110F  0.37  39.9  ± 1.0  68 %  1.73  ± 0.08  108 %  23.0 63 %  
Y110H  0.37  10.2  ± 0.7  17 %  1.89  ± 0.23  118 %  5.4  15 %  
Y110A  0.37  2.6  ± 0.1  4 %  1.07  ± 0.09  67 %  2.5 7 %  
               
               WT  0.55  64.6  ± 3.4  100 %  1.14 ± 0.12  100 %  56.6 100 %  
Y110F  0.55  52.7  ± 2.8  82 %  1.46  ± 0.14  128 %  36.1 64 %  
Y110H  0.55  14.0  ± 0.3  22 %  1.89  ± 0.06  166 %  7.4 13 %  
Y110A  0.55  3.6  ± 0.4  6 %  1.25  ± 0.24 110 %  2.9 5 %  
               
               WT  0.74  72.9 ± 3.4  100 %  1.10 ± 0.10  100 %  66.5  100 %  
Y110F 0.74 63.4  ± 4.9  87 % 1.32  ± 0.19  120 % 48.0  72 %  
Y110H  0.74  16.0  ± 1.1  22 %  1.64  ± 0.18  149 %  9.7 15 %  
Y110A  0.74  5.6  ± 0.2  8 %  1.52  ± 0.12 138 %  3.7  6 %  
               
                          [GSH]  kcat
app
(HEDS) 
a  Km
app
(HEDS) 
a  kcat
app/Km
app
(HEDS) 
ScGrx7  (mM)  (s-1)  (mM)  (mM-1s-1) 
         
               WT  0.3  34.1 ± 4.1  100 %  0.92 ± 0.18  100 %  36.9 100 %  
Y110F  0.3  31.2 ± 15.8 91 %  1.78 ± 1.20  193 %  17.5 47 %  
Y110H  0.3  10.2 ± 1.9  30 %  2.27 ± 0.53  245 %  4.5 12 %  
Y110A  0.3  1.7 ± 0.3 5 %  1.10 ± 0.33  120 %  1.5 4 %  
               
               WT  0.5  63.9 ± 4.1  100 %  1.33 ± 0.12  100 %  47.8 100 %  
Y110F  0.5  78.5 ± 31 123 %  3.40 ± 1.58  256 %  23.1 48 %  
Y110H  0.5  13.8 ± 1.6  22 %  2.02 ± 0.30  152 %  6.9 14 %  
Y110A  0.5  2.0 ± 0.3  3 %  0.67 ± 0.18 50 %  3.0 6 %  
               
               WT  1.0  81.1 ± 8.9  100 %  0.90 ± 0.16  100 %  90.1 100 %  
Y110F  1.0  104.4 ± 19.4 129 %  2.59 ± 0.59 288 %  40.2 45 %  
Y110H  1.0  20.4 ± 0.8 25 %  1.65 ± 0.15  183 %  12.3 14 %  
Y110A  1.0  4.5 ± 0.9  6 %  0.79 ± 0.26  88 %  5.8 6 %  
               
               
WT 1.5 90.0 ± 12.5  100 % 0.82 ± 0.19  100 % 110 100 %  
Y110F  1.5  138.9 ± 28.9 154 %  2.85 ± 0.71  1348 %  48.8 44 %  
Y110H  1.5  25.8 ± 3.6 29 %  1.77 ± 0.32 216 %  14.6 13 %  
Y110A  1.5  4.2 ± 0.1  5 %  0.61 ± 0.02  74 %  6.8 6 %  
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6.4.3	Secondary	plots	for	the	ScGrx7Y110X	mutants	in	the	HEDS	assay	
 
 
 
Supplementary	figure	8	|	Secondary	plots	for	the	ScGrx7Y110X	mutants	obtained	from	the	HEDS	assay.	Values	
for	Km
app	and	kcat
app	were	obtained	from	the	Michaelis-Menten	plots	 in	supplementary	figure	7.	(a)	Secondary	
plots	of	the	kcat
app	values	at	different	concentrations	of	HEDS	(left	side)	and	GSH	(right	side).	(b)	Secondary	plots	
of	the	Km
app	values	at	different	concentrations	of	HEDS	(left	side)	and	GSH	(right	side).	Outliers	based	on	the	r2	
values	 (in	 brackets)	were	 omitted	 from	 the	 linear	 regression	 analysis.	 All	 data	 points	 represent	 the	mean	 ±	
standard	 deviation	 from	 three	 independent	 experiments.	 WT:	 ScGrx7	 wild-type;	 Y110F:	 ScGrx7Y110F;	 Y110H:	
ScGrx7Y110H;	Y110A:	ScGrx7Y110A.	
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6.5 Kinetics	of	ScGrx7D144X mutants	in	the	GSSCys	assay
6.5.1	Steady-state	kinetics	of	ScGrx7D144X	mutants	in	the	GSSCys	assay	
 
 
 
Supplementary	 figure	 9	 |	 Steady-state	 kinetics	 of	 ScGrx7D144X	mutants	 in	 the	 GSSCys	 assay.	 (a)	Michaelis-
Menten	 plots	 showing	 the	 GSH-dependent	 reaction	 velocity	 at	 different	 fixed	 GSSCys-concentrations.	 (b)	
Lineweaver-Burk	 plots	 of	 the	 data	 shown	 in	 (a)	 reveal	 ping-pong	 kinetic	 patterns.	 (c)	 Lineweaver-Burk	 plots	
showing	the	GSSCys-dependent	reaction	velocity	at	different	fixed	GSH	concentrations.	All	data	points	represent	
the	mean	±	standard	deviation	from	three	independent	experiments.	WT:	ScGrx7	wild-type;	D144A:	ScGrx7D144A;	
D144K:	ScGrx7D144K.		
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6.5.2	Apparent	rate	constants	of	ScGrx7D144X	mutants	in	the	GSSCys	assay	
 
Supplementary	table	5	|	Apparent	rate	constants	of	ScGrx7D144X	mutants	in	the	GSSCys	assay.	Selected	kcat
app	
and	 Km
app	 values	 of	 the	 GSSCys	 assays	 with	 the	 ScGrx7wt	 enzyme	 and	 D144X	 mutants	 obtained	 from	
supplementary	figure	9.	aMean±SD	from	Michaelis-Menten	plots	of	supplementary	figure	9	of	three	independent	
protein	purifications.	Percentages	are	relative	to	ScGrx7wt.	WT:	ScGrx7	wild-type;	D144A:	ScGrx7D144A;	D144K:	
ScGrx7D144K.	
	
           [GSSCys]  kcat
app
(GSH) 
a  Km
app
(GSH) 
a  kcat
app/Km
app
(GSH) 
ScGrx7  (µM)  (s-1)  (µM)  (mM-1s-1) 
         
               WT  25  16.2  ± 0.2  100 %  67.5 ± 4.4 100 %  240  100 %  
D144A  25  13.0  ± 0.1  80 %  68.6 ± 2.6  102 %  190  79 %  
D144K  25  10.9  ± 0.1  67 %  25.2 ± 1.2  37 %  433 180 %  
               
               
WT  50  30.4  ± 0.4  100 %  120 ± 5.6  100 %  253 100 %  
D144A  50  23.1  ± 0.2  76 %  103  ± 4.2  86 %  225  89 %  
D144K  50  24.9  ± 0.4  82 %  64.0  ± 5.6  53 %  389 154 %  
               
WT  100  53.3  ± 0.9  100 %  211 ± 11.1  100 %  253 100 %  
D144A  100  40.0  ± 1.0  75 %  194  ± 16.4  92 %  214 85 %  
D144K  100  42.2  ± 0.7  79 %  82.6  ± 6.2 38 %  511 202 %  
               
               
WT  150  68.0 ± 2.4  100 %  244 ± 27.1  100 %  279  100 %  
D144A  150  58.7  ± 1.3  86 %  275 ± 18.1  113 %  214 77 %  
D144K  150  58.2  ± 1.7  86 %  138 ± 13.1 56 %  422  151 %  
               
                          [GSH]  kcat
app
(GSSCys) 
a  Km
app
(GSSCys) 
a  kcat
app/Km
app
(GSSCys) 
ScGrx7  (µM)  (s-1)  (µM)  (mM-1s-1) 
         
               WT  50  13.3 ± 0.5  100 %  22.1 ± 3.3  100 %  603 100 %  
D144A  50  16.0 ± 0.8  120 %  44.4 ± 6.0  201 %  360 60 %  
D144K  50  22.7 ± 0.8 171 %  50.2 ± 4.9  227 %  453 75 %  
               
               
WT  100  23.2 ± 0.7  100 %  36.4 ± 3.1  100 %  639 100 %  
D144A  100  26.2 ± 0.9  112 %  62.7 ± 5.3  172 %  418 65 %  
D144K  100  41.3 ± 4.4  178 %  89.2 ± 19.5 245 %  463 72 %  
               
               
WT  200  45.8 ± 2.6  100 %  70.7 ± 9.0  100 %  648 100 %  
D144A  200  42.3 ± 4.4 92 %  89.3 ± 19.1  126 %  473 73 %  
D144K  200  95.2 ± 5.3  208 %  213 ± 18.1  301 %  446 69 %  
               
               
WT  1000  114 ± 13.0  100 %  155 ± 29.9  100 %  735 100 %  
D144A  1000  122 ± 12.5 107 %  252 ± 37.3 163 %  485 66 %  
D144K  1000  182 ± 37.1  160 %  377 ± 103  243 %  483 66 %  
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6.5.3	Secondary	plots	for	the	ScGrx7D144X	mutants	in	the	GSSCys	assay	
 
 
 
Supplementary	figure	10	|	Secondary	plots	for	the	ScGrx7D144X	mutants	obtained	from	the	GSSCys	assay.	Values	
for	Km
app	and	kcat
app	were	obtained	from	the	Michaelis-Menten	plots	 in	supplementary	figure	9.	(a)	Secondary	
plots	of	the	kcat
app	values	at	different	concentrations	of	GSSCys	(left	side)	and	GSH	(right	side).	(b)	Secondary	plots	
of	the	Km
app	values	at	different	concentrations	of	GSSCys	(left	side)	and	GSH	(right	side).	Outliers	based	on	the	r2	
values	 (in	 brackets)	were	 omitted	 from	 the	 linear	 regression	 analysis.	 All	 data	 points	 represent	 the	mean	 ±	
standard	 deviation	 from	 three	 independent	 experiments.	WT:	 ScGrx7	wild-type;	 D144A:	 ScGrx7D144A;	 D144K:	
ScGrx7D144K.	
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6.6 Kinetics	of	ScGrx7E147X mutants	in	the	GSSCys	assay
6.6.1	Steady-state	kinetics	of	ScGrx7E147X	mutants	in	the	GSSCys	assay	
 
 
 
Supplementary	 figure	 11	 |	 Steady-state	 kinetics	 of	ScGrx7E147X	mutants	 in	 the	GSSCys	 assay.	 (a)	Michaelis-
Menten	 plots	 showing	 the	 GSH-dependent	 reaction	 velocity	 at	 different	 fixed	 GSSCys-concentrations.	 (b)	
Lineweaver-Burk	 plots	 of	 the	 data	 shown	 in	 (a)	 reveal	 ping-pong	 kinetic	 patterns.	 (c)	 Lineweaver-Burk	 plots	
showing	the	GSSCys-dependent	reaction	velocity	at	different	fixed	GSH	concentrations.	All	data	points	represent	
the	mean	±	standard	deviation	from	three	independent	experiments.	WT:	ScGrx7	wild-type;	E147A:	ScGrx7E147A;	
E147K:	ScGrx7E147K.		
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6.6.2	Apparent	rate	constants	of	ScGrx7E147X	mutants	in	the	GSSCys	assay	
 
Supplementary	table	6	|	Apparent	rate	constants	of	ScGrx7E147X	mutants	in	the	GSSCys	assay.	Selected	kcat
app	
and	 Km
app	 values	 of	 the	 GSSCys	 assays	 with	 the	 ScGrx7wt	 enzyme	 and	 E147X	 mutants	 obtained	 from	
supplementary	 figure	 11.	 aMean±SD	 from	 Michaelis-Menten	 plots	 of	 supplementary	 figure	 11	 of	 three	
independent	 protein	 purifications.	 Percentages	 are	 relative	 to	 ScGrx7wt.	 WT:	 ScGrx7	 wild-type;	 E147A:	
ScGrx7E147A;	E147K:	ScGrx7E147K.	
	
           [GSSCys]  kcat
app
(GSH) 
a  Km
app
(GSH) 
a  kcat
app/Km
app
(GSH) 
ScGrx7  (µM)  (s-1)  (µM)  (mM-1s-1) 
         
               WT  25  16.2  ± 0.2  100 %  67.5 ± 4.4 100 %  240  100 %  
E147A  25  17.0  ± 0.1  105 %  77.6  ± 2.3  115 %  219  91 %  
E147K  25  18.0  ± 0.3  111 %  47.4 ± 4.9  70 %  379  158 %  
               
               
WT  50  30.4  ± 0.4  100 %  120 ± 5.6  100 %  253 100 %  
E147A  50  32.3  ± 0.5  106 %  145  ± 0.5  121 %  223 88 %  
E147K  50  34.4  ± 0.6  113 %  87.2  ± 6.5  73 %  395 156 %  
               
WT  100  53.3  ± 0.9  100 %  211 ± 11.1  100 %  253 100 %  
E147A  100  60.4  ± 1.0  113 %  237  ± 12.4  112 %  255 101 %  
E147K  100  67.3  ± 0.8  126 %  139  ± 6.3 66 %  486 192 %  
               
               
WT  150  68.0 ± 2.4  100 %  244 ± 27.1  100 %  279  100 %  
E147A  150  82.9  ± 1.3  122 %  344  ± 14.0  141 %  241 86 %  
E147K  150  77.2  ± 1.4  114 %  142  ± 9.2 58 %  543  195 %  
               
                          [GSH]  kcat
app
(GSSCys) 
a  Km
app
(GSSCys) 
a  kcat
app/Km
app
(GSSCys) 
ScGrx7  (µM)  (s-1)  (µM)  (mM-1s-1) 
         
               WT  50  13.3 ± 0.5  100 %  22.1 ± 3.3  100 %  603 100 %  
E147A  50  13.6 ± 0.4  102 %  25.8 ± 2.5  117 %  526 87 %  
E147K  50  30.9 ± 1.3 232 %  60.9 ± 6.0  276 %  508 84 %  
               
               
WT  100  23.2 ± 0.7  100 %  36.4 ± 3.1  100 %  639 100 %  
E147A  100  25.8 ± 1.8  111 %  41.1 ± 8.0  113 %  629 98 %  
E147K  100  57.5 ± 2.2  248 %  104 ± 7.9 287 %  550 86 %  
               
               
WT  200  45.8 ± 2.6  100 %  70.7 ± 9.0  100 %  648 100 %  
E147A  200  45.0 ± 1.4 98 %  70.4 ± 4.9  100 %  640 99 %  
E147K  200  77.9 ± 3.3  170 %  117 ± 9.2  165 %  665 103 %  
               
               
WT  1000  114 ± 13.0  100 %  155 ± 29.9  100 %  735 100 %  
E147A  1000  139 ± 7.3 122 %  189 ± 15.6 122 %  737 100 %  
E147K  1000  363 ± 33.2  318 %  509 ± 54.2  328 %  714 97 %  
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6.6.3	Secondary	plots	for	the	ScGrx7E147X	mutants	in	the	GSSCys	assay	
 
 
 
Supplementary	figure	12	|	Secondary	plots	for	the	ScGrx7E147X	mutants	obtained	from	the	GSSCys	assay.	Values	
for	Km
app	and	kcat
app	were	obtained	from	the	Michaelis-Menten	plots	in	supplementary	figure	11.	(a)	Secondary	
plots	of	the	kcat
app	values	at	different	concentrations	of	GSSCys	(left	side)	and	GSH	(right	side).	(b)	Secondary	plots	
of	the	Km
app	values	at	different	concentrations	of	GSSCys	(left	side)	and	GSH	(right	side).	Outliers	based	on	the	r2	
values	 (in	 brackets)	were	 omitted	 from	 the	 linear	 regression	 analysis.	 All	 data	 points	 represent	 the	mean	 ±	
standard	 deviation	 from	 three	 independent	 experiments.	 WT:	 ScGrx7	 wild-type;	 E147A:	 ScGrx7E147A;	 E147K:	
ScGrx7E147K.	
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6.7 Kinetics	of	ScGrx7R153X mutants	in	the	GSSCys	assay
6.7.1	Steady-state	kinetics	of	ScGrx7R153X	mutants	in	the	GSSCys	assay	
 
 
 
Supplementary	 figure	 13	 |	 Steady-state	 kinetics	 of	ScGrx7R153X	mutants	 in	 the	GSSCys	 assay.	 (a)	Michaelis-
Menten	 plots	 showing	 the	 GSH-dependent	 reaction	 velocity	 at	 different	 fixed	 GSSCys-concentrations.	 (b)	
Lineweaver-Burk	 plots	 of	 the	 data	 shown	 in	 (a)	 reveal	 ping-pong	 kinetic	 patterns.	 (c)	 Lineweaver-Burk	 plots	
showing	the	GSSCys-dependent	reaction	velocity	at	different	fixed	GSH	concentrations.	All	data	points	represent	
the	mean	±	standard	deviation	from	three	independent	experiments.	WT:	ScGrx7	wild-type;	R153A:	ScGrx7R153A;	
R153E:	ScGrx7R153E.	
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6.7.2	Apparent	rate	constants	of	ScGrx7R153X	mutants	in	the	GSSCys	assay	
 
Supplementary	table	7	|	Apparent	rate	constants	of	ScGrx7R153X	mutants	in	the	GSSCys	assay.	Selected	kcat
app	
and	 Km
app	 values	 of	 the	 GSSCys	 assays	 with	 the	 ScGrx7wt	 enzyme	 and	 R153X	 mutants	 obtained	 from	
supplementary	 figure	 13.	 aMean±SD	 from	 Michaelis-Menten	 plots	 of	 supplementary	 figure	 13	 of	 three	
independent	 protein	 purifications.	 Percentages	 are	 relative	 to	 ScGrx7wt.	 WT:	 ScGrx7	 wild-type;	 R153A:	
ScGrx7R153A;	R153E:	ScGrx7R153E.	
	
           [GSSCys]  kcat
app
(GSH) 
a  Km
app
(GSH) 
a  kcat
app/Km
app
(GSH) 
ScGrx7  (µM)  (s-1)  (µM)  (mM-1s-1) 
         
               WT  25  16.2  ± 0.2  100 %  67.5 ± 4.4 100 %  240  100 %  
R153A  25  6.6  ± 0.1  41 %  32.8  ± 2.0  49 %  201  84 %  
R153E  25  3.5  ± 0.0  22 %  27.1 ± 2.8  40 %  128  53 %  
               
               WT  50  30.4  ± 0.4  100 %  120 ± 5.6  100 %  253 100 %  
R153A  50  12.9  ± 0.1  42 %  56.2  ± 2.7  47 %  230  91 %  
R153E  50  6.6  ± 0.1  22 %  54.3  ± 3.4  45 %  122 48 %  
               
               WT 100 53.3  ± 0.9  100 % 211 ± 11.1  100 % 253 100 %  
R153A  100  24.2  ± 0.3  45 %  110  ± 4.8  52 %  221 87 %  
R153E  100  13.4  ± 0.1  25 %  101  ± 4.3 48 %  133 53 %  
               
               WT  150  68.0 ± 2.4  100 %  244 ± 27.1  100 %  279  100 %  
R153A  150  31.6  ± 0.6  46 %  118  ± 8.0  48 %  268 96 %  
R153E  150  17.0  ± 0.2  25 %  130 ± 6.2 53 %  131  47 %  
               
                          [GSH]  kcat
app
(GSSCys) 
a  Km
app
(GSSCys) 
a  kcat
app/Km
app
(GSSCys) 
ScGrx7  (µM)  (s-1)  (µM)  (mM-1s-1) 
         
               WT  50  13.3 ± 0.5  100 %  22.1 ± 3.3  100 %  603 100 %  
R153A  50  14.1 ± 0.3  106 %  66.5 ± 3.5  306 %  212 35 %  
R153E 50 8.1 ± 1.5 61 % 64.1 ± 27.3  290 % 126 21 %  
               
               WT  100  23.2 ± 0.7  100 %  36.4 ± 3.1  100 %  639 100 %  
R153A  100  22.5 ± 1.2  97 %  88.5 ± 9.5  243 %  254 40 %  
R153E  100  11.9 ± 2.0  51 %  82.7 ± 30.3 227 %  144 23 %  
               
               WT  200  45.8 ± 2.6  100 %  70.7 ± 9.0  100 %  648 100 %  
R153A  200  37.1 ± 1.2 81 %  135 ± 7.6  191 %  276 43 %  
R153E  200  19.5 ± 2.6  43 %  136 ± 32.2  192 %  144 22 %  
               WT  1000  114 ± 13.0  100 %  155 ± 29.9  100 %  735 100 %  
R153A  1000  79.0 ± 5.8 69 %  270 ± 28.2 174 %  293 40 %  
R153E  1000  52.2 ± 4.1  46 %  332 ± 19.0  214 %  145 20 %  
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6.7.3	Secondary	plots	for	the	ScGrx7R153X	mutants	in	the	GSSCys	assay	
 
 
 
Supplementary	figure	14	|	Secondary	plots	for	the	ScGrx7R153X	mutants	obtained	from	the	GSSCys	assay.	Values	
for	Km
app	and	kcat
app	were	obtained	from	the	Michaelis-Menten	plots	in	supplementary	figure	13.	(a)	Secondary	
plots	of	the	kcat
app	values	at	different	concentrations	of	GSSCys	(left	side)	and	GSH	(right	side).	(b)	Secondary	plots	
of	the	Km
app	values	at	different	concentrations	of	GSSCys	(left	side)	and	GSH	(right	side).	Outliers	based	on	the	r2	
values	 (in	 brackets)	were	 omitted	 from	 the	 linear	 regression	 analysis.	 All	 data	 points	 represent	 the	mean	 ±	
standard	 deviation	 from	 three	 independent	 experiments.	 WT:	 ScGrx7	 wild-type;	 R153A:	 ScGrx7R153A;	 R153E:	
ScGrx7R153E.	
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6.8	Statistical	analyses	of	kinetic	data	
Supplementary	table	8	|	Statistical	analyses	of	kinetic	data.	Statistical	analysis	of	kcat
app	and	Km
app	values	from	
the	indicated	measurements	of	PfGrx and	ScGrx7 mutants.	P-values	from	one	way	ANOVA	analysis	followed	by	
a	Holm-Sidak	test	were	calculated	in	SigmaPlot	13	(P	>	0.05:	ns;	P	≤	0.05:	*;	P	≤	0.01:	**,	P	≤	0.001:	***).		
 
A) GSSCys assay PfGrx (Fig. 34, Supplementary Fig. 1 and Supplementary Table 1) 
A1.1) kcatapp(GSSCys) @ 300 µM GSH 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A <0.001 *** 
K26A à D90A <0.001 *** 
 
A1.2) kcatapp(GSSCys) @ 500 µM GSH 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A <0.001 *** 
K26A à D90A <0.001 *** 
 
A1.3) kcatapp(GSSCys) @ 1000 µM GSH 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A <0.001 *** 
K26A à D90A <0.001 *** 
 
A1.4) kcatapp(GSSCys) @ 2000 µM GSH 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A <0.001 *** 
K26A à D90A <0.001 *** 
 
A2.1) kcatapp(GSH) @ 25 µM GSSCys 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A <0.001 *** 
K26A à D90A <0.001 *** 
 
A2.2) kcatapp(GSH) @ 50 µM GSSCys 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A   0.002 ** 
K26A à D90A <0.001 *** 
 
A2.3) kcatapp(GSH) @ 100 µM GSSCys 
Comparison           P-value 
DM à K26A <0.001 ***
DM  à D90A   0.247 ns 
K26A à D90A <0.001 *** 
 
A2.4) kcatapp(GSH) @ 150 µM GSSCys 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A   0.354 ns 
K26A à D90A <0.001 *** 
A3.1) Kmapp(GSSCys) @ 300 µM GSH 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A <0.001 *** 
K26A à D90A   0.002 ** 
 
A3.2) Kmapp(GSSCys) @ 500 µM GSH 
Comparison           P-value 
DM à K26A   0.002 ** 
DM  à D90A   0.004 ** 
K26A à D90A   0.006 ** 
 
A3.3) Kmapp(GSSCys) @ 1000 µM GSH 
Comparison           P-value 
DM à K26A   0.004 ** 
DM  à D90A <0.001 *** 
K26A à D90A   0.018 * 
 
A3.4) Kmapp(GSSCys) @ 2000 µM GSH 
Comparison           P-value 
DM à K26A   0.006 ** 
DM  à D90A <0.001 *** 
K26A à D90A   0.028 * 
 
A4.1) Kmapp(GSH) @ 25 µM GSSCys 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A   0.002 ** 
K26A à D90A   0.001 *** 
 
A4.2) Kmapp(GSH) @ 50 µM GSSCys 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A   0.007 ** 
K26A à D90A   0.001 *** 
 
A4.3) Kmapp(GSH) @ 100 µM GSSCys 
Comparison           P-value 
DM à K26A <0.001 ***
DM  à D90A   0.232 ns 
K26A à D90A <0.001 *** 
A4.4) Kmapp(GSH) @ 150 µM GSSCys 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A   0.002 ** 
K26A à D90A <0.001 ***
	 	 6	Supplementary	Data	
 
	
130 
B) HEDS assay PfGrx (Fig. 35, Supplementary Fig. 3 and Supplementary Table 2) 
B1.1) kcatapp(HEDS) @ 250 µM GSH 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A <0.001 *** 
K26A à D90A <0.001 *** 
 
B1.2) kcatapp(HEDS) @ 500 µM GSH 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A <0.001 *** 
K26A à D90A <0.001 *** 
 
B1.3) kcatapp(HEDS) @ 1000 µM GSH 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A <0.001 *** 
K26A à D90A <0.001 *** 
 
B1.4) kcatapp(HEDS) @ 2000 µM GSH 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A   0.933 ns 
K26A à D90A <0.001 *** 
 
B2.1) kcatapp(GSH) @ 0.18 mM HEDS  
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A <0.001 *** 
K26A à D90A <0.001 *** 
 
B2.2) kcatapp(GSH) @ 0.37 mM HEDS
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A <0.001 *** 
K26A à D90A <0.001 *** 
 
B2.3) kcatapp(GSH) @ 0.55 mM HEDS 
Comparison           P-value 
DM à K26A <0.001 *** 
DM à D90A 0.004 **
K26A à D90A <0.001 *** 
 
B2.4) kcatapp(GSH) @ 0.74 mM HEDS 
Comparison           P-value 
DM à K26A <0.001 *** 
DM  à D90A   0.013 * 
K26A à D90A <0.001 *** 
 
 
 
 
B3.1) Kmapp(HEDS) @ 250 µM GSH 
Comparison           P-value 
DM à K26A   0.187 ns 
DM  à D90A   0.020 * 
K26A à D90A   0.281 ns 
 
B3.2) Kmapp(HEDS) @ 500 µM GSH 
Comparison           P-value 
DM à K26A   0.324 ns 
DM  à D90A   0.127 ns 
K26A à D90A   0.354 ns 
 
B3.3) Kmapp(HEDS) @ 1000 µM GSH 
Comparison           P-value 
DM à K26A   0.137 ns 
DM  à D90A   0.004 ** 
K26A à D90A   0.241 ns 
 
B3.4) Kmapp(HEDS) @ 2000 µM GSH 
Comparison           P-value 
DM à K26A   0.049 * 
DM  à D90A   0.007 ** 
K26A à D90A   0.672 ns 
 
B4.1) Kmapp(GSH) @ 0.18 mM HEDS 
Comparison           P-value 
DM à K26A   0.542 ns 
DM  à D90A   0.042 * 
K26A à D90A   0.029 * 
 
B4.2) Kmapp(GSH) @ 0.37 mM HEDS
Comparison           P-value 
DM à K26A   0.190 ns 
DM  à D90A   0.015 * 
K26A à D90A   0.038 * 
 
B4.3) Kmapp(GSH) @ 0.55 mM HEDS 
Comparison           P-value 
DM à K26A   0.069 ns 
DM à D90A 0.118 ns
K26A à D90A   0.735 ns 
B4.4) Kmapp(GSH) @ 0.74 mM HEDS 
Comparison          P-value
DM à K26A   0.005 ** 
DM  à D90A   0.262 ns 
K26A à D90A   0.006 ** 
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C) GSSCys assay ScGrx7Y110X (Fig. 36, Supplementary Fig. 5 and Supplementary Table 3)  
 
C1.1) kcatapp(GSSCys) @ 50 µM GSH 
Comparison           P-value 
WT  à Y110F 0.019 * 
WT  à Y110H     < 0.001 *** 
WT à Y110A     <0.001 ***
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A     < 0.001 *** 
Y110H à Y110A     < 0.001 *** 
 
 
C1.2) kcatapp(GSSCys) @ 100 µM GSH 
Comparison           P-value 
WT  à Y110F 0.101 ns 
WT  à Y110H 0.033 * 
WT à Y110A     <0.001 ***
Y110F à Y110H 0.004 ** 
Y110F à Y110A     < 0.001 ***  
Y110H à Y110A     < 0.001 *** 
 
 
C1.3) kcatapp(GSSCys) @ 200 µM GSH 
Comparison           P-value 
WT  à Y110F 0.070 ns 
WT  à Y110H 0.009 * 
WT  à Y110A     < 0.001 *** 
Y110F à Y110H 0.001 *** 
Y110F à Y110A     < 0.001 ***  
Y110H à Y110A 0.012 * 
 
 
C1.4) kcatapp(GSSCys) @ 1000 µM GSH 
Comparison           P-value 
WT  à Y110F 0.413 ns 
WT  à Y110H 0.013 * 
WT  à Y110A 0.002 ** 
Y110F à Y110H 0.032 * 
Y110F à Y110A 0.004 **  
Y110H à Y110A 0.199 ns 
 
C2.1) kcatapp(GSH) @ 25 µM GSSCys 
Comparison           P-value 
WT  à Y110F 0.017 * 
WT  à Y110H     < 0.001 *** 
WT à Y110A     <0.001 ***
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A     < 0.001 ***  
Y110H à Y110A     < 0.001 *** 
 
 
C2.2) kcatapp(GSH) @ 50 µM GSSCys 
Comparison           P-value 
WT  à Y110F     < 0.001 *** 
WT  à Y110H     < 0.001 *** 
WT à Y110A     <0.001 ***
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A     < 0.001 ***  
Y110H à Y110A 0.001 *** 
 
 
C2.3) kcatapp(GSH) @ 100 µM GSSCys 
Comparison           P-value 
WT  à Y110F 0.001 *** 
WT  à Y110H     < 0.001 *** 
WT  à Y110A     < 0.001 *** 
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A     < 0.001 ***  
Y110H à Y110A 0.001 *** 
 
 
C2.4) kcatapp(GSH) @ 150 µM GSSCys 
Comparison           P-value 
WT  à Y110F     < 0.001 *** 
WT  à Y110H     < 0.001 *** 
WT  à Y110A     < 0.001 *** 
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A      0.004 **  
Y110H à Y110A     < 0.001 *** 
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C3.1) Kmapp(GSSCys) @ 50 µM GSH 
Comparison           P-value 
WT  à Y110F 0.991 ns 
WT  à Y110H       0.011 * 
WT  à Y110A      0.032 * 
Y110F à Y110H        0.013 * 
Y110F à Y110A        0.041 * 
Y110H à Y110A     0.520 ns
 
 
C3.2) Kmapp(GSSCys) @ 100 µM GSH 
Comparison           P-value 
WT  à Y110F 0.807 ns 
WT  à Y110H     < 0.001 *** 
WT  à Y110A 0.237 ns 
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A 0.236 ns  
Y110H à Y110A 0.006 **
 
 
C3.3) Kmapp(GSSCys) @ 200 µM GSH 
Comparison           P-value 
WT  à Y110F 0.747 ns 
WT  à Y110H 0.012 * 
WT  à Y110A 0.283 ns 
Y110F à Y110H 0.016 * 
Y110F à Y110A 0.317 ns  
Y110H à Y110A 0.111 ns 
 
 
C3.4) Kmapp(GSSCys) @ 1000 µM GSH 
Comparison           P-value 
WT  à Y110F 0.114 ns 
WT  à Y110H 0.672 ns 
WT  à Y110A 0.214 ns 
Y110F à Y110H 0.310 ns 
Y110F à Y110A 0.667 ns  
Y110H à Y110A 0.379 ns 
 
C4.1) Kmapp(GSH) @ 25 µM GSSCys 
Comparison           P-value 
WT  à Y110F 0.004 ** 
WT  à Y110H     < 0.001 *** 
WT  à Y110A 0.001 *** 
Y110F à Y110H 0.001 *** 
Y110F à Y110A 0.223 ns  
Y110H à Y110A 0.004 **
 
 
C4.2) Kmapp(GSH) @ 50 µM GSSCys 
Comparison           P-value 
WT  à Y110F 0.355 ns 
WT  à Y110H 0.001 *** 
WT  à Y110A 0.151 ns 
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A 0.051 ns  
Y110H à Y110A 0.012 *
 
 
C4.3) Kmapp(GSH) @ 100 µM GSSCys 
Comparison           P-value 
WT  à Y110F 0.949 ns 
WT  à Y110H 0.003 ** 
WT  à Y110A 0.072 ns 
Y110F à Y110H 0.003 ** 
Y110F à Y110A 0.096 ns  
Y110H à Y110A 0.071 ns 
 
 
C4.4) Kmapp(GSH) @ 150 µM GSSCys 
Comparison           P-value 
WT  à Y110F 0.608 ns 
WT  à Y110H     < 0.001 *** 
WT  à Y110A 0.017 * 
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A 0.012 *  
Y110H à Y110A 0.002 ** 
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D) HEDS assay ScGrx7Y110X (Fig. 37, Supplementary Fig. 7 and Supplementary Table 4)  
 
D1.1) kcatapp(HEDS) @ 300 µM GSH 
Comparison           P-value 
WT  à Y110F 0.596 ns 
WT  à Y110H 0.007 ** 
WT à Y110A     0.001 ***
Y110F à Y110H 0.011 * 
Y110F à Y110A      0.002 **  
Y110H à Y110A     0.262 ns 
 
 
D1.2) kcatapp(HEDS) @ 500 µM GSH 
Comparison           P-value 
WT  à Y110F 0.223 ns 
WT  à Y110H     < 0.001 *** 
WT à Y110A     <0.001 ***
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A     < 0.001 ***  
Y110H à Y110A 0.196 ns 
 
 
D1.3) kcatapp(HEDS) @ 1000 µM GSH 
Comparison           P-value 
WT  à Y110F 0.298 ns 
WT  à Y110H      0.011 * 
WT  à Y110A      0.004 ** 
Y110F à Y110H      0.003 ** 
Y110F à Y110A      0.001 ***  
Y110H à Y110A      0.325 ns 
 
 
D1.4) kcatapp(HEDS) @ 1500 µM GSH 
Comparison           P-value 
WT  à Y110F 0,033 * 
WT  à Y110H 0,012 * 
WT  à Y110A 0.003 ** 
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A     < 0.001 ***  
Y110H à Y110A 0.218 ns 
 
D2.1) kcatapp(GSH) @ 0.18 mM HEDS 
Comparison           P-value 
WT  à Y110F     < 0.001 *** 
WT  à Y110H     < 0.001 *** 
WT à Y110A     <0.001 ***
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A     < 0.001 ***  
Y110H à Y110A      0.139 ns 
 
 
D2.2) kcatapp(GSH) @ 0.37 mM HEDS 
Comparison           P-value 
WT  à Y110F     < 0.001 *** 
WT  à Y110H     < 0.001 *** 
WT à Y110A     <0.001 ***
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A     < 0.001 ***  
Y110H à Y110A 0.005 ** 
 
 
D2.3) kcatapp(GSH) @ 0.55 mM HEDS 
Comparison           P-value 
WT  à Y110F      0.010 ** 
WT  à Y110H     < 0.001 *** 
WT  à Y110A     < 0.001 *** 
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A     < 0.001 ***  
Y110H à Y110A 0.010 ** 
 
 
D2.4) kcatapp(GSH) @ 0.74 mM HEDS 
Comparison           P-value 
WT  à Y110F      0.057 ns 
WT  à Y110H     < 0.001 *** 
WT  à Y110A     < 0.001 *** 
Y110F à Y110H     < 0.001 *** 
Y110F à Y110A     < 0.001 ***  
Y110H à Y110A      0.081 ns 
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D3.1) Kmapp(HEDS) @ 300 µM GSH 
Comparison           P-value 
WT  à Y110F 0.511 ns 
WT  à Y110H      0.511 ns 
WT  à Y110A 0.511 ns  
Y110F à Y110H      0.511 ns 
Y110F à Y110A 0.511 ns  
Y110H à Y110A 0.511 ns
 
 
D3.2) Kmapp(HEDS) @ 500 µM GSH 
Comparison           P-value 
WT  à Y110F 0.182 ns 
WT  à Y110H 0.182 ns 
WT  à Y110A 0.182 ns 
Y110F à Y110H 0.182 ns 
Y110F à Y110A 0.182 ns 
Y110H à Y110A 0.182 ns
 
 
D3.3) Kmapp(HEDS) @ 1000 µM GSH 
Comparison           P-value 
WT  à Y110F 0.039 * 
WT  à Y110H      0.289 ns 
WT  à Y110A 0.816 ns 
Y110F à Y110H 0.305 ns 
Y110F à Y110A 0.033 *  
Y110H à Y110A 0.293 ns 
 
 
D3.4) Kmapp(HEDS) @ 1500 µM GSH 
Comparison           P-value 
WT  à Y110F 0.037 * 
WT  à Y110H 0.250 ns 
WT  à Y110A 0.723 ns 
Y110F à Y110H 0.261 ns 
Y110F à Y110A 0.026 *  
Y110H à Y110A 0.272 ns 
 
 
D4.1) Kmapp(GSH) @ 0.18 mM HEDS 
Comparison           P-value 
WT  à Y110F 0.966 ns 
WT  à Y110H 0.966 ns 
WT  à Y110A 0.966 ns 
Y110F à Y110H 0.966 ns 
Y110F à Y110A 0.966 ns  
Y110H à Y110A 0.966 ns
 
 
D4.2) Kmapp(GSH) @ 0.37 mM HEDS 
Comparison           P-value 
WT  à Y110F 0.884 ns 
WT  à Y110H 0.525 ns 
WT  à Y110A 0.159 ns 
Y110F à Y110H     0.470 ns 
Y110F à Y110A 0.156 ns  
Y110H à Y110A 0.022 *
 
 
D4.3) Kmapp(GSH) @ 0.55 mM HEDS 
Comparison           P-value 
WT  à Y110F 0.443 ns 
WT  à Y110H 0.057 ns 
WT  à Y110A 0.621 ns 
Y110F à Y110H 0.277 ns 
Y110F à Y110A 0.594 ns  
Y110H à Y110A 0.084 ns 
 
 
D4.4) Kmapp(GSH) @ 0.74 mM HEDS 
Comparison           P-value 
WT  à Y110F 0.146 ns 
WT  à Y110H 0.146 ns 
WT  à Y110A 0.146 ns  
Y110F à Y110H 0.146 ns  
Y110F à Y110A 0.146 ns 
Y110H à Y110A 0.146 ns 
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E) GSSCys assay ScGrx7D144X (Fig. 38, Supplementary Fig. 9 and Supplementary Table 5)  
 
E1.1) kcatapp(GSSCys) @ 50 µM GSH 
Comparison           P-value 
WT  à D144A 0.040 * 
WT  à D144K     < 0.001 *** 
D144A à D144K     0.001 ***
 
E1.2) kcatapp(GSSCys) @ 100 µM GSH 
Comparison          P-value
WT  à D144A 0.453 ns 
WT  à D144K      0.008 ** 
D144A à D144K      0.013 * 
 
E1.3) kcatapp(GSSCys) @ 200 µM GSH 
Comparison           P-value 
WT  à D144A 0.576 ns 
WT  à D144K     < 0.001 *** 
D144A à D144K     < 0.001 *** 
 
E1.4) kcatapp(GSSCys) @ 1000 µM GSH 
Comparison           P-value 
WT  à D144A 0.682 ns 
WT  à D144K      0.038 * 
D144A à D144K      0.043 * 
 
 
E2.1) kcatapp(GSH) @ 25 µM GSSCys 
Comparison           P-value 
WT  à D144A     <0.001 *** 
WT  à D144K     < 0.001 *** 
D144A à D144K     < 0.001 *** 
 
E2.2) kcatapp(GSH) @ 50 µM GSSCys 
Comparison           P-value 
WT  à D144A     < 0.001 *** 
WT  à D144K     < 0.001 *** 
D144A à D144K      0.012 * 
 
E2.3) kcatapp(GSH) @ 100 µM GSSCys 
Comparison           P-value 
WT  à D144A     < 0.001 *** 
WT  à D144K     < 0.001 *** 
D144A à D144K       0.131 ns 
 
E2.4) kcatapp(GSH) @ 150 µM GSSCys 
Comparison           P-value 
WT  à D144A 0.027 * 
WT  à D144K      0.032 * 
D144A à D144K      0.855 ns 
 
E3.1) Kmapp(GSSCys) @ 50 µM GSH 
Comparison           P-value 
WT  à D144A 0.035 * 
WT  à D144K      0.020 * 
D144A à D144K     0.437 ns
 
E3.2) Kmapp(GSSCys) @ 100 µM GSH 
Comparison          P-value
WT  à D144A 0.034 * 
WT  à D144K      0.005 ** 
D144A à D144K      0.066 ns 
 
E3.3) Kmapp(GSSCys) @ 200 µM GSH 
Comparison           P-value 
WT  à D144A 0.443 ns 
WT  à D144K      0.002 ** 
D144A à D144K      0.003 ** 
 
E3.4) Kmapp(GSSCys) @ 1000 µM GSH 
Comparison           P-value 
WT  à D144A 0.119 ns 
WT  à D144K      0.018 * 
D144A à D144K      0.112 ns 
 
 
E4.1) Kmapp(GSH) @ 25 µM GSSCys 
Comparison           P-value 
WT  à D144A 0.813 ns 
WT  à D144K     < 0.001 *** 
D144A à D144K     < 0.001 *** 
 
E4.2) Kmapp(GSH) @ 50 µM GSSCys 
Comparison           P-value 
WT  à D144A 0.056 ns 
WT  à D144K     < 0.001 *** 
D144A à D144K      0.004 ** 
 
E4.3) Kmapp(GSH) @ 100 µM GSSCys 
Comparison           P-value 
WT  à D144A 0.366 ns 
WT  à D144K     < 0.001 *** 
D144A à D144K      0.001 *** 
 
E4.4) Kmapp(GSH) @ 150 µM GSSCys 
Comparison           P-value 
WT  à D144A 0.325 ns 
WT  à D144K      0.020 * 
D144A à D144K      0.009 ** 
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F) GSSCys assay ScGrx7E147X (Fig. 39, Supplementary Fig. 11 and Supplementary Table 6)  
F1.1) kcatapp(GSSCys) @ 50 µM GSH 
Comparison           P-value 
WT  à E147A 0.999 ns 
WT  à E147K     < 0.001 *** 
E147A à E147K     < 0.001 *** 
 
F1.2) kcatapp(GSSCys) @ 100 µM GSH 
Comparison           P-value 
WT  à E147A 0.317 ns 
WT  à E147K     < 0.001 *** 
E147A à E147K     < 0.001 *** 
 
F1.3) kcatapp(GSSCys) @ 200 µM GSH 
Comparison           P-value 
WT  à E147A 0.840 ns 
WT  à E147K     < 0.001 *** 
E147A à E147K     < 0.001 *** 
 
F1.4) kcatapp(GSSCys) @ 1000 µM GSH 
Comparison           P-value 
WT  à E147A 0.427 ns 
WT  à E147K     < 0.001 *** 
E147A à E147K     < 0.001 *** 
 
 
F2.1) kcatapp(GSH) @ 25 µM GSSCys 
Comparison           P-value 
WT  à E147A 0.054 ns 
WT  à E147K      0.006 ** 
E147A à E147K      0.058 ns 
 
F2.2) kcatapp(GSH) @ 50 µM GSSCys 
Comparison           P-value 
WT  à E147A 0.037 * 
WT  à E147K      0.004 ** 
E147A à E147K      0.042 * 
 
F2.3) kcatapp(GSH) @ 100 µM GSSCys 
Comparison           P-value 
WT  à E147A 0.003 ** 
WT  à E147K     < 0.001 *** 
E147A à E147K      0.002 ** 
 
F2.4) kcatapp(GSH) @ 150 µM GSSCys 
Comparison           P-value 
WT  à E147A 0.003 ** 
WT  à E147K      0.021 * 
E147A à E147K      0.063 ns 
 
 
F3.1) Kmapp(GSSCys) @ 50 µM GSH 
Comparison           P-value 
WT  à E147A 0.550 ns 
WT  à E147K      0.002 ** 
E147A à E147K      0.002 ** 
 
F3.2) Kmapp(GSSCys) @ 100 µM GSH 
Comparison           P-value 
WT  à E147A 0.641 ns 
WT  à E147K      0.001 *** 
E147A à E147K      0.001 *** 
 
F3.3) Kmapp(GSSCys) @ 200 µM GSH 
Comparison           P-value 
WT  à E147A 0.984 ns 
WT  à E147K      0.012 * 
E147A à E147K      0.018 * 
 
F3.4) Kmapp(GSSCys) @ 1000 µM GSH 
Comparison           P-value 
WT  à E147A 0.539 ns 
WT  à E147K      0.002 ** 
E147A à E147K      0.001 *** 
 
 
F4.1) Kmapp(GSH) @ 25 µM GSSCys 
Comparison           P-value 
WT  à E147A 0.125 ns 
WT  à E147K      0.025 * 
E147A à E147K      0.005 ** 
 
F4.2) Kmapp(GSH) @ 50 µM GSSCys 
Comparison           P-value 
WT  à E147A 0.042 * 
WT  à E147K      0.025 * 
E147A à E147K      0.003 ** 
 
F4.3) Kmapp(GSH) @ 100 µM GSSCys 
Comparison           P-value 
WT  à E147A 0.122 ns 
WT  à E147K      0.005 ** 
E147A à E147K      0.002 ** 
F4.4) Kmapp(GSH) @ 150 µM GSSCys
Comparison           P-value 
WT  à E147A 0.008 ** 
WT  à E147K      0.016 * 
E147A à E147K     < 0.001 *** 
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G) GSSCys assay ScGrx7R153X (Fig. 40, Supplementary Fig. 13 and Supplementary Table 7) 
 
G1.1) kcatapp(GSSCys) @ 50 µM GSH 
Comparison           P-value 
WT  à R153A 0.549 ns 
WT  à R153E      0.013 * 
R153A à R153E     0.010 **
 
G1.2) kcatapp(GSSCys) @ 100 µM GSH 
Comparison          P-value
WT  à R153A 0.710 ns 
WT  à R153E      0.004 ** 
R153A à R153E      0.004 ** 
 
G1.3) kcatapp(GSSCys) @ 200 µM GSH 
Comparison           P-value 
WT  à R153A 0.033 * 
WT  à R153E     < 0.001 *** 
R153A à R153E      0.003 ** 
 
G1.4) kcatapp(GSSCys) @ 1000 µM GSH 
Comparison           P-value 
WT  à R153A 0.125 ns 
WT  à R153E      0.005 ** 
R153A à R153E      0.021 * 
 
 
G2.1) kcatapp(GSH) @ 25 µM GSSCys 
Comparison           P-value 
WT  à R153A     < 0.001 *** 
WT  à R153E     < 0.001 *** 
R153A à R153E     < 0.001 *** 
 
G2.2) kcatapp(GSH) @ 50 µM GSSCys 
Comparison           P-value 
WT  à R153A     < 0.001 *** 
WT  à R153E     < 0.001 *** 
R153A à R153E     < 0.001 *** 
 
G2.3) kcatapp(GSH) @ 100 µM GSSCys 
Comparison           P-value 
WT  à R153A     < 0.001 *** 
WT  à R153E     < 0.001 *** 
R153A à R153E     < 0.001 *** 
 
G2.4) kcatapp(GSH) @ 150 µM GSSCys 
Comparison           P-value 
WT  à R153A     < 0.001 *** 
WT  à R153E     < 0.001 *** 
R153A à R153E     < 0.001 *** 
 
G3.1) Kmapp(GSSCys) @ 50 µM GSH 
Comparison           P-value 
WT  à R153A 0.043 * 
WT  à R153E      0.036 * 
R153A à R153E     0.857 ns
 
G3.2) Kmapp(GSSCys) @ 100 µM GSH 
Comparison          P-value
WT  à R153A 0.039 * 
WT  à R153E      0.043 * 
R153A à R153E      0.713 ns 
 
G3.3) Kmapp(GSSCys) @ 200 µM GSH 
Comparison           P-value 
WT  à R153A 0.015 * 
WT  à R153E      0.021 * 
R153A à R153E      0.950 ns 
 
G3.4) Kmapp(GSSCys) @ 1000 µM GSH 
Comparison           P-value 
WT  à R153A 0.008 ** 
WT  à R153E      0.011 * 
R153A à R153E      0.970 ns 
 
 
G4.1) Kmapp(GSH) @ 25 µM GSSCys 
Comparison           P-value 
WT  à R153A     < 0.001 *** 
WT  à R153E     < 0.001 *** 
R153A à R153E      0.255 ns 
 
G4.2) Kmapp(GSH) @ 50 µM GSSCys 
Comparison           P-value 
WT  à R153A     < 0.001 *** 
WT  à R153E     < 0.001 *** 
R153A à R153E      0.760 ns 
 
G4.3) Kmapp(GSH) @ 100 µM GSSCys 
Comparison           P-value 
WT  à R153A     < 0.001 *** 
WT  à R153E     < 0.001 *** 
R153A à R153E      0.454 ns 
G4.4) Kmapp(GSH) @ 150 µM GSSCys 
Comparison           P-value 
WT  à R153A 0.005 ** 
WT  à R153E      0.006 ** 
R153A à R153E      0.611 ns
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